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1 Summary  
Gangliosides are sialic acid-containing glycosphingolipids (GSLs), which are 
especially abundant in the brain of vertebrates. The precise function of the complex 
patterns of brain gangliosides including the role of different alkyl chain lengths within 
the lipid part is not known.  
Quantification of gangliosides is usually achieved by staining after chromatographic 
separation, most often by thin layer chromatography and subsequent densitometric 
analysis (1, 2). These procedures are usually not suitable for the determination of 
different lipoforms of a given ganglioside. 
Within recent years, ganglioside patterns have been increasingly analyzed by mass 
spectrometry (section 2.2.3). Due to the lack of suitable standard substances for 
internal calibration, MS gives no reliable information on the amount of complex 
gangliosides in samples of biological origin: Standard substances are only available 
for gangliosides GM1, GM2, and GM3 (Fig. 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1: 
Internal 
ganglioside 
standards that 
are 
commercially 
available (3). 
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Fig. 1.2: Internal ganglioside standards of the major brain gangliosides. 
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The goal of this work was to establish methods for the synthesis of modified 
gangliosides that are suitable as internal standards for mass spectrometry. During 
this work the following structural analogs of brain gangliosides have been prepared 
from mixtures of bovine brain gangliosides (Fig. 1.2). 
Also standard substances for the tumor-associated gangliosides GM2 and GD2 have 
been prepared (Fig. 1.3). They are important targets for immunotherapy because 
they are highly expressed on human tumors of neuroectodermal origin while they are 
only minor gangliosides in healthy tissue (4, 5). Furthermore, the quantification of 
GM2 is of interest in lysosomal storage diseases (section 2.2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, a method based on an olefin metathesis has been established that is 
suitable for the synthesis of modified lysogangliosides. By this, non-natural lipoforms 
have been prepared that are suitable as internal standards for lyso-GM1 and lyso-
GM2.  
Currently, the standard substances are applied for the analysis of the brains of 
genetically engineered mice with deficiency of ceramide synthase 4 (CerS4). 
Fig. 1.3: Internal standards of GM2 and GD2. 
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Fig. 1.4: Internal standards of lyso-GM1 and lyso-GM2. 
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2 Introduction 
 
2.1 Gangliosides 
 
2.1.1 Structure 
 
  
Gangliosides are sialic acid-containing glycosphingolipids (6). Most glycosphingo-
lipids consist of a ceramide moiety attached to one or more sugar units. Ceramide 
consists of a sphingoid base, often C18-sphingosine ((2S,3R,E)-2-aminooctadec-4-
ene-1,3-diol) acylated by a fatty acid. In lysoglycosphingolipids the sugars are 
attached to a sphingoid base. The gangliosides of mammals contain mostly C18- and 
C20-sphingosine acylated by stearic acid, which constitute more than 80 % of the total 
ganglioside fatty acid content in the nervous system (7). C18-sphingosine-containing 
gangliosides are present in all tissues while C20-sphingosine-containing gangliosides 
can only be found in the nervous system of mammals in significant amounts (8). In 
human skin fibroblasts, where GM3 and GD3 (Fig. 2.1.4) are the major gangliosides, 
C18-sphingosine and C18-sphinganine (dihydrosphingosine) are the major sphingoid 
bases of gangliosides, and the major fatty acids are behenic acid (C22:0) and 
lignoceric acid (C24:0) (9). There is also a spatial distribution of the C18/C20-
sphingosine ratio in mouse brain, and an increase of the C20-sphingosine content has 
been observed during ageing. The function of this is not fully understood but it is 
Fig. 2.1.1: Structure of one lipoform of ganglioside GM1a. 
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known that C20-sphingosine-containing gangliosides are more effective in reducing 
membrane fluidity (7, 8). An accumulation of C20-sphingosine-containing gangliosides 
might increase the risk for neuronal diseases like Alzheimer disease because these 
species preferentially accumulate in the entorhinal cortex, which is severely affected 
in Alzheimer disease (8, 10). Changes in the fatty acid composition of gangliosides 
were not investigated in the study of Sugiura et al. In humans it is reported that the 
fatty acid content in the brain gangliosides changes for C18:0 from 95 % to 78 % and 
for C20:0 from 2.7 % to 9.5 % during ageing (11).  
Glycosphingolipids show characteristic carbohydrate sequences, linkages, and 
anomeric configurations. They can be divided into so called series. The ganglio 
series is characterized by the sequence Galβ1-3GalNAcβ1-4Galβ1-4-Glcβ1-1’Cer. 
Sialic acids are frequently occurring terminal sugars in glycoconjugates on the 
plasma membrane of eukaryotic cells (12). They are primarily found in the 
deuterostome lineage of animals. There are more than 50 kinds of sialic acids known 
in nature. All of them are derivatives of neuraminic acid, which is the 5-amino 
derivative of 2-keto-3-deoxy-nononic acid (Kdn) (13). The most abundant sialic acids 
in gangliosides are N-acetylneuraminic acid and N-glycolylneuraminic acid (14), but 
other modifications like O-acetylation in position 4, 7 or 9 or N-deacetylation, O-
methylation, sulfatation, and lactonization can occur. In humans N-glycolylneuraminic 
acid can only be found in traces, which is explained by inactivation of the CMP-N-
acetylneuraminic acid hydroxylase gene during evolution (12). Exceptions are human 
cancers and fetal tissues. In nonhuman mammals N-glycolylneuraminic acid can be 
found in every tissue except the brain where the levels are very low, for instance 1-
2 % in the gangliosides in the grey matter of bovine brain (15) or 3 % in the 
gangliosides of whole equine brain (16). N-glycolylneuraminic acid is absent with a 
few exceptions in sauropsides (birds and reptiles) and monostremes (platypus) (17).  
 
 
2.1.2 Nomenclature 
For the nomenclature of gangliosides, the Svennerholm system is most frequently 
applied (18). It consists of four signs: The first sign describes the series, where G 
indicates the ganglio-series (Galβ1-3GalNAcβ1-4Galβ1-4-Glcβ1-1’Cer). The second 
sign specifies the number of the sialic acids in the ganglioside, where M means one, 
D means two, T means three, and so on. The third sign indicates the number (5 – n) 
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of neutral sugar residues. For example, ganglioside GM1 contains 5 – 1 = 4 neutral 
sugar residues. In the ganglio series the fourth sign indicates the number of sialic 
acids that are attached to the inner galactosyl residue (a = 1, b = 2, etc.). Exceptions 
of this rule are the gangliosides GM1b and GD1c of the 0-series (Fig. 2.1.4). In 
addition, gangliosides containing a sialic acid residue in α2-6 linkage at the inner N-
acetylgalactosamine residue are called α-series gangliosides (19). The IUPAC-
IUBMB suggests a nomenclature where the series is abbreviated (for instance Gg for 
ganglio) and the number of neutral sugars is subscripted behind the symbol. The 
position of the sialic acids is described by roman numbers which describe the number 
of the sugar they are attached to. The number of the hydroxyl group they are bound 
to is described by a superscripted Arabic number behind the Roman number. For 
instance, the name of GD1a (NeuAcα2-3Galβ1-3GalNAcβ1-4(NeuAcα2-3)Galβ1-4-
Glcβ1-1’Cer (Fig. 1.2)) is lV3-α-NeuAc,ll3-α-NeuAc-Gg4Cer (20). When lipoforms are 
specified, the ceramide part is designated as d18:1/18:0, where the first part 
characterizes the sphingoid base by the number of hydroxyl groups (m = mono, d = 
di, t = tri) and the number of carbon atoms:double bonds (21). The same applies to 
the remaining numbers, which describe the fatty acid chain.  
  
 
2.1.3 Occurrence 
Gangliosides can be found in vertebrates and, with few exceptions, not in 
invertebrates. They occur in all tissues and are especially abundant in neuronal 
tissues, where their content is one to two orders of magnitude higher than in 
extraneural tissues (22). In the brain they are five times more abundant in the grey 
matter than in the white matter (14). The main gangliosides in the brain of mammals 
are GM1, GD1a, GD1b, GT1b, 9-O-Ac-GT1b, and GQ1b (7). Here, they contribute to 
10-12 % of the total lipid content. Gangliosides can also be found in serum, where 
they occur mainly on serum lipoproteins, predominantly LDL (66 %), HDL (25 %) and 
VLDL (7 %) (14). The main gangliosides in serum are GM3, GM2, GD3, GD1a, 
GD1b, GT1b, GQ1b and sialylneolactotetraosylceramide. Subcellularly, the majority 
of gangliosides can be found in the plasma membrane. Additionally, GD3 can be 
found in the mitochondria, but only during apoptosis. In response to cell dead signals 
like TNF-α GD3 is transported from the plasma membrane to the membranes of 
mitochondria. It is assumed that GD3 contributes to mitochondrial fission, which is 
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associated with apoptosis execution (23). Furthermore, gangliosides GM1 and GD1a 
occur in the outer and inner membrane of the nuclear envelope. GM1 on the inner 
nuclear membrane forms a complex with the Na+/Ca2+-exchanger (NCX) that 
meditates the Ca2+ transport from the nucleoplasm to the nuclear envelope (NE) 
lumen and hence to the ER, which serves as a major storage site for cellular Ca2+ 
(24). The Ca2+ concentration of the nucleoplasm and the cytosol are in a homeostatic 
equilibrium via nuclear pores. GD1a has no proven function in the nucleus and 
apparently serves only as precursor of GM1. The conversion of GD1a to GM1 is 
catalyzed by Neu1 in the outer membrane of the nuclear envelope and by a Neu3 
isoform in the inner membrane (24). Gangliosides are also able to form lactones, for 
instance GD1b-lactone I, which can contribute up to 3.5 % of total lipid bound sialic 
acid in human brain (25), and GM3-lactone, which occurs on tumor cells like 
melanoma (26). GD1b-lactone is termed l if only the terminal sialic acid is lactonized, 
and termed ll if both sialic acids are lactonized (27). The biological function of 
ganglioside lactones is mostly uninvestigated, but it is known that GM3-lactone, 
which occurs on tumor cells in much higher concentration than on normal cells, is 
much more immunogenic than GM3 (26).  
 
 
 
 
 
 
 
 
 
Fig. 2.1.2: Structure of GD1b-lactone l 
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2.1.4 Biosynthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1.3: Biosynthesis of d18:1/18:0-
ceramide as a precursor of gangliosides. 
10 
 
In eukaryotic cells gangliosides can be synthesized de novo or within a salvage 
pathway, where the building blocks of gangliosides are recycled. The de novo 
biosynthesis starts with the formation of ceramide at the cytoplasmic leaflet of the ER 
membrane. The first and rate-determining step is the condensation of L-serine and 
palmitoyl CoA, resp. stearoyl CoA, catalyzed by serine palmitoyltransferase (7). The 
resulting 3-ketosphinganine is reduced to sphinganine by 3-ketosphinganine 
reductase using NADPH + H+ as co-substrate. In the case of ceramides with stearoyl 
moiety sphinganine is acylated with stearoyl CoA to dihydroceramide catalyzed by 
CerS1 or CerS4. Synthesis of ceramides with other acyl chain lengths is catalyzed by 
other ceramide synthases (28). The last step is the dehydrogenation of 
dihydroceramide to ceramide catalyzed by dihydroceramide desaturase des1 using 
NADPH + H+ and O2 as co-substrates (29). Then, ceramide, the common precursor 
of ganglioside biosynthesis, is transported to the Golgi apparatus by the transport 
protein CERT (14). The next step in the biosynthesis of most gangliosides is the 
glycosylation of ceramide with UDP-glucose catalyzed by UDP-glucose ceramide 
glucosyltransferase, which occurs at the cytoplasmic face of the Golgi membrane. 
GlcCer is then translocated across the membrane to the luminal face of the Golgi 
apparatus, at least in vitro, mediated by ABC transporters. In the next step GlcCer is 
glycosylated with UDP-galactose to LacCer catalyzed by beta-1,3-
galactosyltransferase l. All gangliosides except GM4, which is synthesized from 
GalCer, are synthesized from LacCer. In the following steps the sialyl-donor is always 
CMP-sialic acid. First, GM3 is synthesized by the addition of sialic acid to LacCer 
catalyzed by LacCer alpha-2,3-sialyltransferase l (ST-l or GM3 synthase) (14, 19). 
Then, GD3 is synthesized by addition of another sialic acid residue to GM3 catalyzed 
by GM3 alpha-2,8-sialyltransferase (ST-ll or GD3 synthase). Subsequently, GT3 can 
be synthesized by addition of a further sialic acid residue to GD3 catalyzed by GD3 
alpha-2,8-sialyltransferase (ST-lll or GT3 synthase). LacCer, GM3, GD3, and GT3 
serve as precursors for higher gangliosides of the 0-, a-, b- and c-series. They are 
substrates of beta-1,4-N-acetylgalactosaminyltransferase l (GalNAcT l or 
GA2/GM2/GD2/GT2 synthase) in order to get GA2, GM2, GD2, and GT2. These 
products are accepted by beta-1,3-galactosyltransferase ll (GalT ll or 
GA1/GM1/GD1b/GT1c synthase) in order to get GA1, GM1, GD1b, and GT1c. Then, 
they can be sialylated by alpha-2,3-sialyltransferase lV (ST-lV or 
GM1b/GD1a/GT1b/GQ1c synthase) to GM1b, GD1a, GT1b, and GQ1c. These 
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products can be further sialylated by alpha-2,3-sialyltransferase V (ST-V or 
GD1c/GT1a/GQ1b/GP1c synthase) to GD1c, GT1a, GQ1b, and GP1c. An alternative 
pathway is the sialylation of GM1b, GD1a, GT1b, and GQ1c in position 6 of the N-
acetylgalactosamine residue, which is catalyzed by alpha-2,6-sialyltransferase Vll 
(ST-Vll or GD1aα/GT1aα/GQ1bα/GP1cα synthase) in order to get GD1aα, GT1aα, 
GQ1bα, and GP1cα. The anabolic pathway for lysogangliosides has not been 
investigated, yet. It is hypothesized that they are synthesized by the same enzymes 
like gangliosides by starting from sphingosine instead of ceramide (30). 
 
 
Fig. 2.1.4: Biosynthesis of gangliosides starting from ceramide at the Golgi 
apparatus. The enzymes are highlighted in red (modified from: (31)). 
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These glycosyltransferases are also described as an assembly line because they 
have a broad specificity and accept a member of every sub-series as a substrate 
(31). In contrast, the enzymes catalyzing the first steps are highly specific for their 
substrates. Therefore, the amounts of LacCer, GM3, GD3, and GT3 determine the 
amounts of 0-, a-, b-, and c-series gangliosides.  
 
 
2.1.5 Biological function of gangliosides 
Major advances in the analysis of the biological function of gangliosides became 
possible with the aid of genetically engineered mice. In 1996, mice were engineered 
that were disrupted in their GalNAcT l gene so that they could not synthesize 
gangliosides beyond GM3, GD3, and GT3. These GalNAcT-(-/-)-mice were viable 
with a normal life span and a mainly intact CNS, but they showed a decreased neural 
conduction velocity in the somatosensory cortex (32) and an age-related CNS- and 
peripheral nerves dysmyelination process (33) resulting in motor defects at the age of 
12 month (34). Furthermore, male GalNAcT-(-/-)-mice are infertile (35). These results 
suggested that higher gangliosides are not essential for survival in mammals but for 
reproduction of males. Also a mouse model with disrupted ST-ll gene, which could 
not synthesize b- and c-series gangliosides, showed no phenotype different from 
normal mice (36). DKO (double knock out) mice (GalNAcT/ST-ll-(-/-)) are unable to 
synthesize gangliosides except GM3. These GM3-only mice showed a sudden death 
phenotype and lethal seizures induced by sound stimuli (36). In 2003, mice were 
engineered that were disrupted in their ST l gene so that only the 0-series 
gangliosides were present. Gangliosides of this series are usually only present in 
traces in adult mammalian brain (14). These ST l-(-/-)-mice were also viable and 
apparently showed no abnormalities in any tissue. The only difference to wild type 
mice was an enhanced insulin signaling response in skeletal muscle, which is the 
major site of glucose uptake, which suggests that gangliosides are involved in the 
regulation of the insulin receptor response (37). Additionally, it was reported that ST l-
(-/-)-mice completely loose hearing 17 days after birth and show a complete loss of 
the organ of Corti 2 month after birth. In wild type mice gangliosides, especially GM3, 
are expressed in all regions of the cochlea in the early phase of hearing maturation, 
which suggests an important role of them in the functional organization of this organ 
(38). In 2005, DKO mice (ST-l/GalNAcT-l-(-/-)) were engineered that showed a 
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complete absence of gangliosides (39). These mice form sulfate-containing GSLs 
instead of gangliosides and show neurologic abnormalities like tremors and 
weakened hind limbs soon after birth and also shrinking and degeneration of the 
brain and the axons, leading usually to death soon after weaning. In humans a very 
rare disruption of the ST l gene and hence a lack of gangliosides beyond the 0-series 
leads to an autosomal recessive infantile-onset symptomatic epilepsy with 
development stagnation, blindness and mental retardation (40). In 2013, also an 
upregulation of the globoside pathway and a secondary dysfunction of the respiratory 
chain could be observed in human ST l-(-/-)-patients (41). Furthermore, these 
patients were deaf. In 2013, also patients with disrupted GalNAcT l gene were 
identified. They developed early onset and slowly progressing spastic paraparesis, 
cognitive impairment, and cerebellar ataxia (42). Another disease with impaired 
sphingolipid biosynthesis is HSAN1 (Hereditary sensory and autonomic neuropathy 
type 1), which is caused by mutations in a serine palmitoyltransferase subunit. In 
human patients, there are no differences in the total levels of sphingolipids (43), but 
the mutation in the SPTLC1 gene causes a substrate specificity shift of the enzyme 
leading to synthesis and accumulation of toxic sphingolipid metabolites, which cause 
neuropathies. Up to now, these are the only anabolic diseases known for 
gangliosides.  
 
 
 
 
 
 
 
 
 
 
 
In the plasma membrane one biological function of gangliosides is the interaction with 
sialic acid binding proteins. This is one example of a so called “trans” interaction with 
Fig. 2.1.5: Left figure: Trans interaction of gangliosides and binding proteins. Right figure: 
Cis interaction of gangliosides and binding proteins (modified from: (44)). 
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carbohydrate binding proteins outside the cell. Another possibility is a “cis” interaction 
with molecules within the same membrane (45). Hereby, it is assumed that 
gangliosides are part of microdomains in the membrane which, when occurring at 
nerve endings, were called glycosynapses (46). Three types have been 
distinguished: GSL clusters organized with signal transducers, O-linked mucin-type 
adhesion epitopes organized with signal transducers in a cholesterol-rich lipid 
microdomain, and adhesion receptors with N-glycosylation complexed with 
tetraspanin and gangliosides in microdomains. In another concept, microdomains on 
membranes have been called lipid rafts, which are defined as dynamic, nanoscale, 
sterol-sphingolipid-enriched, ordered assemblies of proteins and lipids. They can also 
be stimulated to merge into larger, more stable rafts (47). The existence of lipid rafts 
was investigated by microscopy techniques like stimulated emission depletion far-
field fluorescence nanoscopy (STED), by mass spectrometry of membrane 
compositions, and by constructing membrane model systems (47). STED nanoscopy 
showed that the free diffusion of sphingolipids and GPI-anchored proteins on the 
plasma membrane in living mammal cell is hindered by transient trapping in 
cholesterol mediated complexes (48). The upper limit for size and life time of these 
complexes is 20 nm and 20 ms. It is assumed that lipid rafts have a functional role in 
membrane-associated processes like T cell signalling, virus budding of HIV and 
influenza, post-Golgi traffic to the cell surface, and glycosphingolipid-mediated 
endocytosis (47).  
In “trans” interactions, gangliosides act as receptors for glycan binding proteins 
(lectins) in cell-cell recognition events. They modulate the cytotoxity of natural killer 
cells by interacting with Siglec-7, an inhibitory receptor on these cells. Siglec-7 
prefers sialic acids in α2-8 linkage, which is rare on glycoproteins but common on b-
series gangliosides (45). Furthermore, gangliosides bind to Siglec-4 (MAG), which is 
expressed in nerve tissue, functions in stabilizing myelin-axon interactions, and limits 
axon regeneration after injury. Siglec-4 recognizes the terminal glycan sequence 
NeuAcα2-3Galβ1-3GalNAc, which is found on GD1a and GT1b. This explains the 
age-related dysmyelination process observed in GalNAcT-(-/-)-mice. Gangliosides 
are also the receptors for E-selectin on neutrophils, which together with P-selectin 
initiates the binding of neutrophils to blood vessels in response to infection or injury 
(45). For this process, neutrophils express special gangliosides of the neolacto series 
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containing long chains of multiple LacNAc (Galβ1-4GlcNAc) units, which contain one 
or more fucosyl residues and one terminal sialic acid residue.  
In “cis” interactions, gangliosides modulate the responsiveness of insulin receptors. 
According to a hypothesis, IRs are usually associated with caveolin-1 in caveolae 
and are immobile, which is necessary for their insulin metabolic signaling. If GM3 
binds to an IR, it becomes mobile and is released from the association with caveolin-
1 which hinders insulin signaling (49). The influence of other gangliosides was not 
investigated, yet. Another example is the regulatory inhibition of the epidermal growth 
factor receptor (EGFR) by GM3, but not by other gangliosides. For activation of 
EGFR, a dimerization is necessary and GM3 stabilizes the inactive monomeric form. 
In vitro, the inhibition could only be observed in liquid ordered phases, which 
suggests an important role of membrane microdomains for this process (50). Third, 
gangliosides are regulators of angiogenesis. Angiogenesis is induced by release of 
vascular endothelial growth factor (VEGF) which binds to VEGF-receptors and 
induces the proliferation of vascular endothelial cells. GD1a and other higher 
gangliosides enhance the effect of VEGF while GM3 suppresses it (51). 
 
 
2.1.6 Lysosomal degradation 
The degradation of gangliosides mainly takes place in endosomes and lysosomes. 
Gangliosides from the plasma membrane reach the lysosomes via endocytosis. At 
the stage of late endosomes gangliosides and other membrane components that are 
designated for degradation are sorted from the perimeter membrane into luminal 
membranes. The lipid composition of both membrane pools is adjusted in a way that 
the perimeter membrane is stabilized while the luminal membranes become 
degradable (52). A lipid that is crucial for endosomal and lysosomal membrane 
degradation is bis(monoacylglycero)phosphate (BMP). The BMP content of the 
luminal membrane increases up to 70 % of total phospholipid content (53) while 
membrane stabilizing lipids like cholesterol and other sterols are transported out of 
the inner membrane (52).  
Lysosomal ganglioside degradation takes place in a sequential manner, in which the 
sialic acid- and monosaccharide units are cleaved from the non-reducing end of the 
glycan chain catalyzed by different glycosidases (Fig. 2.1.7) (14). 
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In the first step, terminal sialic acid residues are cleaved by sialidase Neu1. Together 
with carboxypeptidase A, GM1 beta-galactosidase, and N-acetylaminogalactose-6-
sulfate sulfatase Neu1 is part of a lysosomal multienzyme complex (54). The 
degradation of GM1 to GM2 and of GA1 to GA2 is catalyzed by GM1 beta-
galactosidase, which requires saposin-B or the GM2-activator as cofactor (14). Then, 
GM2 is degraded to GM3 and GA2 to LacCer by one of the beta-hexosaminidase 
isoenzymes, which require the GM2-activator as a cofactor. GM3 is subsequently 
degraded to LacCer by Neu1. LacCer is degraded to GlcCer by GalCer beta-
galactosidase using the cofactor saposin-C or by GM1 beta-galactosidase using the 
cofactor saposin-B. Then, GlcCer is degraded to ceramide catalyzed by 
glucosylceramide-beta-glucosidase using saposin-C as a cofactor. Ceramide is 
degraded to sphingosine by acid ceramidase using Saposin-D as a cofactor. The 
final degradation products are able to leave the lysosome (55).   
Defects in enzymes and cofactors involved in the degradation of gangliosides and 
also of other GSLs can lead to inherited diseases, the lysosomal storage diseases 
(56). They are all inherited autosomal recessive except Fabry disease (55). Defects 
in the Neu1 gene lead to the very rare disorder sialidosis. The stored substances are 
mainly sialyloligosaccharides and sialylglycoproteins. The storage of gangliosides is 
Fig. 2.1.6: Model of lysosomal degradation of glycosphingolipids. Gradients of 
pH-value, cholesterol, BMP, sphingomyelin (SM) and ceramide (Cer) are 
shown (modified from: (52)). 
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increased in visceral organs, but not in the brain (57). The reasons for this have not 
been investigated, yet. A defect in the GM1 beta-galactosidase gene leads to GM1 
gangliosidosis, which is also called Landing disease (14). Here, the stored 
substances are GM1 and GA1. A defect in the beta-hexosaminidase gene leads to 
GM2 gangliosidosis. The enzyme beta-hexosaminidase consists of two subunits, 
which can be an α- or a β-subunit. beta-Hexosaminidase A consists of an α- and a β-
subunit, beta-hexosaminidase B consists of two β-subunits, and beta-
hexosaminidase S consists of two α-subunits. A defect in the α-subunit leading to 
deficient beta-hexosaminidase A and S is called Tay-Sachs disease or B-variant, and 
the stored substance is mainly GM2. A defect in the β-subunit leading to deficient 
beta-hexosaminidase A and B is called Sandhoff disease or 0-variant, and the stored 
substances are mainly GM2, GA2, globotetraosylceramides, and oliogosaccharides 
(55). Also a variant with deficient GM2 activator is known which is called AB-variant. 
A defect in the glucosylceramide beta-glucosidase gene leads to storage of GlcCer. 
This disease is called Gaucher disease, which is the most common sphingolipidosis 
(56). A variant of Gaucher disease can also be caused by a deficiency in saposin-C. 
A deficiency in the acid ceramidase leads to Farber disease. Here, the stored 
substance is ceramide. Gaucher disease and Farber disease are not referred to as 
gangliosidoses.   
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Fig. 2.1.7: Lysosomal degradation of gangliosides. The storage diseases of 
each step are highlighted in red (modified from:(56)).  
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2.2 Internal standards for mass spectrometric quantifica-
tion of gangliosides 
 
2.2.1 Mass spectrometric quantification  
The goal of quantification is to measure the amount of an analyte in absolute terms 
(absolute quantification) or relative to another analyte (relative quantification) (58). 
Mass spectrometry is applicable to most type of biomolecules, shows high sensitivity, 
high specificity, is suitable for coupling to chromatographic methods, and has a wide 
dynamic range and a high speed of analysis. Special mass spectrometers are 
needed for quantification. Mostly, electrospray ionization (ESI) is used, which is a 
mild ionization technique where no or only very little fragmentation of the analyte is 
possible. For many applications, the mass spectrometer is preferably a tandem mass 
spectrometer because detection sensitivity and specificity can be enhanced by 
special operating modes. In general, the analyzing steps of a tandem mass 
spectrometer can be performed tandem in space or tandem in time (59). A tandem in 
space MS contains three structurally separated analyzers, for example a triple 
quadrupole. A tandem in time MS contains an ion trap analyzer, which can perform 
multiple analyzing steps successively at the same place, for example as a Q-Trap 
MS.                                            
 
 
An appropriate mode for quantification is selected ion monitoring (SIM), where only a 
particular mass instead of the whole mass spectrum is measured, which results in a 
1000-fold gain in detection sensitivity (58). A disadvantage of this method is the lack 
of specificity, because isobaric compounds of the analyte cannot be distinguished. 
Another approach is the parent ion scan, where the first analyzer is in scan mode, the 
second analyzer is in CID (collision-induced dissociation) mode, and the third 
Fig. 2.2.1: Schematic structure of a triple-quadrupole mass 
spectrometer (modified from: (60)). 
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analyzer is in SIM mode. All masses are measured by the first analyzer and are 
fragmented by the second analyzer. The third analyzer is measuring only one 
particular fragment.  
 
 
 
 
 
If a characteristic fragment of the analyte is uncharged, the neutral loss scan 
technique can be used in which analyzer 1 and 3 are in a synchronized scan mode. 
The first analyzer scans the whole spectrum, the second analyzer is in CID mode, 
and the third analyzer scans the masses that lost a particular uncharged mass (61). 
The highest specificity, but not the highest sensitivity, can be achieved by selected 
reaction monitoring (SRM) and multiple reaction monitoring (MRM). Here, the first 
analyzer is in SIM mode, the second analyzer is in CID mode, and the third analyzer 
is in SIM mode. The first analyzer measures only a particular mass, which is then 
Fig. 2.2.2: Schematic view of MS modes which are suited 
for MS quantification (modified from: (61)). 
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fragmented, and the third analyzer measures only a particular fragment ion. The 
measuring of more than one reaction at the same time is termed multiple reaction 
monitoring (MRM). 
 
 
2.2.2 Calibration 
For quantification, calibration of the instrument has to be performed, which is here 
defined as the determination of a correlation between analyte concentration and 
mass spectrometer response (58). Three principle methods can be distinguished. In 
external calibration the standard used is identical to the analyte. Approximately five 
different concentrations are measured and the intensity of the response is plotted 
against the concentration. The calibration curve obtained after linear regression can 
be described by the following equation (62): 
 
, ,
 i std EC i std ECI a c b= ⋅ +  
 
(Ii,std: intensity measured for calibration standard, ci,std: concentration of calibration 
standard, aEC: slope of external calibration, bEC: y-axis intercept of external 
calibration) 
Then, the analyte is measured and its concentration is calculated from the regression 
line. Accuracy and precision of the calibration are limited because analyte and 
standard are measured in different sample matrices at different times. An advance is 
the standard addition method. Here, the standard used is also identical to the 
analyte. First, the analyte is measured alone. Then, a defined amount of standard is 
added and the response of the whole amount is measured. This is repeated for 
several different standard concentrations and the intensity is plotted against the 
standard concentration. The calibration curve can be described by the following 
equation:  
 
, ,
 i an added SAC i added SACI a c b+ = ⋅ +  
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(Ii,an+added: intensity measured for analyte and added standard, ci,added: concentration 
of added calibration standard, aSAC: slope of standard addition calibration, bSAC: y-
axis intercept of standard addition calibration) 
The x-axis intercept provides the concentration of the analyte. Accuracy and 
precision of the method are higher because analyte and standard are measured in 
the same sample matrix at the same time. However, this method cannot compensate 
analyte losses during purifications steps of the sample. Another problem are 
fluctuations in the mass spectrometer response, which are also not compensated. 
These problems can be overcome by the internal standard method, in which the 
standard used is a chemically and physically similar but non-isobaric derivative of the 
analyte. The standard is added in a defined amount to the sample at an early stage 
of sample handling. After purification of the sample, the ratio of the mass 
spectrometric response of analyte and standard are measured. The concentration of 
the analyte can be calculated by the following equation (62): 
 
an
an IS IS an
IS
I
c c CF I
I
= ⋅ = ⋅
 
 
(I: intensity measured for internal standard respectively analyte, c: concentration of 
internal standard respectively analyte, CFIS: calibration factor)  
One advantage of internal standard calibration is a reduced analysis time because it 
is a one point calibration (62). Furthermore, accuracy and precision of the method are 
high because the internal standard acts as a self correcting system for analyte losses 
during purification steps and for fluctuations in mass spectrometer response. 
There are five criteria for a good internal standard. First, its chemical and physical 
properties should match those of the analyte as closely as possible. Second, its 
chromatographic behavior should be similar so that standard and analyte elute close 
to each other if LC-MS is used. Third, the molecular mass of the standard must be 
distinct from that of the analyte. Fourth, its mass spectrometric behavior must be 
similar to that of the analyte. Fifth, it should not be a constituent of the sample which 
is measured.  
In general, there are three types of internal standards (58). The first type is any 
compound that has similar physical and chemical properties to those of the analyte 
and that is not isobaric. Usually accuracy and precision of such standards are low. 
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The second type are homologous compounds of the analyte. The third type are 
isotope labeled versions of the analyte and often 2H and 13C are used. Second and 
third types of internal standards have very similar chemical and physical properties to 
the analyte and thus show high accuracy and precision. 
 
 
2.2.3 Ganglioside quantification  
One goal of ganglioside quantification is ganglioside pattern investigation. In 2009, 
Fong et al. quantified the ganglioside levels of GM1, GM2, GM3, GD3, GD1a, GD1b, 
GT1b, and GQ1b in the brains of 2-day-old and 80-day-old Wistar rats by using an 
external standard calibration. They found an increase of the total ganglioside levels 
of more than two-fold by ageing. In two day old rats GD1a (28 % of lipid bound sialic 
acid) and GQ1b (28 %) were the most abundant gangliosides while at the age of 80 d 
GM1 (25 %), GD1a (28 %), GD1b (17 %), and GT1b (17 %) were more frequent (63). 
GQ1b decreased to 9 % at the age of 80 d. In 2011, the same group quantified GM3 
and GD3 in dairy milk products, where GM3 and GD3 are the main gangliosides 
(80 % of total ganglioside content in bovine milk) (64). They used an external 
standard method and a standard addition method as a control. The measured values 
for GD3 in different dairy milk products were in the range of 120 µg/g to 15000 µg/g 
based on dry weight. The GM3 levels were only in the range of less than 1 % of the 
GD3 levels in most products, but 5-10 % in G600 milkfat extract. In 2013, Lee et al. 
quantified GD3 and GM3 in bovine milk during different lactation periods (65). They 
found GD3 values of 15.2 mg/L and GM3 values of 0.98 mg/L in colostrums, which 
decreased to 2.4 mg/L and 0.15 mg/L, respectively, 90 days after calving.  
Second, ganglioside quantification can also be used in the field of quantitative 
imaging mass spectrometry. MS methods applied are MALDI-MS, secondary ion MS 
(SIMS), and desorption electrospray ionization (DESI) (59). If internal standard are 
used, they have to be added uniformly to the tissue by microspotting or spray coating 
(66). There are few applications for gangliosides, yet. In 2013, NanoSIMS was used 
to image the phase separation of 18-F-GM1 (contains one fluorine atom at position 
18 of the fatty acid part) into lipid rafts in a model membrane system. It was 
synthesized from lyso-GM1 and activated 18-F-stearic acid. The 18-F-GM1 served as 
analyte as well as an internal standard for quantitative analysis (67).    
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Another goal is the quantification of stored substances in lysosomal storage 
diseases, where GM1, GM2, lyso-GM1, and lyso-GM2 are of relevance as primary 
storage substances in GM1- and GM2 gangliosidosis. Furthermore, gangliosides also 
play a role as secondary storage substances in various lysosomal storage diseases. 
In Niemann-Pick disease type C1 and C2, in which the cholesterol transport proteins 
NPC1 resp. NPC2 are deficient (68), secondary storage of GM1 is observed (57). 
NPC1 and NPC2 are responsible for the efflux of cholesterol from the luminal 
membrane of the late endosomes to the perimeter membrane. Hereby, NPC2 
transports cholesterol from the luminal membrane to NPC1, which is an integral 
protein of the perimeter membrane. Subsequently, NPC1 inserts cholesterol into the 
perimeter membrane (52). Mutations of these proteins lead to accumulation of 
cholesterol in the luminal membrane and hence to their stabilization against 
degradation (68). Therefore, lipids like cholesterol, GM1, GM2, GM3, and others are 
stored. Secondary storage was also reported for galactosialidosis (GD1a, GM1, 
GM2, and GM3 are stored), Gaucher disease (GD3, GM1, GM2, and GM3 are 
stored), GM1 gangliosidosis (GM2 and GM3 are stored), for various forms of 
mucopolysaccharidoses (mostly GM2 and GM3 are stored), and α-mannosidosis 
(GM2 and GM3 are stored) (57). There are few reports on the MS-determination of 
gangliosides, yet. In 2008, Gu et al. quantified GM1 and GM2 in human 
cerebrospinal fluid samples of infantile Tay Sachs patients by using d18:1/C18:0-
GM1-d3 and d18:1/C18:0-GM2-d3 as internal standards. They compared the GM1 
and GM2 levels of these patients with those of healthy controls. Furthermore, they 
tested the clinical effectiveness of bone marrow transplantation over a period of one 
year (69).  
Up to now, standards of type 2 or type 3 for GM1, GM2 and GM3 have been 
synthesized and are commercially available (3). Standards for GD1a, GD1b, GT1b 
and GQ1b have not been synthesized yet and are not commercially available (59).  
 
 
2.2.4 Application of the standards to CerS1- and CerS4-deficient 
mice 
The acylation of sphinganine with stearoyl CoA to d18:0/18:0-dihydroceramide 
catalyzed by CerS1, which is mainly expressed in brain and skeletal muscle, and 
CerS4, which is expressed in leukocytes, skin, heart, spleen, but also in brain (28), is 
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a crucial step in the biosynthesis of gangliosides, and a deficiency of these enzymes 
can also affect ganglioside levels. In 2012, Ginkel et al. reported that 18 month old 
CerS1-/- mice show decreased ganglioside levels in cerebellum (GM1, 36 %; GD1a, 
30 %; GD1b, 19 %; GT1b, 56 %) and forebrain (GM1, 55 %; GD1a, 72 %; GD1b, 59 
%; GT1b, 37 %) compared to wild type mice (70). The ganglioside levels were 
quantified by TLC and densitometry. Also a decrease of the expression of MAG, 
which prefers GD1a and GT1b as ligands, down to 40 % was measured in both 
tissues, which suggests that a particular ganglioside concentration is necessary for 
myelin stabilization by MAG. Furthermore, the size of the cerebellum was reduced by 
40 % and the mice showed altered behavior like decreased exploration of novel 
objects, locomotion, and running speed. Naturally occurring mutations in the lass1 
gene, which encodes CerS1, are associated with Purkinje cell degeneration and 
lipofuscin accumulation, but do not lead to differences in lifespan (71). CerS4 is the 
least studied ceramide synthase and CerS4-(-/-)-mice have not been reported (72), 
but have been created in the workgroup Willecke. Besides CerS1, CerS4 is the only 
ceramide synthase that accepts stearoyl CoA as substrate and is also expressed in 
the brain. The application of the synthesized internal standards is planned for the 
quantification of the ganglioside levels in the brain of CerS4-(-/-)-mice. Also the 
determination of ganglioside levels in CerS1-(-/-)-mice by MS methods and 
comparison to those in CerS4-(-/-)- and wild type mice is planned with the aid of the 
standard substances prepared in this work.    
 
 
 
2.3 The olefin cross-metathesis  
 
2.3.1 General considerations 
In this work olefin metathesis is applied as the key step to the synthesis of artificial 
lysoganglioside lipoforms. The olefin metathesis, for which the Nobel Prize in 
chemistry was awarded in 2005, is a reorganization of C-C double bonds (73). It 
allows access to olefins that are cumbersome to prepare from olefins that are easy to 
prepare. The olefin metathesis can be classified into three categories: cross 
metathesis, ring-closing metathesis, and ring opening metathesis. The catalysts used 
are Schrock carbenes with molybdenum or ruthenium as central atom. Mo catalysts 
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are more active, sensitive to hard nucleophils and electrophils like water, alcohols, 
carboxylic acids, and carbonyls, and insensitive to soft ones like amines and 
phosphanes. The reverse holds for Ru catalysts which are less active, sensitive to 
amines and phosphanes, and insensitive to alcohols, carboxylic acids or carbonyls 
and also water (73). The structures of some of the most important achiral catalysts 
are shown in fig. 2.3.1. The advantages of the Hoveyda-Grubbs catalysts over the 
Grubbs catalysts are a higher thermal stability and a higher oxygen- and moisture 
tolerance (74). 
 
 
 
 
The mechanism of the olefin metathesis consists of two steps: catalyst’s initiation to 
generate the active catalyst and catalyst’s propagation, where the active catalyst 
promotes additional cycles (Fig. 2.3.2) (75).  
 
 
 
 
 
 
 
 
 
 
Fig. 2.3.1: Important achiral olefin metathesis catalysts 
(Cy = cyclohexyl, Mes = mesityl) 
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Fig. 2.3.2: Mechanism of olefin cross metathesis (modified 
from: (75)). 
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In the first step for Ru catalysts a phosphane ligand or the iso-propoxystyrene ligand 
is dissociated to form a 14-electron species that subsequently coordinates an olefin 
ligand, which acts primarily as a π-acid (73). For Hoveyda-Grubbs catalysts, this step 
is interchange rather than dissociative (74). The next step is a [2 + 2] cycloadditon to 
form a metallacyclobutane followed by a [2 + 2] cycloreversion to release a different 
olefin and regeneration of the active catalyst. For first generation catalysts, the 
metallacyclobutane formation is the rate-determining step while for second 
generation catalyst it is the dissociation step (76). In the propagation steps the active 
catalyst reacts with every available olefin in the same manner to get different olefins 
until the catalyst is deactivated. Every reaction step is reversible so that the driving 
force for olefin cross metathesis is the entropy of mixing. If terminal olefins are used, 
the equilibrium can be moved to the product side by removal of ethylene.         
 
 
2.3.2 Product selectivity and E/Z-stereoselectivity of olefin cross 
metathesis 
The product selectivity of olefin cross metathesis depends on the reactivity of the 
cross partners (77). Grubbs et al. subdivided terminal olefins into four categories 
dependent on their reactivity towards the applied catalyst. Type 1 olefins show rapid 
homodimerization and the homodimers are consumable. Type 2 olefins show slow 
homodimerization and the homodimers are sparingly consumable. Type 3 olefins 
show no homodimerization and can only react with type 1 or type 2 olefins. Type 4 
olefins are inert to cross metathesis, but do not deactivate the catalyst. In general, if 
two olefins of the same type are crossed, a nonselective cross metathesis will result 
because parts of the educts are wasted as homodimers. In this case, an excess of 
one partner is necessary to provide a high yield of the cross product. High product 
selectivity can be obtained if two olefins of different types are crossed because the 
less reactive olefin will not make homodimers and the reaction product will not 
undergo secondary metathesis.  
The E/Z-stereoselectivity of an olefin cross metathesis depends mainly on the steric 
bulkiness of the residues on the olefins, which favors the E-product (78). Also a 
redistribution of the products by secondary metathesis favors the thermodynamically 
more stable E-product (78).    
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2.3.3 Isomerization 
Olefin isomerization along an alkyl chain is a side reaction in olefin metathesis that 
can significantly decrease the yield and hamper product purification. Factors that 
promote isomerization are high temperatures, high dilution, long reaction times, and 
high catalyst loadings (79). Isomerizations are caused by ruthenium hydride 
complexes (Fig. 2.3.3), which are formed by decomposition of two catalyst molecules 
(80). The isomerization of olefins could proceed by insertion of the olefin into the 
Ru-H bond and subsequent β-hydride elimination, but the exact mechanism is 
unknown. Isomerizations can be prevented by addition of hydride scavengers which 
do not reduce catalyst activity like acetic acid or p-benzoquinone. p-Benzoquinone is 
a Michael acceptor and also a type 4 olefin. In many cases, p-benzoquinone is more 
effective than acetic acid due to his twofold acceptor groups. Electron deficient 
benzoquinones like tetrafluoro-1,4-benzoquinone are even more effective than the 
parent compound.  
 
 
 
 
 
 
   
 
 
 
 
 
 
2.4 Aims 
 
2.4.1 Partial synthesis of homologous ganglioside standards 
Internal ganglioside standards can be prepared by total synthesis (81) or by partial 
synthesis starting from natural gangliosides. Until today, total syntheses have been 
developed for the most common gangliosides with major contributions by the group 
Fig. 2.3.3: Main product which is formed by 
decomposition of two catalyst molecules 
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of Richard R. Schmidt (82-84). GQ1b, for instance, can be synthesized in a 
convergent synthesis in 26 steps starting from methyl [phenyl 5-acetamido-8-O-(5-
acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyrano-
sylono-1,9-lactone)-4,7-di-O-acetyl-3,5-dideoxy-2-thio-D-glycero-D-galacto-2-nonulo-
pyranosid]-onate a, (2-trimethylsilyl)-ethyl 3,6-di-O-benzyl-β-D-galactopyranoside b, 
phenyl 2-deoxy-2-N-(2,2,2-trifluoroethoxy)carbonylamido-1-thio-β-D-galactopyranosi-
de c, allyl 4,6-O-(4-methoxybenzylidene)-β-D-glucopyranoside d, and 3-O-
benzoylceramide e (85) (Fig. 2.4.1). The synthesis of these building blocks requires 
additional 3 steps for the synthesis of a from colominic acid (86, 87), which is a 
commercially available α2-8 polymer of N-acetylneuraminic acid from Escheria coli 
K235 (88). Furthermore, it requires 4 steps for the synthesis of b from D-galactose 
(89-91), 3 steps for the synthesis of c from D-galactosamine (92, 93), 3 steps for the 
synthesis of d from 2,3,4,6-tetra-O-acetyl-α-D-glycopyranosyl bromide (94, 95), and 
10 steps for the synthesis of e from D-xylose (96-98).    
 
                         
Fig. 2.4.1: Common building blocks for the total synthesis of gangliosides (85) (SE = 2-
(trimethylsilyl)-ethyl, Troc = 2,2,2-trichloroethoxycarbonyl, PMP = p-methoxyphenyl)  
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In an alternative approach 3-benzoyl-2-azidosphingosine has been used instead of e 
because it has yields in the range of 80 % (98) in glycosylations with 
trichloroacetimidate-activated glycosyl donors compared to 48 % (85) reported for e. 
Another advantage of the use of protected azidosphingosine as glycosyl acceptor is 
its applicability for the total synthesis of lysogangliosides, which can be obtained by 
reduction of the azido group after the glycosylation step.  
Due to the high effort required for total syntheses we chose partial syntheses of the 
title compounds. A partial synthesis of gangliosides was, for instance, described by 
Clasen for ganglioside GM3. He purified 3’-sialyl lactose from bovine colostrum and 
activated it as a trichloroacetimidate. Then, it was coupled to (2S,3R,E)-2-azido-1-
hydroxyoctadec-4-en-3-yl benzoate by the method of Schmidt et al (98). After 
reduction, acylation, and removal of the protective groups he obtained GM3 in 7 
steps (99). In another example Schwarzmann et al. synthesized 14C-labeled GM1 
containing a thioglycosidic bond to the ceramide part starting from natural GM1 (100). 
Thioglycosidic bonds are not cleavable by catabolic enzymes and thus can be used 
for metabolic studies of glycosphingolipids (101). First, the ganglioside sugar was 
isolated by the method of Wiegandt et al (102). Then, it was peracetylated and 
converted into an α-glycosyl bromide, which was treated with thioacetate in the next 
step. Conversion with an 1-Iodo-2-dichloroacetamido derivative of protected 
ceramide under weak alkaline conditions, removal of the protecting groups, and 
introduction of a labeled fatty acid lead to labeled SGM1 (Fig. 2.4.2).  
 
 
Fig. 2.4.2: 14C-labeled thio-GM1 synthesized by partial synthesis starting from 
natural GM1 (100) 
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One concept for the synthesis of pure ganglioside lipoforms is the modification of the 
fatty acid residue. A new concept is the modification of the sphingosine part, which 
has only been applied to ceramides, yet (103).  
 
 
The fatty acid part of gangliosides can be modified by deacylation to lysogangliosides 
and subsequent reacylation by an activated fatty acid (104). Up to now, three 
methods have been reported for the first step (Fig. 2.4.4). The first method is a 
chemical deacylation under alkaline conditions (105). As a reason for the 
regioselectivity in the deacylation of ganglioside GM1 to lyso-GM1 (105) it can be 
assumed that the negative charge of the sialic acid group repels the attacking 
hydroxide ion. If this assumption is correct, the method should also be applicable to 
the regioselective deacylation of oligosialogangliosides. The second method is a 
three-step synthesis in which gangliosides are completely deacylated except on their 
N-acetylgalactosamine residue in the first step (Fig. 2.4.5). Then, the amino group in 
the sphingosine part is regioselectively protected by an Fmoc-group. Subsequently, 
the remaining amino groups are reacetylated and the protecting group is removed. 
The overall yield is 30 % for GM1, GM2, GM3, and GD1a (106). The third method is 
an enzymatic deacylation by using sphingolipid ceramide N-deacylase (SCDase), 
which is reported to be regioselective for GM1 (107), GM2, GM3, GD3, GD1a, and 
GQ1b (108). In the work of Kurita et al (107). and Ito et al (108) the extent of 
hydrolysis for the mentioned gangliosides was determined by densitometry. The 
products were not purified and the yields were not determined. The next step in this 
work should be a reacylation by activated myristic acid or heptadecanoic acid, which 
Fig. 2.4.3: Concepts for the partial synthesis of ganglioside lipoforms 
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could be activated as N-hydroxysuccinimide esters (104). This method should be 
applied to lyso-GM1, lyso-GD1a, lyso-GD1b, lyso-GT1b, and lyso-GQ1b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4.4: Modification of the acyl chain of gangliosides  
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Fig. 2.4.5: Three step procedure for the preparation of lysogangliosides   
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2.4.2 Purification of the educts 
 
 
 
 
For the partial synthesis planned in this work, a sufficient amount of starting material 
was required. A source that was available to us is a commercial mixture of 
gangliosides purified from bovine brain for pharmaceutical purposes (Cronassial®). It 
consists of 21 % of GM1, 40 % of GD1a, 16 % of GD1b, 19 % of GT1b, and 4 % of 
other gangliosides (109). As the first purification step we decided to use a separation 
into mono-, di-, tri- and tetrasialogangliosides by anion-exchange chromatography 
using a modified method of Momoi et al (110). The next step was a further 
purification of these ganglioside classes by NP-chromatography to get GM1, GD1a, 
GD1b, and GT1b. Then, the C18- and C20-sphingosine homologs of each ganglioside 
were separated by RP-chromatography. 
 
 
Fig. 2.4.6: Plan for the separation of the ganglioside mixture Cronassial®. The RP chromato-
graphy step is shown only for GM1, but was also applied to the other gangliosides. 
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2.4.3 Preparation of ganglioside standards by degradation of other 
standards 
Another approach to prepare ganglioside standards is the enzymatic degradation of 
already prepared ganglioside standards with modified lipid part. We used a beta-
galactosidase from bovine testes, an exoglycosidase, which can hydrolyze terminal 
galactosyl residues in β1-3, β1-4, and β1-6 linkage from saccharides, 
glycosaminoglycans, glycoproteins, and glycolipids (111).  
 
 
 
The degradation of GM1 to GM2 by this enzyme has been reported by Larsson et al. 
for fluorescence labeled GM1 in a yield of 54 % and for fluorescence labeled asialo-
GM1 in a yield of 58 % (112). Therefore, it should be possible to prepare a GM2-
standard from the GM1-standard and, as a new approach, a GD2-standard from the 
GD1b-standard.   
 
 
Fig. 2.4.7: Plan for the enzymatic degalactosylation of already 
synthesized ganglioside standards 
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2.4.4 Development of a new synthetic method to modify the 
sphingosine chain of gangliosides 
An alternative method for the synthesis of artificial ganglioside lipoforms can be a 
modification of the sphingosine chain. One appropriate reaction sequence might be 
an ozonolysis to a ganglioside aldehyde followed by a Wittig reaction.  
 
 
 
Ozonolysis was rarely used for the synthesis of ganglioside aldehydes because of 
fragmentation under alkaline conditions and formation of a side product by 
isomerization of the allyl alcohol, which was reported by Wiegandt et al (113). In 
2009, aldehydes of GM1 and GM3 obtained after ozonolysis have been used for 
reductive amination reactions (114). Yields for the ozonolysis reaction were not 
reported in this study. Usually, ozonolysis has been used to isolate the 
oligosaccharide part of glycosphingolipids after subsequent alkaline fragmentation of 
the aldehyde (115). The overall yield for ozonolysis and alkaline fragmentation was 
reported to be 60 % (100). A procedure to obtain protected ganglioside aldehydes 
after dihydroxylation and periodate cleavage has been reported by Hakomori et al 
(116). But this method was also just used to isolate the oligosaccharide part of 
gangliosides and not to isolate the aldehyde.  
An alternative approach can be an olefin cross metathesis. The first step would be a 
peracetylation of the ganglioside in order to make it soluble in unpolar solvents. The 
second step can be an ethenolysis in order to get gangliosides bearing terminal olefin 
groups. However, ethenolysis (tested by the model methyl oleate using standard Ru-
based catalysts) has yields only in the range of 13 to 57 % (117) resp. 13 to 24 % 
(118). In the recent years, more effective catalysts for ethenolysis have been 
developed, which give yields up to 95 % (119) resp. 80 % (120), but only for (Z)-
olefins. These catalysts are much more reactive towards (Z)-olefins than towards (E)-
olefins because the residues of the olefin are forced into the same direction in the 
metallacyclobutane formation by bulky ligands (78). Presumably, these catalysts 
Fig. 2.4.8: Synthesis of ganglioside aldehydes 
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Fig. 2.4.9: Plan of synthesis for the modification of the sphingosine chain of gangliosides 
cannot be applied to gangliosides, which contain (E)-double bonds. In 2006, Patel et 
al. suggested a 2-butenolysis instead of an ethenolysis. They could achieve a yield of 
96 % in the 2-butenolysis of methyl oleate (121). Based on this approach, we 
investigated a stilbenolysis for the modification of the sphingosine chain of 
gangliosides (Fig. 2.4.9).  
 
 
 
The concept has three advantages: First, the phenyl group facilitates the 
chromatographic purification because it is more polar than the alkyl group, which is a 
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key requirement for the preparation of ganglioside standards. Second, the phenyl 
group serves as an UV-probe. Third, stilbene is not prone to isomerizations because 
the phenyl group stops the migration of the double bond. The next step should be 
another olefin metathesis in which an excess of hexacos-13-ene is used. A direct 
reaction of a peracetylated ganglioside lactone is impracticable because of 
separation problems. In the last step, the protecting groups should be cleaved by 
alkaline hydrolysis.  
 
 
 
3 Results 
 
3.1 Purification of gangliosides 
 
3.1.1 Purification of GM1, GD1a, GD1b, GT1b, and GQ1b from 
Cronassial® 
An attempt was made to separate Cronassial® by isocratic NP column 
chromatography using CHCl3/MeOH/0.2 % aq. CaCl2 60:35:8 v/v/v as eluent. Salts 
like CaCl2 are used because they improve the separation of gangliosides (122), 
which is explained by an association of strongly ionized cations with the gangliosides 
to ion pairs, which can be better separated (123). By this, GM1 and GD1a were 
obtained in pure form. GD1b could not be separated from GD1a and GT1b could not 
be separated from GQ1b by this method. From 1.02 g of Cronassial® 135 mg of GM1 
and 246 mg of GD1a were obtained after desalting.  
In another approach, Cronassial® was separated into mono-, di-, tri-, and 
tetrasialogangliosides by anion-exchange chromatography using the weak anion 
exchanger DEAE-sephadex® (diethylaminoethyl-sephadex). In contrast to Momoi et 
al. (110), a step gradient instead of a linear gradient was applied. The 
monosialogangliosides did not adsorb completely so they were partially eluted by 
pure CHCl3/MeOH/H2O 30:60:8 v/v/v. The reason for this could be a slightly 
overloading of the column, but it did not disturb the separation. Another part was 
eluted by an NH4OAc-concentration of 0.05 mol/L. The disialogangliosides and also 
the trisialogangliosides were successively eluted by an NH4OAc-concentration of 
40 
 
0.15 mol/L and could be separated without overlap. The tetrasialogangliosides, which 
consisted only of GQ1b, were eluted by an NH4OAc-concentration of 0.45 mol/L. The 
ganglioside classes were analyzed by HPTLC (Fig. 5.2.1). From 5.03 g of Cronassial 
4.79 g of gangliosides (27 % monosialogangliosides, 58 % disialogangliosides, 14 % 
trisialogangliosides and 0.88 % tetrasialogangliosides) were obtained after desalting 
(95 % recovery) (Tab. 5.2.1).  
In the next step the ganglioside classes were separated by NP column 
chromatography using different techniques and different solvent systems. From 
1.28 g of monosialogangliosides only 300 mg GM1 were obtained in pure form 
because of impurities migrating close to GM1 like GM2 and GM3, which could only 
partially be separated. It was observed that GD1a and GD1b, which make up the 
greater part of the disialogangliosides, cannot be separated well by isocratic elution. 
This problem was overcome by using a step gradient of CHCl3/MeOH/2.5 M NH3 
60:35:6 v/v/v for the elution of GD1a and CHCl3/MeOH/2.5 M NH3 60:35:8 v/v/v for 
the elution of GD1b. From 1.00 g of disialogangliosides 472 mg of GD1a and 158 mg 
of GD1b were obtained. GT1b makes up the greater part of the trisialogangliosides. 
From 672 mg of trisialogangliosides 382 mg of pure GT1b were obtained. GQ1b was 
already obtained in pure form after anion-exchange chromatography and subsequent 
desalting. From 5.03 g of Cronassial 41.5 mg of GQ1b were obtained.  
 
Ganglioside Amount (mg) 
GM1 300 
GD1a 472 
GD1b 158 
GT1b 382 
GQ1b 41.5 
 
 
 
The purified gangliosides were analyzed by HPTLC, ESI-MS and ESI-MS/MS. The 
NP-HPTLCs showed only one band for each ganglioside (Fig. 3.1.1). The RP-TLCs 
showed two distinct bands for each ganglioside (Fig. 3.1.2, presented for GQ1b). 
Hereby, the upper band corresponds to the more polar d18:1/18:0-lipoform and the 
lower band to the less polar d20:1/18:0-lipoform. 
 
Tab. 3.1.1:  Gangliosides that were obtained 
by purification of Cronassial®  
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By ESI-MS, it was demonstrated that GM1, GD1a, GD1b, and GQ1b consist mainly 
of d18:1/18:0- and d20:1/18:0-ceramide. For GT1b, also the occurrence of a 
d20:1/20:0-species, which made up to 11 % of the total GT1b content, was measured 
(Fig. 3.1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.1: NP HPTLC of the purified gangliosides. 
Solvent system: CHCl3/MeOH/0.2 % aq. CaCl2  
45:55:10 v/v/v.  
Fig. 3.1.2: RP HPTLC of GQ1b. 
Solvent system: MeOH/H2O  
90:20 v/v.  
Fig. 3.1.3: ESI-MS of GT1b 
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This species could not be measured in the other gangliosides, so it might have been 
separated in previous chromatography steps. The structure of the ganglioside 
species was analyzed by ESI-MS/MS of the most intensive peaks. Hereby, the 
structure of the oligosaccharide chain is derived from B- and C-series fragments 
while the structure of the ceramide base is derived from Z- and Y-series fragments. 
The gangliosides analyzed contained exclusively d18:1/18:0-ceramide species resp. 
d20:0/18:0-ceramide species. But isobaric d20:1/18:0- and d18:1/20:0-ceramide 
species, which can occur in traces, could not be differentiated by ESI-MS and also 
not by RP-TLC.   
 
 
3.1.2 Purification of ganglioside lipoforms by RP column chromato-
graphy 
In the next step the gangliosides were separated isocratically by RP column 
chromatography using MeOH/H2O in different compositions as eluent. The results 
are given in Table 3.1.2. After separation, the obtained ganglioside lipoforms were 
purified from column material (section 5.1.8) by NP-chromatography. Every 
ganglioside fraction contained significantly more d20:1/18:0-lipoform than d18:1/18:0-
lipoform. Beside these lipoforms, also compounds were observed that migrated in-
between the main lipoforms on RP-TLC (Fig. 3.1.4), but they could not be separated 
and analyzed.  
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Gang-
lioside m (input) (mg) 
m (d18:1/18:0-
lipoform) (mg) 
m (d20:1/18:0-
lipoform) (mg) Solvent system 
GM1 300 64.8  100 MeOH/H2O 90:25 v/v 
GD1a 472 89.5 not determined MeOH/H2O 90:49 v/v 
GD1b 76 not determined 19.1 MeOH/H2O 90:40 v/v 
GT1b 382 not determined 40.4 MeOH/H2O 90:40 v/v 
GQ1b 125 not determined 55.3 MeOH/H2O 90:50 v/v 
 
 
 
 
 
Pure ganglioside lipoforms were obtained in amounts of 19.1 mg to 100 mg (Tab. 
3.1.2). They were analyzed by RP TLC (Fig. 3.1.6), ESI-MS, ESI-MS/MS, 1H-NMR, 
and CHN analysis. ESI-MS demonstrated a clear separation of the d18:1- and d20:1 
lipoforms. The ESI-MS of d20:1/18:0-GT1b·3NH3 showed traces of d20:1/20:0-
GT1b·3NH3 in a quantity of 6.0 % (Fig. 3.1.5). The fragments in the ESI-MS/MS 
spectra could clearly be correlated to the structure of the lipoforms on the basis of the 
Z- and Y-series fragments. In the 1H-NMR spectra, the olefinic protons, the anomeric 
protons, the acetyl protons, and the methyl and methylene protons of the ceramide 
Tab. 3.1.2:  Results of the purification of the gangliosides GM1, GD1a, 
GD1b, GT1b, and GQ1b by RP column chromatography. The purified 
amounts of the ganglioside lipoforms are given in column 3 and 4. 
GM1                                          fractions 37-60 
Fig. 3.1.4: RP HPTLCs of the separation of GM1 by RP 
column chromatography.  
Solvent system: MeOH/H2O 90:10 v/v.  
Visualization: Kägi-Miescher reagent 
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part could be assigned. Other assignments were made by comparison to literature 
(124, 125) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The signal at 1.98 ppm was correlated to H-6 of the ceramide part also by 
comparison to literature (105). The 1H-NMR spectra of GD1b, GT1b, and GQ1b were 
assigned by comparison to the spectra of GM1 and GD1a. The signal at 1.88 ppm 
indicated the presence of further acetyl groups in the spectra of GD1a, GD1b, GT1b, 
and GQ1b. The integral of the multiplet at 1.22 ppm indicated the lengths of the alkyl 
chains. 
Quantification of gangliosides by sialic acid determination is necessary because 
weighing is inaccurate due to residual water content and residual column material. 
The usage of pure Neu5Ac and α1-acid glycoprotein, which contains 12.6 wt% 
Neu5Ac (106), as external were tested for d18:1/18:0-GM1·NH3 (1) and d18:1/18:0-
GD1a·2NH3 (3), but gave deviant results. Hence, we decided to analyze the purity of 
the ganglioside lipoforms by elemental analysis and to use these substances as 
calibration standards for other probes. The purity of the obtained ganglioside 
lipoforms was 86-95 % (Tab. 3.1.3). The discrepancy of the values is due to residual 
water content as it is observed in monosaccharides. 
   
Fig. 3.1.5: ESI-MS of 
d20:1/18:0-GT1b·3NH3 
Fig. 3.1.6: RP HPTLC of 
d20:1/18:0-GT1b. 
Solvent system: MeOH/H2O  
90:9 v/v.  
  GT1b           d20:1/ 
                 18:0-GT1b 
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Ganglioside Purity (wt%) 
d18:1/18:0-GM1·NH3 (1) 88.5 
d20:1/18:0-GM1·NH3 (2) 94.8 
d18:1/18:0-GD1a·2NH3 (3) 90.4 
d20:1/18:0-GD1b·2NH3 (4) 90.1 
d20:1/18:0-GT1b·3NH3 (5) 86.9 
d20:1/18:0-GQ1b·4NH3 (6) 85.7 
 
 
 
Although the two GM1 lipoforms were purified by the same procedure, 2 was more 
anhydrous than 1. The reason is that it was dried in vacuum instead of lyophilization. 
The water content of gangliosides was also demonstrated by 1H-NMR of d18:1/18:0-
GD1a·2NH3 (3) (Fig. 3.1.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 3.1.3:  Results of the elemental analysis 
of the purified ganglioside lipoforms 
Fig. 3.1.7: Comparison of 1H-NMR spectra of d18:1/C18:0-GD1a·2NH3 (3).The range from 2.4 to 
4.9 ppm is shown. 
Left figure: 1H-NMR spectrum without exchanging of exchangeable protons. The water signal can 
be seen at 3.35 ppm. Right figure: 1H-NMR spectrum after exchanging all exchangeable protons by 
deuterium. The water signal has vanished.  
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3.2 Preparation of lysogangliosides 
 
3.2.1 Chemical preparation of lysogangliosides 
This part of the work was focused on one step preparations of lysogangliosides. In 
the chemical deacylation potassium hydroxide in an alcohol was used. The reaction 
is an amide hydrolysis under alkaline conditions.  
 
 
  
 
The reaction is reported to be regioselective for the preparation of lyso-GM1 in a yield 
of 54 % (105). For the preparation of lyso-GM3 from GM3, a yield of 36-40 % by 
using sodium tert-butoxide in MeOH has been reported, which is more a statistical 
deacylation rather than a regioselective deacylation (127). In this work, KOH in 1-
propanol was applied to d18:1/18:0-GM1·NH3 and d18:1/18:0-GD1a·2NH3 (Tab. 
3.2.1).   
 
Lysoganglioside Amount (mg) Yield (%) 
d18:1-lyso-GM1·NH3 (7) 8.69 52 
d18:1-lyso-GD1a·2 NH3 (8) 1.23 4.8 
 
 
 
d18:1-Lyso-GM1·NH3 was obtained in a yield of 52 %. In the case of GD1a, however, 
the yield of lyso-GD1a dropped to 4.8 % due to the formation of other deacylation 
products. The ESI-MS spectra of the products showed no impurities of other 
ganglioside lipoforms. Sialic acid determination demonstrated a product content of 
Fig. 3.2.1: Mechanism of the amide 
hydrolysis under alkaline conditions (126)
 
Tab. 3.2.1:  Results of the chemical 
preparation of lyso-gangliosides 
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97.5 % resp. 80.2 % compared to the weighed quantity. Two experiments were 
performed in order to increase the yield of the chemical preparation of lyso-GD1a. 
First, the reaction was performed anhydrously by using potassium tert-butoxide 
instead of KOH, which contains a residual water content of 15 %. After a reaction 
time of 12 h, TLC-analysis revealed no increase in the regioselectivity. In a second 
experiment the reaction temperature was reduced to 80 °C and the quantity of educt 
and product were analyzed after different reaction times. After 12 h reaction time, six 
compounds were present in the reaction medium in both experiments. Densitometric 
analysis of a 4 µL aliquot of the reaction mixtures revealed the following distribution:   
 
Band Rf Ganglioside Quantity (%) (Exp. 1) Quantity (%) (Exp. 2) 
1 0.38 d18:1/18:0-GD1a
 
25.1 64.1 
2 0.31 Byproduct 1 23.3 23.9 
3 0.27 d18:1-lyso-GD1a 14.7 12.0 
4 0.22 Byproduct 2 10.0 0.0 
5 0.18 Byproduct 3 17.4 0.0 
6 0.11 Byproduct 4 9.4 0.0 
 
 
 
 
 
These results demonstrate that after 12 h at 90 °C approximately 60 % of the educt is 
converted to byproducts while only 14.7 % is converted to product. After 12 h at 
80 °C only 12 % of the educt is converted to product whereas 23.9 % is converted to 
a byproduct migrating slightly faster on NP-TLC. This product could be 
monodeacetyl-GD1a. The quantity of the educt and the product were also analyzed 
at different reaction times. 4 µL of the reaction mixture was taken each time and 
quantified by HPTLC followed by densitometry (Fig. 3.2.2).  
Tab. 3.2.2: Densitometric analysis of the chemical deacylation of d18:1/18:0-GD1a· 2 
NH3 after 12 h reaction time. Quantities were calculated by the following equation: 
i
i
Aquantitiy
A
=
∑
. 
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The results demonstrated that after 6 h a minor amount of 10-15 % is converted to 
lyso-GD1a. In the following 9 h of reaction time the amount of lyso-GD1a remained 
constant while further amounts of educt were converted to byproducts.     
 
 
3.2.2 Enzymatic preparation of lysogangliosides 
The enzyme sphingolipid ceramide N-deacylase (SCDase) catalyzes the hydrolysis 
and also the reverse reaction of various glycosphingolipids, but not ceramides, in a 
reversible manner (128). Its enzyme classification number is EC 3.5.1.69, which 
means it is a hydrolase that acts on amide bonds other than peptide bonds in linear 
amides (129).       
 
 
 
Fig. 3.2.2: 
Densitometric 
analysis of 
d18:1/18:0-
GD1a·2NH3 and 
d18:1-lyso-
GD1a·2NH3 in 
the chemical 
deacylation at 
different reaction 
times 
Fig. 3.2.3: Reaction catalyzed by the enzyme 
sphingolipid ceramide N-deacylase 
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The site of the equilibrium depends mainly on the reaction conditions. A pH value of 
5-6 favors the hydrolysis while a pH value of 7 favors the condensation. A high 
detergent concentration favors the hydrolysis while a low detergent concentration 
favors the condensation. In general, the vmax value but also the Km value of the 
condensation reaction is one order of magnitude higher than for the hydrolysis 
reaction so that the catalytic efficacy k (	k	=	 vmaxKm ) is comparable (128). The reaction 
mechanism of SCDase is unknown. But it could be demonstrated that Trp- and Arg 
residues are essential and that hydrolysis and condensation are catalyzed by the 
same active site (128). The method was applied to d18:1/18:0-GD1a·2NH3, 
d20:1/18:0-GD1b·2NH3, d20:1/18:0-GT1b·3NH3, and d20:1/18:0-GQ1b·4NH3 (Tab. 
3.2.3).    
 
Lysoganglioside nSCDASE/nsubstrate (mU/µmol) 
Amount of Lyso-
ganglioside (mg) Yield (%) 
d18:1-lyso-GD1a·2NH3 (8) 110 0.74 47 
d20:1-lyso-GD1b·2NH3 (9) 110 1.72 53 
d20:1-lyso-GT1b·3NH3 (10) 73.6 1.16 60 
d20:1-lyso-GQ1b·4NH3 (11) 74.3 0.97 44 
 
 
 
Yields were in the range of 44 to 60 %. The ESI-MS spectrum of d18:1-lyso-
GD1a·2NH3 showed no impurities of other ganglioside lipoforms. By comparing the 
[M + 2H]2+ peaks, it was found that d20:1-lyso-GD1b·2NH3 contained an impurity of 
3.1 % of d18:1-lyso-GD1b·2NH3, which is due to traces of d18:1/20:0-GD1b·2NH3 in 
the precursor, which could not be separated by RP column chromatography. Also, 
d20:1-lyso-GT1b·3NH3 contained 4.7 % of d18:1-lyso-GT1b·3NH3. For d20:1-lyso-
GQ1b·4NH3 no other GQ1b-lipoforms could be detected. The fragments in the ESI-
MS/MS spectra could clearly be correlated to the structure of the lysoganglioside 
lipoforms.  
 
 
 
 
 
Tab. 3.2.3:  Results of the enzymatic 
preparation of lysogangliosides 
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3.3 Reacylation of lysogangliosides 
Tetradecanoic acid and heptadecanoic acid were activated as N-hydroxysuccinimide 
esters by a modified method of Lapidot et al (130). 
 
 
 
 
 
 
Fig. 3.3.1: Mechanism of carboxylic acid activation by 
DCC and N-hydroxysuccinimide (131) 
Fig. 3.3.2: Reacylation of lysogangliosides 
by N-hydroxysuccinimide esters 
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N-Hydroxysuccinimide esters do not react with hard nucleophils like carboxyl groups 
or hydroxyl groups but with softer ones like amino groups (130). The activation of 
tetradecanoic acid and heptadecanoic acid was performed in a yield of 72 % resp. 
66 %. The products were characterized by 1H-NMR, 13C-NMR, EI-MS, and CHN-
analysis. In the next step, the lysogangliosides were reacylated by a method of 
Schwarzmann and Sandhoff (104). An excess of the non-nucleophilic Hünig’s base 
was applied for two reasons. First, amino groups are better nucleophils than hydroxyl 
groups under weak alkaline conditions. Second, the zwitterionic form of the 
lysogangliosides has to be deprotonated. The reaction was applied to d18:1-lyso-
GM1·NH3, d18:1-lyso-GD1a·2NH3, d20:1-lyso-GD1b·2NH3, d20:1-lyso-GT1b·3NH3, 
and d20:1-lyso-GQ1b·4NH3 (Tab. 3.3.1).  
 
Ganglioside standard Amount (mg) Yield (%) 
d18:1/14:0-GM1·NH3 (14) 6.32 28 
d18:1/14:0-GD1a·2NH3 (15) 0.88 42 
d18:1/17:0-GD1a·2NH3 (16) 0.98 86 
d20:1/14:0-GD1b·2NH3 (17) 1.28 70 
d20:1/14:0-GT1b·3NH3 (18) 0.40 34 
d20:1/14:0-GQ1b·4 NH3 (19) 0.19 19 
 
 
 
Yields were in the range of 19 to 86 %. The ESI-MS of 14, 15, 16, and 19 showed no 
traces of other ganglioside lipoforms than the desired products. The ESI-MS of 
d20:1/14:0-GD1b·2NH3 (17) showed an impurity of 3.4 % of d18:1/14:0-GD1b·2NH3 
and the ESI-MS of d20:1/14:0-GT1b·3NH3 18 showed an impurity of 4.8 % of 
d18:1/14:0-GT1b·3NH3 as it was observed in their precursors. The fragments in the 
ESI-MS/MS spectra could clearly be correlated to the structure of the ganglioside 
lipoforms. Yields were estimated by weighing followed by sialic acid determination. 
For d18:1/14:0-GM1·NH3 also densitometry was applied. The deviation between the 
value obtained by densitometry and the one determined by sialic acid determination 
was -8.4 %. Densitometric quantification bears some inaccuracies because the 
regression line is measured by only 3 values and also different lipoforms have 
different absorption coefficients. So this method was not further applied in this work. 
The values obtained by weighing were always higher than the values obtained by 
Tab. 3.3.1:  Ganglioside standards that were 
synthesized by modification of the fatty acid part 
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sialic acid determination and the deviation became higher for amounts much smaller 
than 1 mg because the weighing error increased. In table 3.3.1, the corrected 
amounts of the synthesized standards are given.   
 
 
3.4 Preparation of ganglioside standards by degradation of 
other standards 
Glycosidases are subdivided into enzymes that catalyze glycoside hydrolysis with 
retention of the configuration of the anomeric center and enzymes that catalyze with 
inversion (132).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beta-galactosidases belong to the first category. Their enzyme classification number 
is EC 3.2.1.23, which means they are hydrolases, subclass glycosylases, and sub-
subclass glycosidases (129). In the first step the alkoxy group of the glycosidic bond 
is cleaved by the assistance of two glutamic acid residues, which reside in the active 
Fig. 3.4.1: Mechanism for retaining glycosidases. The amino acid numbering 
refers to beta-galactosidase from Escheria coli (132). 
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site of the enzyme (Fig. 3.4.1). Glu537 activates the alkoxy leaving group by donating 
a proton while Glu461 stabilizes the arising carboxonium ion intermediate. A 
hydrogen bond between the carboxyl group and the hydroxyl group in position 2 
stabilizes the transition state of the deglycosylation step as well as the one for the 
glycosylation step (133). In the next step a nucleophil which is usually water or an 
alcohol attacks on the same face resulting in retention of the anomeric configuration. 
The deprotonated Glu537 accepts a proton from the nucleophil, which facilitates the 
nucleophilic addition. The reaction is thermodynamically controlled so every step is 
reversible (132). If the reaction is carried out in an aqueous solvent, the equilibrium is 
shifted to the product site.  
In this work the commercially available enzyme beta-galactosidase from bovine 
testes was chosen because it preferentially cleaves terminal galactose residues in 
β1-3 linkage (111). The reaction was applied to the preparation of d18:1/14:0-
GM2·NH3 and d20:1/14:0-GD1b·2NH3.  
 
 
 
The optimal reaction conditions were investigated by preparation of d18:1/18:0-
GM2·NH3 and d20:1/18:0-GD1b·2NH3. The applicability of the method to lyso-
gangliosides was tested by the preparation of d18:1-lyso-GM2·NH3. The results are 
given in table 3.4.1. 
Fig. 3.4.2: Preparation of d18:1/14:0-GM2 
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Product nenzyme/nsubstrate (mU/µmol) 
Amount of 
ganglioside (mg) Yield (%) 
d18:1/18:0-GM2·NH3 (20) 306 0.22 36 
d18:1/14:0-GM2·NH3 (21) 300 1.84 77 
d20:1/18:0-GD2·2NH3 (22) 530 0.28 60 
d20:1/14:0-GD2·2NH3 (23) 359 0.25 61 
d18:1-lyso-GM1·NH3 (24) 277 0.41 78 
 
 
The yields of the preparation of GM2 derivatives are in the range of 75-80 %. In 
contrast, the yields of the preparation of GD2 derivatives are in the range of 60 %. 
This is due to a slight desialylation of GD1b, which occurs at the applied pH value of 
4.5. This could be demonstrated by a control experiment, in which the reaction 
conditions described in section 5.5.3 were applied but without enzyme. By TLC 
analysis, it could be demonstrated that GD1b is slightly converted to GM1 (Fig. 
3.4.3). In order to reduce the reaction time for the preparation of GD1b derivatives, 
the concentration of enzyme and detergents were doubled.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ESI-MS of 20, 21, 22 and 24 showed no traces of other ganglioside lipoforms 
than the desired products. The ESI-MS of 23 showed an impurity of 3.2 % of 
d18:1/14:0-GD2·2NH3 as it was observed in the precursor.  
 
Fig. 3.4.3: HPTLC analysis of the control 
experiment for the degalactosylation of 
d20:1/C18:0-GD1b. 
Lane 1: d20:1/18:0-GD1b. 
Lane 2: Reaction mixture after 21 h. 
Lane 3: d20:1/18:0-GM1 
Lane 4: d18:1/18:0-GM2 
Solvent system: CHCl3/MeOH/2.5 M NH3  
60:44:12 v/v/v.  
 GD1b  21 h   GM1   GM2 
Tab. 3.4.1:  Results of the degalactosylation of ganglioside derivatives 
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3.5 Development of a new synthetic method to modify the 
sphingosine chain of gangliosides 
 
3.5.1 Synthesis of a model compound  
It was planned to apply an olefin cross metathesis to peracetylated GM1 for a 
modification of the sphingosine chain. To test the reaction conditions, methyl oleate 
was chosen as a model compound (Fig. 3.5.1). In the first step (E)-stilbene was 
applied in a tenfold excess. Methyl (E)-10-phenyldec-9-enoate (25) was obtained in a 
yield of 84 %. It was analyzed by 1H-NMR, 13C-NMR, and GC-MS. The 1H-NMR did 
not show a triplet of the terminal methyl group in the range of 0.9 ppm, which 
indicates that the product was free of educt. 
 
 
 
For the olefinic protons, a doublet at 6.37 ppm and a doublet of triplets at 6.21 ppm 
were found. The coupling constant was 15.8 Hz, which demonstrates an E-
configuration of the double bond. In the GC-MS chromatogram two peaks with very 
similar retention times were found. The mass spectra proved that these compounds 
had the same mass. It can be concluded that the first compound (proportion 0.75 %) 
is methyl (Z)-10-phenyldec-9-enoate and the second compound (proportion 99.25 %) 
is methyl (E)-10-phenyldec-9-enoate.  
Fig. 3.5.1: Synthesis of methyl (E)-tetradec-9-enoate 
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In the second step, 25 was converted to methyl (E)-tetradec-9-enoate (26) by using 
an tenfold excess of (E)-5-decene under the same reaction conditions. A yield of 
64 % was obtained. The 1H-NMR spectrum showed a triplet at 0.89 ppm and no 
signals of the phenyl group anymore. For the olefinic protons, only a broad triplet was 
found which should be a non-resolved triplet of triplets. The coupling of the olefinic 
protons could not be measured because they are chemically equivalent. GC-MS 
analysis revealed 3 peaks. The mass spectra demonstrated that peak 1 (proportion 
2.91 %) is methyl tridecenoate, peak 2 (proportion 91.54 %) is methyl tetradec-9-
enoate, and peak 3 (proportion 5.55 %) is methyl pentadecenoate. These results 
demonstrated that the method in principle works but isomerization occurs in a 
proportion of 8.5 % if no hydride scavengers are used.  
 
 
3.5.2 Application of the method to d20:1/18:0-GM1 (2) 
In the first step (E)-hexacos-13-ene was synthesized because it is commercially not 
available.  
 
 
Previous attempts for the synthesis of this compound demonstrated that only a 
statistical mixture of isomers of hexacos-13-ene is obtained if no hydride scavenger 
is used. By using 20 mol% of p-benzoquinone an isomeric purity of the synthesized 
product of 98.21 % was obtained. GC-MS analysis revealed four peaks. The mass 
spectra demonstrated that peak 1 (proportion 0.45 %) was tetracosene, peak 2 
(proportion 0.49 %) was pentacosene, peak 3 (proportion 98.21 %) was hexacos-13-
ene, and peak 4 (proportion 0.84 %) was octacosene. The yield was 30 %. The E/Z-
configuration of the product could not be analyzed due to the chemical equivalence 
of the olefinic protons. Since they showed only one signal in the 1H-NMR- and 13C-
Fig. 3.5.2: Synthesis of (E)-hexacos-13-ene 
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NMR spectra, it was concluded that selectively the E-isomer was formed. In a second 
experiment, the purity of the product could be enhanced to 100 % by using 
tetrafluoro-1,4-benzoquinone as hydride scavenger. The yield was 32 %. 
In the next step, d20:1/18:0-GM1 (2) was peracetylated by a modified method of 
Schwarzmann et al (100). Under these reaction conditions the formation of a lactone 
was observed, which is explained by activation of the carboxylic acid to a mixed 
anhydride and subsequent lactone formation to a six-membered ring (Fig. 3.5.3). A 
yield of 62 % was obtained. The product was analyzed by 1H-NMR, ESI-MS, and 
ESI-MS/MS. The peracetylation of GM1 leads to a low field shift of the sugar protons. 
The olefinic proton H-5 was assigned to a doublet of triplets. The E-configuration of 
the product was demonstrated by a coupling constant of 15.1 Hz. The anomeric 
protons of GalNAc, of one Gal residue, and of the Glc residue were assigned. 
Because of their coupling constants, also H-4, H-5, and H-3e of the NeuAc residue 
could be assigned. The singlets of the 51 acetyl protons were found in the range of 
2.0 ppm. For the ceramide part, a multiplet assigned to H-3’, a broad multiplet 
assigned to 54 CH2 protons, and a triplet assigned to the two methyl groups were 
found. In the ESI-MS spectrum only peaks of the product and a methyl ester of the 
product were found. The formation of the methyl ester is explained by opening of the 
lactone ring by methanol, which is used as solvent in the measurement. The 
fragments in the ESI-MS/MS spectra could be correlated to the desired product. The 
observed fragment [Y0 + 2H – stearic acid – H3CCO2H]+ at 292.30 demonstrated the 
composition of the fatty acid part of the product. In the next step, 28 was converted 
by a tenfold excess of stilbene and 14 mol% of Grubbs catalyst 2nd gen. to 29 in a 
yield of 68 %. In the 1H-NMR the signals of the phenyl group were found in the range 
of 7.1 to 7.4 ppm. The olefinic proton H-5 showed a doublet at 6.65 ppm while H-4 
showed a doublet of doublets at 6.09 ppm. The coupling constant was 15.9 Hz 
indicating the E-configuration of the product. The loss of 14 CH2 groups and one 
methyl group was demonstrated by the integral of the broad multiplet at 1.2 ppm and 
of the triplet at 0.86 ppm.  
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In the ESI-MS only peaks of the product and the methyl ester of the product were 
found. In the next step, 29 was converted to 30 by a twentyfold excess of (E)-
hexacos-13-ene (27) under the reaction conditions described in fig. 3.5.3. The yield 
was 61 %. Some attempts were made to optimize the reaction conditions. First, the 
more effective hydride scavengers tetrafluoro-1,4-benzoquinone and 2,6-dichloro-
1,4-benzoquinone were tested. Second, the Stewart-Grubbs catalyst, which contains 
Fig. 3.5.3: Summary of the synthetic steps of the synthesis of d17:1-lyso-GM1 
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N-tolyl groups instead of N-mesityl groups in the N-heterocyclic carbene ligand, was 
tested. This catalyst is reported to be more active in cross metatheses of sterically 
challenging olefines (134).  
 
 
 
 
 
 
 
 
 
 
Catalyst (20 mol%) Hydride Scavenger Conversion (%) 
Hoveyda-Grubbs cat. 2nd gen. p-benzoquinone (40 mol%) 30 
Hoveyda-Grubbs cat. 2nd gen. p-benzoquinone (20 mol%) 60 
Hoveyda-Grubbs cat. 2nd gen. tetrafluoro-1,4-benzoquinone (40 mol%)   < 5   
Hoveyda-Grubbs cat. 2nd gen. tetrafluoro-1,4-benzoquinone (20 mol%)   < 5   
Hoveyda-Grubbs cat. 2nd gen. tetrafluoro-1,4-benzoquinone (1 mol%)   < 5   
Hoveyda-Grubbs cat. 2nd gen. 2,6-dichloro-1,4-benzoquinone (20 mol%)   < 5   
Hoveyda-Grubbs cat. 2nd gen. 2,6-dichloro-1,4-benzoquinone (5 mol%)   < 5   
Hoveyda-Grubbs cat. 2nd gen. 2,6-dichloro-1,4-benzoquinone (1 mol%)   < 5   
Stewart-Grubbs. cat.  p-benzoquinone (20 mol%) 0 
Stewart-Grubbs. cat.  tetrafluoro-1,4-benzoquinone (20 mol%) 0 
Stewart-Grubbs. cat.  2,6-dichloro-1,4-benzoquinone (20 mol%) 0 
 
 
 
 
The results are given in table 3.5.1. Unexpectedly, the more active hydride 
scavengers tetrafluoro-1,4-benzoquinone and 2,6-dichloro-1,4-benzoquinone 
suppressed the catalyst activity even when they were added in low amounts. 
Furthermore, the Stewart-Grubbs catalyst showed no activity towards 29 regardless 
of the hydride scavenger tested. So the most effective reaction conditions are 
20 mol% of Hoveyda-Grubbs cat. 2nd gen. and 20 mol% of p-benzoquinone.  
The 1H-NMR spectrum of 30 was similar to that of 28. The coupling constant of the 
olefinic protons was 15.2 Hz. The loss of 3 CH2 groups was indicated by the integral 
Fig. 3.5.4: Stewart-Grubbs catalyst 
Tab. 3.5.1:  Results for the synthesis of 30 under different reaction conditions. Conversions were 
estimated by TLC analysis after a reaction time of 1 d. 
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of the broad multiplet at 1.25 ppm. The ESI-MS showed only peaks of the desired 
product. In the last step, the protecting groups and also the acyl chain were removed 
from 30 by alkaline hydrolysis to get d17:1-lyso-GM1·NH3 (31). The yield was 34 %. 
The ESI-MS showed that the product contained 4.8 % of d16:1-lyso-GM1, which 
indicates that isomerizations on the second olefin metathesis step could not be 
completely suppressed. Other isomers were not found. This isomer was removed by 
isocratic RP-column chromatography. The ESI-MS/MS confirmed the structure of the 
product. A proportion of 31 was used for the preparation of d17:1-lyso-GM2·NH3 (32) 
by enzymatic degalactosylation. The yield was 69 %. 
 
 
3.5.3 Validation of the lysoganglioside lipoforms as calibrators 
As a proof of principle, the synthesized lysoganglioside standards 31 and 32 were 
tested for the quantification of pure d18:1-lyso-GM1·NH3 (7) and d18:1-lyso-
GM2·NH3 (24) (Fig. 3.5.5). Good linearity of Ian/IIS and can was obtained for both 
compounds in the applied concentration range. As expected, quantification of pure 
substances is possible in the full scan mode but for biological samples MS/MS 
modes have to be applied.          
 
 
 
 
Fig. 3.5.5:  Quantification of pure lyso-GM1·NH3 and lyso-GM2·NH3. A concentration series of 
pure d18:1-lyso-GM1 (7) and d18:1-lyso-GM2 (24) was quantified by using the internal standards 
d17:1-lyso-GM1·NH3 (31) and d17:1-lyso-GM2·NH3 (32). 
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4 Discussion 
 
4.1 Purification of gangliosides 
For the synthesis of non-natural ganglioside lipoforms suitable as MS-standards, we 
chose a partial synthesis rather than a total synthesis (section 2.4.1) because of the 
high effort necessary for the latter. The first part was a chromatographic separation of 
a ganglioside mixture from bovine brain to isolate homologous pure ganglioside 
lipoforms. Conditions for isocratic NP column chromatography were found to obtain 
pure GM1 and GD1a in sufficient amounts from Cronassial®. This was not successful 
for GD1b, GT1b, and GQ1b. By using anion-exchange chromatography, all the 
mentioned ganglioside classes were separated without overlap. Momoi reported that 
NH4OAc in MeOH leads to a better separation than NH4OAc in CHCl3/MeOH/H2O 
30:60:8 v/v/v (110)., but we found them to be equally suitable. The quantities of 
ganglioside classes obtained were mainly in accordance with those reported by 
Zamfir et al. (109). We obtained 27 % of monosialogangliosides and 14 % of 
trisialogangliosides while they reported quantities of 21 % and 19 % of the mentioned 
ganglioside classes. In the next step, the major bovine brain gangliosides and also 
GQ1b were obtained by isocratic or step gradient NP column chromatography. In 
order to modify the fatty acid part (section 2.4.1), gangliosides with homogenous 
sphingoid bases as educts were necessary, which were obtained by RP column 
chromatography of the purified gangliosides. In general, this method worked 
sufficiently for every ganglioside. It was confirmed that bovine brain gangliosides 
mainly contain d18:1/18:0- and d20:1/18:0-lipoforms. In the case of GT1b, also the 
existence of a d20:1/20:0-lipoform was demonstrated by ESI-MS. For other 
gangliosides, it has to be concluded that the corresponding d20:1/20:0 species were 
separated in the NP column chromatography step. We found no indication for the 
presence of N-glycolylneuraminic acid in the title compounds. Usually, the purity of 
gangliosides is analyzed by fluorimetric (135) or photometric (136, 137) sialic acid 
determination, sphingoid base determination by HPLC (138), GC-FID (110) or 
densitometry (139). Initially, we used photometric sialic acid determination with pure 
Neu5Ac or α1-acid glycoprotein as external standards. Since we obtained deviating 
results (section 5.2.12), we concluded that these standards were not appropriate. 
Hence, we decided to use elemental analysis to analyze the purified ganglioside 
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lipoforms and to use these compounds as external standards for the analysis of 
compounds derived from them. The results of the elemental analysis demonstrated 
that there is residual water content of 10-15 % in the gangliosides after lyophilization. 
By drying in vacuum, this can be reduced to 5 % (Tab. 3.1.3).  
 
     
4.2 Preparation of lysogangliosides 
In this work lysogangliosides have been prepared by chemical and enzymatical 
deacylation. The yield of 52 % for the preparation of lyso-GM1 demonstrated that this 
method is regioselective for the deacylation of GM1. But the yield of 4.8 % for the 
preparation of lyso-GD1a demonstrated no regioselectivity for the deacylation of 
GD1a. Additionally, Sonnino et al. reported yields of 36-40 % for the chemical 
deacylation of GM3, which also demonstrates no regioselectivity (127). From these 
three results it can be concluded that the N-Acetyl groups of the NeuAc residue at the 
inner galactose are protected against nucleophilic attacks, but only when the Galß1-
3GalNAcß1-4 residue is present. In this case the N-Acetyl group of the GalNAc 
residue is also protected. It can be assumed that in the deacylation of GA1 also no 
regioselectivity would be observed.   
The enzymatic deacylation of gangliosides turned out to be more appropriate: yields 
were in the range of 44 to 60 % for lyso-GD1a, lyso-GD1b, lyso-GT1b, and lyso-
GQ1b. This is comparable to the results of Ando et al. They prepared lyso-GM1 and 
lyso-GM2 from GM1 and GM2 in order to test the applicability of SCDase. They 
obtained yields of 62 % resp. 52 % for lyso-GM1 and lyso-GM2 (140). 
Oligosialogangliosides were not investigated in their study.  
The prepared d20:1-lyso-GD1b·2NH3 and d20:1-lyso-GT1b·3NH3 contained 3.1 % 
resp. 4.7 % of their d18:1-lipoform, which we decided not to remove by RP column 
chromatography because it does not disturb the mass spectrometric application of 
the standards. These residues must originate from d18:1/20:0-lipoforms, which could 
not be separated by RP-column-chromatography before because they have the same 
chromatographic properties like the d20:1/18:0-lipoforms. The presence of 
d18:1/20:0-lipoforms could not be verified at the ganglioside stage because neither 
RP-TLC nor ESI-MS/MS can differentiate between those isobaric lipoforms. Hereby, 
MS3 of the Z0 fragments could have been a useful method (141) but could not be 
performed with the mass spectrometer available to us. Taken together, enzymatic 
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deacylation using SCDase is a very selective and reliable method for the preparation 
of complex lysogangliosides. The disadvantage of the method are the high costs for 
the enzyme (≈ 820 €/250 mU). A regeneration of the enzyme after the preparation 
has not been described, yet. Fluorimetric sialic acid determination was used for the 
analysis of the lysogangliosides because of its higher sensitivity compared to 
photometric sialic acid determination. The required amount of sialic acid was in the 
range of 2 µg per measurement while photometric sialic acid determination requires 
approximately 20 µg. The deviance of both methods was 0.3 %, which was estimated 
for d18:1-lyso-GD1a·2 NH3 8. The disadvantage of the method is the high price for 
the assay kit. The amount of sialic acid required for photometric sialic acid 
determination was reduced fourfold from 20 µg to 5 µg in this work by using 
Eppendorf tubes and only the minimal volume which is required for photometry 
(section 5.1.9.6). Lysogangliosides can also be analyzed by derivatization with o-
phtalaldehyde, ethanethiol and subsequent HPLC analysis (138). But we were not 
able to reproduce the results reported by Kobayashi et al. Presumably, this was due 
to the lack of an appropriate HPLC-column.     
 
 
4.3 Reacylation of lysogangliosides 
The activation of the fatty acids as succinimide esters was carried out in yields of 
around 70 %. This is comparable to the results of Georgiades et al. who obtained 
2,5-dioxopyrrolidin-1-yl tridecanoate in a yield of 76 % (142). Succinimde esters were 
chosen because they selectively react with amino groups in the presence of hydroxyl 
groups (130). The reacylation of the lysogangliosides was carried out in yields in the 
range of 19 to 86 %. In general, the reaction worked accurate for 
monosialolysogangliosides and disialolysogangliosides giving yields in the range of 
70 to 86 %. This is comparable to the yields of 80 % obtained by Schwarzmann et al. 
for reacylation of lyso-GM1 (104). The yield of 28 % for the reacylation of lyso-GM1 
obtained by us is due to a loss of substance during the chromatographic purification, 
so this value is not optimized. For lyso-GT1b and lyso-GQ1b the yields dropped to 
34 % and 19 %, respectively. This can be explained by the greater number of 
carboxylic acid groups, which hamper the deprotonation of the protonated amino 
group. Additionally, the greater ammonium ion content destroys a greater part of the 
acylating agent. An optimization of the reaction conditions for these substrates 
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should be performed in the future. Additionally, the crude product could be treated 
with methanolic KOH in order to convert putative ester- or anhydride like byproducts 
which could have arisen in this reaction to the desired product, although we could not 
detect any byproducts by TLC during the reaction. 
 
    
4.4 Preparation of ganglioside standards by enzymatic 
degalactosylation 
The commercially available enzyme beta-galactosidase from bovine testes was 
chosen because of its preference in cleaving terminal β-1,3 linked galactose residues 
and its acceptable price (300 €/500 mU). For the degradation of GM1 to GM2, a yield 
of 77 % was obtained under optimized reaction conditions, which is higher than the 
yield of 54 % obtained by Larsson et al (112). For the degradation of lyso-GM1 
derivatives, comparable yields of 69 % resp. 78 % were obtained. The method is also 
applicable to GD1b derivatives although we observed a slight degradation to GM1 
due to the applied pH-value. Hereby, sufficient yields in the range of 60 % were 
obtained. As far as we know this method has not been applied to lyso-GM1- and 
GD1b derivatives in the literature.      
 
 
4.5 Modification of the sphingosine chain of gangliosides 
The preparation of the required starting materials for the regioselective deacylation of 
gangliosides which are homologous in their sphingosine parts requires tedious 
chromatographic steps. As an alternative, we developed a synthetic method for the 
preparation of gangliosides with homogenous (and, if required, artificial) sphingoid 
bases. An ozonolysis followed by Wittig reaction is a problematic concept because of 
isomerizations of the allyl alcohol, alkaline fragmentation, and the need for separation 
of E/Z-mixtures. The Schlosser modification is less helpful because the alkaline 
conditions required are incompatible with hydroxyl groups and carboxylic acid groups 
(143).  
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Hence, the olefin metathesis seems to be a suitable reaction for this purpose 
because it is performed under neutral conditions and tolerates hard nucleophils. 
Ethenolysis has only been carried out for Z-olefins in sufficient yields therefore we 
investigated a stilbenolysis. As a model compound methyl (E)-tetradec-9-enoate 26 
was synthesized from methyl oleate in two steps in a total yield of 54 %. By GC-MS, 
it was proven that the stilbenolysis step is not prone to isomerizations. However, in 
the exchange of the phenyl group for a pentyl group in the second step 
isomerizations in a proportion of 8.5 % occurred. So we decided to use p-
benzoquinone derivatives as hydride scavengers.  
First, (E)-hexacos-13-ene was synthesized in a yield of 32 %. p-Benzoquinone turned 
out to be a sufficient hydride scavenger because isomerizations occurred only in a 
proportion of 1.8 %. A complete suppression of isomerizations was achieved by using 
tetrafluoro-1,4-benzoquinone. Then, d20:1/18:0-GM1·NH3 was peracetylated in a 
yield of 62 %, which is slightly less than the yield of 72 % obtained by Schwarzmann 
et al. for the peracetylation of ll3-α-NeuAcGg4 (100). In the future, it should be tested 
if an extension of the reaction time increases the yield because as a side product 
incompletely peracetylated d20:1/C18:0-GM1 sialoyl-ll2-lactone lacking only one 
acetyl group was obtained. In the next step, a phenyl group was introduced into the 
sphingosine part by an olefin metathesis in a sufficient yield of 68 %. Isomerizations 
were not observed. The exchange of the phenyl group for a dodecyl group by an 
excess of (E)-hexacos-13-ene was performed in a sufficient yield of 61 %. Hereby, a 
larger amount of catalyst was required. An improvement of the reactions conditions 
by using more efficient hydride scavengers or the Stewart-Grubbs catalyst, which is 
reported to be more active towards sterically hindered olefins, was not successful. 
Electron deficient benzoquinone derivatives suppress the catalytic activity of the 
Hoveyda-Grubbs catalyst 2nd gen. even when they are added in low amounts. The 
Stewart-Grubbs catalyst shows no activity towards 29 regardless of the hydride 
scavenger. This is a surprising result because the catalyst is reported to be more 
active in the cross metathesis of sterically hindered olefins than the Hoveyda-Grubbs 
catalyst 2nd gen. It can be explained by the preference of an unproductive pathway 
during the metallacyclobutane formation (Fig. 4.5.1). But this pathway is usually only 
preferred in the cross metathesis of 1,1-disubstituted olefins.  
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In the next step, the protective groups and also the acyl group were removed by 
alkaline hydrolysis in a yield of 34 % (105). This result is slightly less than the yield of 
52 % which was obtained by us for the chemical preparation of d18:1-lyso-GM1. So 
the total yield for the synthesis of d17:1-lyso-GM1 is 8.7 %. If the yield for the 
removal of the acetyl groups is estimated to be 90 %, the total yield for the synthesis 
of d17:1/18:0-GM1 from d20:1/18:0-GM1 would be 23 %. In comparison, the method 
of Neuenhofer et al. has a total yield of 29 % for the synthesis of, for example, 
d18:1/17:0-GM1 from d18:1/18:0-GM1 (104, 106). The enzymatic preparation has the 
highest overall yield of approx. 42 % for the same product (Fig. 4.5.2). The 
disadvantage of this method is the high price of SCDase. But in contrast to our 
method, the other methods require homologous pure gangliosides as starting 
materials.  
The position of the unnatural alkyl chain in the fatty acid part or the sphingosine part 
should not influence the mass spectrometric quantification because usually the 
transition [Ganglioside – H]-/[Neu5Ac – H]- is monitored if MRM is used. The reason 
is that these peaks usually show the greatest intensities (69, 144). If neutral loss scan 
is used, the loss of sialic acid would be monitored and if parent ion scan is used, the 
Fig. 4.5.1: Productive and unproductive pathways in olefin cross 
metathesis (134). 
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parent ions of [Neu5Ac – H]- would be scanned because these transitions show the 
greatest intensities.  
                                                                                                                                                                                                             
 
 
 
 
 
During the second olefin metathesis step isomerizations occurred in a proportion of 
4.8 %. This result demonstrates that p-benzoquinone cannot suppress isomerizations 
completely but to an extent of greater than 90 %.  
The method developed by us has a wide scope: First, it should be applicable not only 
to gangliosides, but also to other sphingolipids and glycosphingolipids like ceramides, 
neutral glycosphingolipids, sphingomyelins, and sulfatides. Second, isotope labeling 
of the sphingosine part can also be achieved because the phenyl group facilitates the 
chromatographic separation of educts and products. Third, the method might be used 
to incorporate fluorescent dyes into the sphingosine part of sphingolipids. In the 
Fig. 4.5.2: Comparison of the published methods for the synthesis of 
ganglioside standards to the new method developed in this work. 
Left: Method of Neuenhofer et al. Center: Enzymatic method. Right: Olefin 
metathesis method. 
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literature, the introduction of fluorescent dyes into the sphingosine part by an olefin 
metathesis was only applied to sphingosines and ceramides yet. In 2005, 
Nussbaumer et al. (145) inserted the fluorescent dye NBD (7-nitro-2,1,3-
benzooxadiazol-4-yl) in the sphingosine part of commercially available ceramide in 
yields of 14 to 71 %.   
 
 
It would be difficult to apply this method to the introduction of non-functionalized alkyl 
chains because the products would not be easily separable from the educts. In the 
recent years, an olefin metathesis method has been used for the total synthesis of 
fluorescence labeled sphingosines and ceramides. It starts from commercially 
available Garner aldehyde (146). In the first step, Garner aldehyde is converted to 
anti-Garner allylic alcohol by addition of vinyl lithium (147). Then, various olefinic 
groups can be inserted by an olefin cross metathesis. After deprotection, 
fluorescence labeled sphingosine is obtained.   
 
  
 
Peters et al. used this method for the synthesis of NBD- and BODIPY 
(borondipyrromethene, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene)-labeled sphingo-
sines (146). Fluorescent labeled sphingosines and ceramides are typically used to 
study uptake, metabolism, intracellular transport, and distribution of sphingolipids in 
Fig. 4.5.3: Partial synthesis of fluorescence labeled ceramide by using an olefin 
cross metathesis (145) 
Fig. 4.5.4: Synthesis of fluorescence labeled ceramide starting from Garner 
aldehyde. 
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cells. In 1992, Schwarzmann et al. used DPH-sphingosine (diphenyl-1,3,5-
hexatrienyl) to investigate the metabolism of this lipid in human fibroblasts (148). 
 
 
 
 
 
 
 
 
DHP-sphingosine was synthesized in a convergent synthesis starting from 
cinnamaldehyde and 2,4-O-benzylidene-D-threose.  
The method of Peters et al. was used in 2011 by Bhabak et al. for the synthesis of 
Sph-NR-Cer (Nile Red) and Sph-NBD-Cer in order to compare their suitability as 
substrates for neutral and acid ceramidase to common Acyl-NR-Cer and Acyl-NBD-
Cer. Unexpectedly, it was found that the more hydrophilic NBD-tagged ceramides 
shows in general a higher cleavage rate than the NR-tagged ceramides (149).  
Up to now, fluorescence labeled gangliosides have been prepared by modification of 
the fatty acid part, for instance, by acylation with 12-(pyren-1-yl)dodecanoic acid 
(104), 6-Tetramethylrhodamine-(β-alanine)-amide (112), or 2-NBD-stearic acid (101). 
Our method enables the possibility of synthesizing double fluorescence labeled 
gangliosides with one label in the sphingosine part and another in the fatty acid part 
as FRET (Förster resonance energy transfer) probes. This concept has been realized 
only for ceramides by Arenz et al (150), yet. In addition, our method provides access 
to pure ganglioside lipoforms that allow functional studies in vitro. 
 
 
 
 
 
 
 
 
 
Fig. 4.5.5: DHP-sphingosine 
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5 Experimental Part 
 
5.1 Materials and methods 
 
5.1.1 Devices 
 
Device  Model, manufacturer and 
place of business 
 
Centrifuges  Rotina 48 R, Hettich, Mühlheim a. d. 
Ruhr, Ger;                               
MiniSpin, Eppendorf, Hamburg, Ger 
Densitometer  TLC Scanner 3, CAMAG, Muttenz, Sui 
Evaporator Reacti-Varp lll, Pierce/Perbio Science, 
Rockford, IL, USA 
Fraction collector Microcol TDC 80, Gilson Medical 
Electronics, Villiers-le-Bel, France 
Heating and stirring module   Reacti-Therm lll, Pierce/Perbio 
Science, Rockford, IL, USA 
Horizontal developing TLC-chamber Camag, Berlin, Ger 
HPLC-System CMB-101 with LC-10AT VP pump and 
RF-10AXL detector Shimadzu, Kyoto, 
Jpn; Model AS-100 HPLC automatic 
sampling system, Bio-Rad, Berkeley, 
USA   
LC pump  Latek-P 402, Latek Labortechnik 
Geräte GmbH &  Co. Analysensys-
teme KG, Eppelheim, Ger 
Micropipettes   Eppendorf Research®, Eppendorf, 
Hamburg, Ger 
Microplate Fluorometer  Fluoroscan ll, Labsystems Oy, 
Helsinki, Fin 
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Nano-ESI-QTOF mass spectrometer QTOF-2 hybrid quadrupole mass 
spectrometer with nanoflow-interface, 
Micromass, Manchester, UK 
pH meter       pH 537, WTW, Weilheim, Ger 
Photometer  Ultrospec III, Pharmacia Biotech, 
Uppsala, Swe 
Shaking water bath  1083, Gesellschaft für Labortechnik, 
Burgwedel, Ger 
Thermomixer     Comfort, Eppendorf, Hamburg, Ger 
TLC plate heater  TLC plate heater lll, CAMAG, Muttenz, 
Sui 
Ultrapure water system  EASYpure UV/UF D8612, Werner 
Reinstwassersysteme, Leverkusen, 
Ger 
Ultrasonic bath      Sonorex RK 100, Bandelin, Berlin, Ger 
Ultrasonic device      Sonifier 250, Branson, Danbury, USA 
UV lamp MinUVis, Desaga, Heidelber, Ger 
Vacuum pump  Rotary vane pump RZ 6, Vacuum-
Brand GmbH & Co. KG, Wertheim, 
Ger 
Vortexer  Vibrofix VF1 electronic, Janke & 
Kunkel IKA-Werk, Staufen, Ger  
Weighing instruments   BP 210 D, Sartorius, Göttingen, Ger;                         
Explorer, Ohaus, Gießen, Ger 
  
 
 
5.1.2 Chemicals 
All chemicals were – unless otherwise indicated – of highest purity available. Water 
used for buffers and solutions was purified by an ultrapure water system. Reactions 
using oxygen- and moisture sensitive reagents were handled by standard Schlenk 
techniques. The native mixture of bovine brain gangliosides Cronassial® was 
available in our lab. Sphingolipid ceramide N-deacylase (SCDase) and beta-
galactosidase from bovine testes were from Sigma Aldrich (Schnelldorf, Ger). 
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Triton™ X-100, sodium taurodeoxycholate, Grubbs catalyst 2nd gen., Hoveyda-
Grubbs cat. 2nd gen., and Stewart-Grubbs catalyst were also from Sigma Aldrich.     
For anion-exchange chromatography, DEAE Sephadex™ A-25 from Amersham 
Pharmacia Biotech AB (Uppsala, Swe) was used.  
 
 
5.1.3 Anhydrous solvents 
Solvents used in reactions of oxygen- and moisture sensitive compounds were in 
anhydrous form. 1-Propanol, methanol, pyridine, and acetic anhydride were 
degassed before use.  
 
 
5.1.4 NP-column chromatography  
For NP-column chromatography, silica gel from Merck (Darmstadt, Ger) (0.040-0.063 
mm or 0.015-0.040 mm) was used.  
 
 
5.1.5 Preparative TLC 
For preparative TLC, Kieselgel 60 plates (10 × 10 cm or 20 × 20 cm) manufactured 
by Merck were used. After developing, bands were made temporarily visible by 
spraying with MeOH/H2O 90:50 v/v. Bands of interest were scraped out with a 
spatula. The scraped out silica gel was collected in a frit and extracted. After 
evaporation of the solvent, residues of silica gel were removed by the method 
described in section 5.1.8.   
 
 
5.1.6 Desalting 
For RP-column chromatography and desalting, filtration columns from Supelco 
(Bellefonte, USA) were used. The stationary phase was LiChroprep RP-18 (0.040-
0.063 mm) from Merck. For desalting, a slightly modified method of Wiliams and 
McCluer was used (151). The LiChroprep RP-18 powder was suspended in MeOH 
and left for 5 h. The supernatant was decanted and the procedure was repeated with 
CHCl3/MeOH 1:1 v/v, then with CHCl3/MeOH 2:1 v/v, and again with MeOH. The 
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suspension was introduced into a filtration column. The column was washed with 3 
column volumes (CVs) of MeOH, 3 CVs of CHCl3/MeOH 1:1 v/v, 2 CVs of MeOH, 2 
CVs of H2O, and 2 CVs of theoretical upper phase (TUP), which is CHCl3/MeOH/0.1 
M aq. KCl 3:48:47 v/v/v (151). Gangliosides were dissolved in TUP in a concentration 
of approx. 1 mg/mL and applied to the column. Then, the column was washed with 6 
CVs of water to remove salts. Afterwards, gangliosides were eluted by MeOH.   
 
 
5.1.7 RP-column chromatography 
Columns were prepared in the same way like for desalting. Gangliosides were 
dissolved in TUP and applied to the column. Then, the column was washed with 
6 CVs of H2O to remove salts. In contrast, lysogangliosides were dissolved and 
applied in water. Subsequently, the substances were separated isocratically by the 
eluent MeOH/H2O in different compositions. 
 
 
5.1.8 Removal of column material 
If polar eluents are used in column chromatography, the purified substances contain 
significant amounts of column material. The following method was used to minimize 
the amount of column material. NP columns of a very small column volume were 
prepared in filtration columns from Supelco using a mobile phase in which the 
substance is retained. The substance was applied to the column and washed with 
three column volumes. Then, the substance is eluted by an appropriate solvent of 
higher polarity.     
 
 
5.1.9 Analytical methods 
 
5.1.9.1 TLC 
For thin layer chromatography, HPTLC Kieselgel 60 F254- and HPTLC Kieselgel 60 
RP-18 plates (10 × 5 cm, 10 × 10 cm, 20 × 10 cm or 20 × 20 cm) manufactured by 
Merck were used. NP-HPTLC plates were developed either by dipping in copper 
sulfate reagent (10 % CuSO4·5H2O in 8 % aq. H3PO4) (152) and subsequent heating 
to 190 °C for a few minutes or by dipping in Kägi-Miescher reagent (EtOH/conc. 
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H2SO4/4-anisaldehyde 18:1:1 v/v/v) (153) and subsequent heating to 136 °C for a 
few minutes. RP-HPTLC plates were developed with Kägi-Miescher reagent in the 
same way.   
 
5.1.9.2 NMR-spectroscopy 
For 1H- and 13C-NMR-spectroscopy, Bruker Avance 300, 400, or 500 instruments 
(Billerica, USA) were used. Chemical shifts were indicated in parts per million (ppm) 
and coupling constants (J) were indicated in Hertz (Hz). Spin multiplicities were 
abbreviated as follows: s: singlet, d: doublet, t: triplet, ps-t: pseudo-triplet, dd: doublet 
of doublets, dt: doublet of triplets, m: multiplet, etc. In order to exchange 
exchangeable protons by deuterium, analytes were dissolved in CD3OD and the 
solvent was removed in a nitrogen stream. This process was repeated three times 
before measurement.   
 
5.1.9.3 Mass spectrometry 
For EI-MS, a MAT 95 XL sector field instrument (Thermo Finnigan MAT GmbH, 
Bremen, Ger) or a MAT 90 sector field instrument (Thermo Finnigan MAT GmbH) 
were used. For ESI-MS and ESI-MS/MS, a nano-ESI-QTOF mass spectrometer 
(Micromass, Manchester, UK) was used. In general, the positive ion mode was used 
because it showed a higher sensitivity towards gangliosides than the negative ion 
mode. For interpretation of the ESI-MS/MS spectra, the nomenclature for 
carbohydrate fragments by Domon et al. was applied (154). The major part of 
fragments in the CID of gangliosides results from heterolytic cleavage of glycosidic- 
and interglycosidic bonds. If a glycosidic bond is cleaved, the fragments are termed 
Bi and Yj. If an interglycosidic bond is cleaved, the fragments are termed Ci and Zj. B 
and C fragments contain a reducing end and Y and Z fragments contain a non-
reducing end. The subscripts i and j indicate the bond which was cleaved, counting 
for B and C fragments from the non-reducing end and for Z and Y fragments from the 
aglycon bond, which is termed 0. If a sugar ring is fragmented, the fragments are 
termed k,lAi and k,lXj. The superscripts k and l indicate the two bonds of the sugar 
which were cleaved. The A fragment contains a non-reducing end while the X 
fragment contain a reducing end. If a glycoconjugate is branched, the “antennas” are 
described by subscripted Greek letters, where α indicates the antenna with the 
largest molecular weight, β indicates the antenna with the second largest molecular 
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weight, etc. If second generation fragmentation occurs, the resulting fragment is 
indicated by the first-order fragment, a slash, and the fragment which was lost by 
second order cleavage (109), for example Y2α/B1β.  
 
 
 
 
5.1.9.4 GC-MS 
For GC-MS, a GCMS-QP2010 Ultra (Shimadzu, Kyoto, Jpn) was used. It was 
equipped with a ZB-5MSi column (l = 30 m, Ø = 0.25 mm, df (film thickness) = 
0.25 µm) containing a 5 % phenyl and 95 % dimethylpolysiloxane stationary phase.  
 
5.1.9.5 CHN-microanalysis 
For CHN-microanalysis, a vario EL cube (Elementar Analysensysteme GmbH, 
Hanau, Ger) was used. 
 
5.1.9.6 Photometric sialic acid determination 
In general, ganglioside yields were calculated by weighing, dissolving in a defined 
volume of methanol and subsequent sialic acid determination.  
Photometric sialic acid determination was performed by the resorcinol method by 
Svennerholm et al. (137) modified by Miettinen et al (136). All standards and analytes 
were measured in duplicate. Standard curves were measured by five different 
concentrations of sialic acid (0 µg/mL, 2.5 µg/mL, 5.0 µg/mL, 10 µg/mL, 15 µg/mL, 
and 20 µg/mL). Resorcinol reagent was prepared by adding 20 mL of an aq. 
Fig. 5.1.1:  Nomenclature of ganglioside ESI-MS/MS 
fragments presented for d18:1/18:0-GD1a  
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10 mg/mL resorcinol solution to 80 mL of 37 % aq. HCl and 0.25 mL of an aq. 
25 mg/mL CuSO4·5 H2O solution. 250 µL of a sample containing 1 to 10 µg of sialic 
acid were applied to an Eppendorf tube. 250 µL of resorcinol reagent were added, 
the tube was vortexed, and heated for 20 min at 100 °C. The mixture was cooled on 
a water/ice bath and 500 µL of n-butyl acetate/n-butanol 85:15 v/v were added. After 
vortexing, 370 µL of the upper phase were measured photometrically at 580 nm.  
 
5.1.9.7 Fluorimetric sialic acid determination 
The sialic acid assay kit EnzyChrom™ ESLA-100 of BioAssay Systems (Hayward, 
USA) was used. All standards and analytes were measured in duplicate. Standard 
curves were measured by five different concentrations of sialic acid (0 mM, 0.02 mM, 
0.04 mM, 0.06 mM, 0.08 mM, and 0.1 mM). 20 µL of a sample containing a sialic acid 
concentration of 0.06-0.6 mM were mixed with 80 µL of hydrolysis reagent and 
incubated at 80 °C for 60 min. The mixture was cooled to RT and 20 µL of 
neutralization reagent were added. After vortexing, 10 µL of each standard and each 
sample were applied to black 96-well-plate and 90 µL of working reagent were 
added. Working reagent contains NANA-aldolase activity, pyruvate oxidase activity to 
produce hydrogen peroxide, p-chlorophenol, and 4-aminoantipyrine (135). After 
incubation at RT for 60 min, the fluorescence was read at λex = 544 nm and λem = 
590 nm. 
 
5.1.9.8 Densitometry 
For densitometry, HPTLC Kieselgel 60 plates (10x10 cm) manufactured by Merck 
were used. After development with Kägi-Miescher reagent, the TLC plates were 
densitometrically scanned at a wavelength of 595 nm. For densitometric 
quantification, the analyte was applied to one lane. A calibration curve was obtained 
by applying 1 µg, 3 µg, and 5 µg of standard to three other lanes. The analyte mass 
was plotted against the absorption in order to simplify the evaluation. The data were 
polynomial evaluated and the analyte concentration was calculated from the 
regression curve. 
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5.2 Purification of gangliosides 
 
5.2.1 Separation of Cronassial© by NP column chromatography 
 
Experimental procedure: 
1.02 g of Cronassial® were separated by NP column chromatography on silica gel 
(Merck-silica gel 60/40-63 µm, 3.0 × 52 cm, isocratic, eluent: CHCl3/MeOH/0.2 % 
CaCl2 60:35:8 v/v/v). By this, fractions of pure GM1 and GD1a were obtained. After 
desalting, evaporation, and drying in vacuum GM1 (135 mg) and GD1a (246 mg) 
were obtained as colorless solids.   
 
 
Analytics: 
The analytics of GM1 are described in section 5.2.3. The analytics of GD1a are 
described in section 5.2.4. 
 
 
5.2.2 Separation of Cronassial® by anion-exchange chromatography 
 
Experimental procedure: 
15 g of DEAE Sephadex® A-25 were suspended in 150 mL of CHCl3/MeOH/0.8 M 
NaOAc 30:60:8 v/v/v, left for 30 min and decanted. The procedure was repeated 4 
times and the anion-exchanger was left in the same solvent overnight. Afterwards, it 
was washed four times with 150 mL of CHCl3/MeOH/H2O 30:60:8 v/v/v and 
introduced into a column (2.2 × 22.2 cm). Then, 5.03 g of Cronassial were dissolved 
in 400 mL of the same solvent and applied to the column (v ≤ 1 mL/min). The column 
was washed with CHCl3/MeOH/H2O 30:60:8 v/v/v until all not adsorbed gangliosides 
were eluted. Then, a step gradient of different NH4OAc-concentrations in MeOH was 
used to elute the different ganglioside classes. Subsequently, each ganglioside class 
was desalted. After evaporation and drying in vacuum, the ganglioside classes were 
obtained as colorless solids in amounts ranging from 41.5 mg to 2.80 g (Tab. 5.2.1).  
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The procedure was repeated one time under slightly modified conditions in order to 
obtain more GQ1b. DEAE-sephadex was swollen in water. Then it was introduced 
into a column and washed by 30 column volumes 1 M aq. NaOAc. The eluate 
showed no Cl- content in an AgCl precipitation test. The column material was 
suspended in CHCl3/MeOH/H2O 30:60:8 v/v/v and introduced into a column (Ø = 2.2 
cm, h = 37.5 cm). Then, 10.0 g of Cronassial were applied. The procedure was the 
same like described above. This time a step gradient of different NH4OAc-
concentrations in CHCl3/MeOH/H2O 30:60:8 v/v/v was used. Monosialogangliosides 
were obtained at c (NH4OAc) = 0.02 mol/L, disialogangliosides at c (NH4OAc) = 0.04 
mol/L, trisialogangliosides at c (NH4OAc) = 0.05 mol/L, and GQ1b at c (NH4OAc) = 
0.08 mol/L. Yields were not estimated for this elution system because the only 
purpose of this experiment was to obtain more GQ1b.
 
 
 
Analytics: 
 
HPTLC: 
 
 
 
 
 
 
 
 
 
 
 
Ganglioside class c(NH4OAc) (mol/L) Amount (g) 
Monosialogangliosides 0.05 1.28 
Disialogangliosides 0.15 2.80 
Trisialogangliosides 0.15 0.674 
Tetrasialogangliosides 0.45 0.0415 
Fig. 5.2.1: NP HPTLC of the 
isolated ganglioside classes. 
Solvent system: 
CHCl3/MeOH/0.2 % CaCl2 
50:42:11 v/v/v.  
      Cronas-   Monosia- Disialo-     Trisialo-   Tetrasia- 
        sial®        logangl.   gangl.     gangl.      logangl. 
GM1    → 
GD1a   → 
GD1b   → 
GT1b   → 
GQ1b  → 
Tab. 5.2.1:  Results of the anion-exchange chromatography of Cronassial® 
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5.2.3 Separation of monosialogangliosides 
 
Experimental procedure: 
1.28 g of monosialogangliosides were separated by NP chromatography on silica gel 
(Merck-silica gel 60/15-40 µm, 3.5 × 25 cm, isocratic, eluent: CHCl3/MeOH/0.2 % 
CaCl2 60:35:8 v/v/v). After desalting, GM1 was obtained as a colorless solid 
(300 mg).   
 
 
Analytics: 
 
Ganglioside Molecular Formula Molecular Weight (g/mol) 
Rf (RP TLC,  MeOH/ 
H2O 90:9 v/v) 
d18:1/18:0-GM1  C73H131N3O31  1546.84  0.24 
d20:1/18:0-GM1  C75H135N3O31  1574.90  0.18 
 
 
MS (ESI, pos. Mode, MeOH, M1 = 1545.88, M2 = 1573.91): m/z (%) = 1591.91 (1.5) 
[M2 + NH4]+, 1577.90 (1.1) [M1 + M2 + 2NH4]2+, 1574.86 (0.50) [M2 + H]+, 1057.95 
(2.0) [M1 + M2 + 3NH4]3+, 815.45 (7.6) [M2 + K + NH4]2+, 807.46 (15) [M2 + Na + 
NH4]2+, 798.96 (7.0) [M2 + Na + H]2+, 804.98 (100) [M2 + 2NH4]2+, 796.46 (49) [M2 + 
NH4 + H]2+, 787.95 (11) [M2 + 2H]2+, 1584.88 (0.46) [M1 + K]+, 1563.88 (1.2) [M1 + 
NH4]+, 801.43 (6.7) [M1 + K + NH4]+, 793.44 (13) [M1 + Na + NH4]2+, 784.94 (3.6) [M1 
+ Na + H]2+, 790.96 (87) [M1 + 2NH4]2+, 782.45 (41) [M1 + NH4 + H]2+, 773.94 (10) [M1 
+ 2H]2+. 
 
MS/MS (m/z = 804.98): m/z (%) = 1265.79 (3.4) [Z2β]+, 1191.76 (14) [Z2α]+, 1103.72 
(7.3) [Z2β/B1α + H]+, 900.67 (25) [Z2β/B2α + H]+, 804.89 (3.5) [M2 + 2NH4]2+, 738.61 
(32) [Z1]+, 594.57 (6.0) [Y0 + 2H]+, 576.56 (65) [Z0]+, 558.55 (14) [Z0 – H2O]+,  366.14 
(100) [B2α]+, 292.29 (36) [B1β]+, 274.08 (48) [B1β – H2O]+, 204.06 (93) [B2α/B1α + H]+, 
186.04 (35) [B2α/B1α + H – H2O]+.          
 
MS/MS (m/z = 790.96): m/z (%) = 1237.74 (2.8) [Z2β]+, 1163.70 (10) [Z2α]+, 1075.71 
(9.5) [Z2β/B1α + H]+, 872.63 (30) [Z2β/B2α + H]+, 710.59 (32) [Z1]+, 566.54 (2.8) [Y0 + 
2H]+, 548.53 (70) [Z0]+, 530.52 (17) [Z0 – H2O]+, 366.14 (100) [B2α]+, 292.09 (20) 
Tab. 5.2.2: Physical properties of GM1 
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[B1β]+, 274.08 (53) [B1β – H2O]+, 204.06 (100) [B2α/B1α + H]+, 186.04 (36) [B2α/B1α + H 
– H2O]+.          
 
 
5.2.4 Separation of disialogangliosides 
 
Experimental procedure: 
1.00 g of disialogangliosides were separated by NP column chromatography on silica 
gel (Merck-silica gel 60/40-63 µm, 2.5 × 21.0 cm, step gradient). The gangliosides 
were applied to the column in CHCl3/MeOH/2.5 M NH3 60:35:4 v/v/v. GD1a was 
eluted by CHCl3/MeOH/2.5 M NH3 60:35:6 v/v/v while GD1b was eluted by 
CHCl3/MeOH/2.5 M NH3 60:35:8 v/v/v. After evaporation and drying in vacuum, the 
disialogangliosides were obtained as colorless solids (GD1a: 472 mg, GD1b: 
158 mg). 
 
 
Analytics: 
 
 
 
MS (ESI, pos. Mode, MeOH, M1 = 1836.97, M2 = 1865.00): m/z (%) = 1882.81 (0.53) 
[M2 + NH4]+, 1866.93 (0.60) [M2 + H]+, 971.46 (7.3) [M2 + 2K]2+, 963.48 (14) [M2 + K + 
Na]2+, 961.00 (21) [M2 + K + NH4]2+, 953.00 (30) [M2 + Na + NH4]2+, 950.53 (100) [M2 
+ 2NH4]2+, 942.01 (33) [M2 + NH4 + H]2+, 933.50 (23) [M2 + 2H]2+, 946.98 (12) [M1 + K 
+ NH4]2+, 936.52 (62) [M1 + 2NH4]2+, 928.00 (21) [M1 + NH4 + H]2+, 919.49 (16) [M1 + 
2H]2+. 
 
MS/MS (m/z = 950.53): m/z (%) = 1866.98 (7.1) [M2 + H]+, 1394.83 (5.5) [Z3α]+, 
1191.77 (13) [Z2α]+, 1103.76 (4.3) [Z3α/B1β + H]+, 950.45 (5.6) [M + 2NH4]2+, 900.67 
Ganglioside Molecular Formula 
Molecular 
Weight (g/mol) 
Rf (RP TLC, MeOH/ 
H2O 90:10 v/v) 
d18:1/18:0-GD1a·2NH3  C84H154N6O39  1872.16  0.32 
d20:1/18:0-GD1a·2NH3  C86H158N6O39  1900.21  0.23 
d18:1/18:0-GD1b·2NH3  C84H154N6O39  1872.16  0.19 
d20:1/18:0-GD1b·2NH3  C86H158N6O39  1900.21  0.13 
Tab. 5.2.3: Physical properties of GD1a and GD1b. The ammonium salts resulted from the 
last purification step in which an ammonia containing eluent was used. 
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(13) [Z2α/B1β + H]+, 756.63 (8.8) [Y1 + 2H]+, 738.62 (31) [Z1]+, 657.23 (63) [B3α]+, 
594.59 (8.3) [Y0 + 2H]+, 576.57 (62) [Z0]+, 558.57 (8.4) [Z0 – H2O]+, 454.15 (13) [B2α]+, 
366.14 (30) [B3α/B1α + H]+, 292.09 (100) [B1α o. B1β]+, 274.08 (92) [B1α o. B1β – H2O]+, 
204.06 (55) [B3α/B2α + H]+, 186.04 (7.4) [B3α/B2α + H – H2O]+. 
 
MS/MS (m/z = 936.52): m/z (%) = 1866.98 (12) [M2 + H]+, 1366.86 (6.1) [Z3α]+, 
1181.73 (6.1) [Y2α + 2H]+, 1163.74 (19) [Z2α]+, 1075.71 (4.4) [Z3α/B1β + H]+, 872.64 
(13) [Z2α/B1β + H]+, 728.60 (13) [Y1 + 2H]+, 710.59 (31) [Z1]+, 657.23 (76) [B3α]+, 
566.57 (9.0) [Y0 + 2H]+, 548.54 (53) [Z0]+, 454.15 (18) [B2α]+, 366.14 (30) [B3α/B1α + 
H]+, 292.10 (100) [B1α o. B1β]+, 274.08 (98) [B1α o. B1β – H2O]+, 204.06 (47) [B3α/B2α + 
H]+, 186.05 (5.8) [B3α/B2α + H – H2O]+. 
 
MS (ESI, pos. Mode, MeOH, M1 = 1836.97, M2 = 1865.00): m/z (%) = 1882.87 (2.2) 
[M2 + NH4]+, 1866.90 (2.9) [M2 + H]+, 963.46 (4.0) [M2 + K + Na]2+, 960.99 (5.2) [M2 + 
K + NH4]2+, 955.48 (5.0) [M2 + 2Na]2+, 952.99 (13) [M2 + Na + NH4]2+, 944.49 (19) [M2 
+ Na + H]2+, 950.51 (27) [M2 + 2NH4]2+, 942.00 (72) [M2 + NH4 + H]2+, 933.49 (100) 
[M2 + 2H]2+, 930.47 (12) [M1 + Na + H]2+, 936.51 (17) [M1 + 2NH4]2+, 927.99 (43) [M1 
+ NH4 + H]2+, 919.48 (62) [M1 + 2H]2+. 
 
MS/MS (m/z = 933.49): m/z (%) = 1866.98 (2.4) [M2 + H]+, 1265.80 (3.5) [Z2α]+, 
1191.77 (6.3) [Z2β/B1α + H]+, 1103.75 (6.9) [Z3β/B2α + H]+, 900.67 (16) [Z2β/B2α + H]+, 
738.62 (19) [Z1]+, 576.56 (53) [Z0]+, 558.56 (12) [Z0 – H2O]+, 454.15 (3,6) [Z2β/B1α/Z1 + 
2H]+, 366.14 (92) [B2β]+, 292.09 (58) [B1α]+, 274.08 (100) [B1α – H2O]+, 204.06 (67) 
[B1β/B1β + H]+, 186.04 (23) [B1β/B1β + H – H2O]+. 
 
MS/MS (m/z = 919.48): m/z (%) = 1866.98 (3.0) [M2 + H]+, 1366.80 (3.2) [Z3β/B1α + 
H]+, 1237.77 (5.2) [Z2α]+, 1163.74 (8.6) [Z2β/B1α + H]+, 1075.72 (8.0) [Z3β/B2α + H]+, 
872.63 (16) [Z2β/B2α + H]+, 728.59 (3.1) [Y1 + 2H]+, 710.59 (17) [Z1]+, 566.55 (4.5) [Y0 
+ 2H]+, 548.54 (40) [Z0]+, 530.53 (6.7) [Z0 – H2O]+, 454.15 (4.5) [Z2β/B1α/Z1 + 2H]+, 
366.14 (100) [B2β]+, 292.09 (67) [B1α]+, 274.08 (80) [B1α – H2O]+, 204.06 (44) [B1β/B1β 
+ H]+, 186.04 (12) [B1β/B1β + H – H2O]+. 
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5.2.5 Separation of trisialogangliosides 
 
Experimental procedure: 
0.674 g of trisialogangliosides were separated by NP column chromatography on 
silica gel (Merck-silica gel 60/40-63 µm, 3.5 × 53 cm, isocratic, eluent: 
CHCl3/MeOH/H2O 50:42:11 v/v/v). After evaporation and drying in vacuum, GT1b 
was obtained as a colorless solid (382 mg).   
 
 
Analytics: 
 
Ganglioside Molecular Formula Molecular Weight (g/mol) 
Rf (RP TLC, MeOH/ 
H2O 90:10 v/v) 
d18:1/18:0-GT1b  C95H165N5O47  2129.35  0.39 
d20:1/18:0-GT1b  C97H169N5O47  2157.41  0.29 
 
 
 
MS (ESI, pos. Mode, MeOH, M1 = 2129.07, M2 = 2157.10, M3 = 2185.13): m/z (%) = 
1866.90 (3.0) [Y3β + 2H]+, 1459.01 (6.6) [2M2 + K + Na + H]3+, 1109.50 (27) [M2 + K + 
Na]2+, 1107.01 (14) [M2 + K + NH4]2+, 1098.53 (73) [M2 + K + H]2+, 1101.52 (58) [M2 + 
2Na]2+, 1090.52 (38) [M2 + Na + H]2+, 1096.57 (63) [M2 + 2NH4]2+, 1088.04 (100) [M2 
+ NH4 + H]2+, 1079.54 (96) [M2 + 2H]2+, 1084.52 (32) [M1 + K + H]2+, 1087.54 (97) [M1 
+ 2Na]2+, 1085.02 (34) [M1 + Na + NH4]2+, 1076.51 (21) [M1 + Na + H]2+, 1082.55 (34) 
[M1 + 2NH4]2+, 1074.04 (44) [M1 + NH4 + H]2+, 1065.51 (54) [M1 + 2H]2+, 1131.50 (11) 
[M3 + 2K]2+, 1123.50 (17) [M3 + K + Na]2+, 1121.00 (15) [M3 + K + NH4]2+, 1112.51 
(31) [M3 + K + H]2+, 1113.01 (25) [M3 + Na + NH4]2+. 
 
MS/MS (m/z = 1088.04): m/z (%) = 1482.89 (3.7) [Z2α]+, 1191.79 (4.5) [Z2α/B1β + H]+, 
1088.04 (11) [M2 + NH4 + H]2+, 941.99 (8.7) [Y3β + 2H + NH4]2+, 900.69 (8.2) [Z2α/B2β 
+ H]+, 738.64 (9.5) [Z1]+, 657.25 (72) [B3α]+, 576.59 (29) [Z0]+, 454.17 (20) [B2α]+, 
366.15 (17) [B3α/B1α + H]+, 292.10 (100) [B1α o. B1β]+, 274.09 (58) [B1α o. B1β – H2O]+, 
204.06 (19) [B3α/B2α + H]+. 
 
Tab. 5.2.4: Physical properties of GT1b 
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MS/MS (m/z = 1065.51): m/z (%) = 1163.73 (5.1) [Z2α/B1β + H]+, 1065.56 (6.9) [M1 + 
2H]2+, 872.65 (7.8) [Z2α/B2β + H]+, 710.64 (6.6) [Z1]+, 657.24 (52) [B3α]+, 548.55 (29) 
[Z0]+, 454.17 (21) [B2α]+, 366.15 (16) [B3α/B1α + H]+, 292.10 (100) [B1α o. B1β]+, 274.08 
(64) [B1α o. B1β – H2O]+, 204.06 (26) [B3α/B2α + H]+. 
 
 
5.2.6 Analytics of GQ1b  
 
GQ1b was already obtained in pure form after anion-exchange chromatography and 
subsequent desalting. 
 
 
Analytics: 
 
Ganglioside Molecular Formula Molecular Weight (g/mol) 
Rf (RP TLC, MeOH/ 
H2O 90:20 v/v) 
d18:1/18:0-GQ1b  C106H182N6O55  2420.59  0.24 
d20:1/18:0-GQ1b  C108H186N6O55  2448.64  0.16 
 
 
 
MS (ESI, pos. Mode, MeOH, M1 = 2420.17, M2 = 2448.20): m/z (%) = 1657.15 (2.0) 
[2M2 + K + 2NH4]3+, 1263.10 (15) [M2 + 2K]2+, 1252.62 (59) [M2 + K + NH4]2+, 1244.13 
(42) [M2 + K + H]2+, 1244.62 (34) [M2 + Na + NH4]2+, 1242.16 (100) [M2 + 2NH4]2+, 
1233.65 (67) [M2 + NH4 + H]2+, 1225.14 (30) [M2 + 2H]2+, 1249.10 (7.9) [M1 + 2K]2+, 
1238.61 (23) [M1 + K + NH4]2+, 1230.61 (13) [M1 + Na + NH4]2+, 1228.15 (41) [M1 + 
2NH4]2+, 1219.63 (28) [M2 + NH4 + H]2+, 1211.12 (13) [M2 + 2H]2+. 
 
MS/MS (m/z = 1242.16): m/z (%) = 1483.88 (4.7) [Z2α]+, 1191.81 (5.0) [Z2α/B1β + H]+, 
948.35 (38) [B4α]+, 918.71 (6.6) [Y2α/B2β + 3H]+, 900.70 (6.8) [Z2α/B2β + H]+, 756.65 
(6.9) [Y1 + 2H]+, 745.27 (11) [B3α]+, 657.25 (20) [B4α/B1α + H]+, 594.59 (12) [Y0 + 2H]+, 
583.21 (25) [B2α o. B2β], 576.59 (26) [Z0]+, 454.17 (33) [B3α/B1α + H]+, 366.15 (11) 
[B4α/B2α + H]+, 292.11 (100) [B1α o. B1β]+, 274.09 (36) [B1α o. B1β – H2O]+, 204.07 (4.6) 
[B4α/B3α + H]+. 
 
Tab. 5.2.5: Physical properties of GQ1b 
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MS/MS (m/z = 1228.15): m/z (%) = 1454.87 (6.5) [Z2α]+, 1228.15 (3.9) [M1 + 2NH4]2+, 
1163.77 (6.6) [Z2α/B1β + H]+, 948.35 (43) [B4α]+, 890.66 (7.4) [Y2α/B2β + 3H]+, 872.67 
(7.1) [Z2α/B2β + H]+, 745.27 (14) [B3α]+, 728.62 (9.2) [Y1 + 2H]+, 710.61 (9.4) [Z1]+, 
657.25 (21) [B4α/B1α + H]+, 583.21 (20) [B2α o. B2β], 548.55 (26) [Z0]+, 454.17 (26) 
[B3α/B1α + H]+, 366.14 (12) [B4α/B2α + H]+, 292.10 (100) [B1α o. B1β]+, 274.09 (37) [B1α 
o. B1β – H2O]+, 204.06 (5.7) [B4α/B3α + H]+. 
 
 
5.2.7 Separation of d20:1/18:0-GM1·NH3 and d18:1/18:0-GM1·NH3   
 
 
Experimental procedure: 
GM1 (300 mg) was separated into its lipoforms by RP column chromatography 
(Merck-LiChroprep RP-18/40-63 µm, 2.0 × 3.5 cm, isocratic, eluent: MeOH/H2O 
90:25 v/v). Column material was removed from both fractions by NP column 
chromatography (Merck-silica gel 60/40-63 µm, 2.0 cm × 3.5 cm, step gradient, 
application: CHCl3/MeOH/2.5 M NH3 60:35:2 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 
60:40:10 v/v/v). After lyophilization, d18:1/18:0-GM1·NH3 (1) (64.8 mg) and 
d20:1/18:0-GM1·NH3 (2) (100 mg) were obtained as colorless powders. 
 
 
Analytics of d18:1/18:0-GM1·NH3 (1): 
 
Molecular Formula:    C73H134N4O31 
Molecular Weight:      1563.87 g/mol 
Rf = 0.20 (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) 
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1H NMR (500 MHz, DMF-d7, RT): δ [ppm] = 8.55 (s, 1H, GalNAc, NH), 7.67 (d, 1H, 
3JNH-H5 = 5,5 Hz, NeuAc, NH), 7.44 (s, 1H, Cer, NH), 5.89 (s, OH), 5.69 – 5.59 (m, 
1H, Cer, H-5), 5.50 (dd, 1H, 3JH4-H5, trans = 15.3 Hz, 3JH4-H3 = 7.1 Hz, Cer, H-4), 5.06 
(bs, OH), 4.51 (d, 1H, 3JH1-H2 = 7.4 Hz, Gal, H-1), 4.40 (m, 1H, Gal, H-1), 4.30 (d, 1H, 
3JH1-H2 = 7.7 Hz, Glc, H-1), 4.22 – 3.16 (m, 35H), 2.74 – 2.69 (m, 1H, NeuAc, H-3e), 
2.16 (t, 2H, 3JH2'-H3' = 7.2 Hz, Cer, H-2'), 2.03 (s, 3H, NeuAc, CH3CO2R), 1.99 (dt, 2H, 
3JH6-H5 = 6,9 Hz, 3JH6-H7 = 6.9 Hz, Cer, H-6), 1.94 – 1.83 (m, 4H, GalNAc (CH3CO2R), 
NeuAc (H-3a)), 1.63 – 1.49 (m, 2H, Cer, H-3'), 1.43 – 1.20 (m, 50H), 0.88 (t, 6H, 
3JH18-H17 = 6.1 Hz, 3JH18'-H17' = 6,1 Hz, Cer, H-18, H-18'). 
 
1H NMR (500 MHz, DMF-d7, RT, exchangeable Protons were exchanged by 
deuterium prior to measurement): δ [ppm] = 5.70 – 5.58 (m, 1H, Cer, H-5), 5.50 (dd, 
1H, 3JH4-H5, trans = 15.4 Hz, 3JH4-H3 = 6.9 Hz, Cer, H-4), 5.02 (d, 1H, 3JH1-H2 = 8.7 Hz, 
GalNAc, H-1), 4.52 (d, 1H, 3JH1-H2 = 7.9 Hz, Gal, H-1), 4.41 (m, 1H, Gal, H-1), 4.31 (d, 
1H, 3JH1-H2 = 7.8 Hz, Glc, H-1), 4.22 – 3.14 (m, 35H), 2.73 – 2.68 (m, 1H, NeuAc, H-
3e), 2.16 (t, 2H, 3JH2'-H3' = 7.2 Hz, Cer, H-2'), 2.02 (s, 3H, NeuAc, CH3CO2R), 1.98 (m, 
2H, Cer, H-6), 1.87 (s, 3H, GalNAc, CH3CO2R), 1.54 (m, 2H, Cer, H-3'), 1.29 (m, 
50H), 0.88 (t, 6H, 3JH18-H17 = 6.7 Hz, 3JH18'-H17' = 6,7 Hz, Cer, H-18, H18'). 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1568.83 (1.1) [M + Na]+, 1563.86 (3.3) [M + 
NH4]+, 1555.35 (1.3) [2M + NH4 + H]2+, 1546.84 (1.7) [M + H]+, 1181.71 (7.7) [Y2α + 
2H]+, 793.40 (4.4) [M + Na + NH4]2+, 790.94 (2.1) [M + 2NH4]2+, 784.91 (6.6) [M + Na 
+ H]2+, 782.43 (12) [M + NH4 + H]2+, 773.92 (100) [M + 2H]2+. 
 
MS/MS (m/z = 773.92): m/z (%) = 1237.73 (4.2) [Z2β]+, 1163.70 (15) [Z2α]+, 1075.69 
(7.3) [Z3α/B1β + H]+, 890.63 (3.8) [Y2α/B1β + 3H]+, 872.62 (17) [Z2α/B1β + H]+, 728.59 
(7.6) [Y1 + 2H]+, 710.58 (19) [Z1]+, 566.54 (5.9) [Y0 + 2H]+, 548.53 (37) [Z0]+, 530.52 
(9,1) [Z0 – H2O]+, 366.14 (100) [B2α]+, 292.10 (28) [B1β]+, 274.10 (39) [B1β – H2O]+, 
204.10 (69) [B2α/B1α + H]+, 186.10 (22) [B2α/B1α + H – H2O]+. 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 56.07   H: 8.64   N: 3.58 
Measured (wt %): C: 49.61   H: 8.51   N: 3.93 
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Analytics of d20:1/18:0-GM1·NH3 (2): 
 
Molecular Formula:    C75H138N4O31 
Molecular Weight:      1591.93 g/mol 
Rf = 0.21 (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1596.88 (2.2) [M + Na]+, 1591.92 (10) [M + 
NH4]+, 1583.40 (1.5) [2M + NH4 + H]2+, 1574.88 (1.3) [M + H]+, 1209.76 (4.5) [Y2α + 
2H]+, 809.92 (4.1) [M + 2Na]2+, 807.43 (7.2) [M + Na + NH4]2+, 804.97 (18) [M + 
2NH4]2+, 798.93 (11) [M + Na + H]2+, 796.46 (41) [M + NH4 + H]2+, 787.94 (100) [M + 
2H]2+. 
 
MS/MS (m/z = 773,92): m/z (%) = 1265.78 (2.8) [Z2β]+, 1191.75 (11) [Z2α]+, 1103.74 
(7.1) [Z3α/B1β + H]+, 900.66 (22) [Z2α/B1β + H]+, 738.62 (25) [Z1]+, 594.57 (3.6) [Y0 + 
2H]+, 576.57 (55) [Z0]+, 558.56 (16) [Z0 – H2O]+, 366.14 (82) [B2α]+, 292.31 (75) [B1β]+, 
274.10 (55) [B1β – H2O]+, 204.10 (100) [B2α/B1α + H]+, 186,09 (47) [B2α/B1α + H – 
H2O]+, 126.09 (18) [acetamidopentenylium]+.  
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 56.59   H: 8.74   N: 3.52 
Measured (wt %): C: 53.63   H: 8.70   N: 3.51 
 
 
5.2.8 Separation of d20:1/18:0-GD1a·2NH3 and d18:1/18:0-
GD1a·2NH3 to obtain d18:1/18:0-GD1a·2NH3 (3) 
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Experimental procedure: 
GD1a (472 mg) was separated into its lipoforms by RP column chromatography 
(Merck-LiChroprep RP-18/40-63 µm, 2.7 × 4.0 cm, isocratic, eluent: MeOH/H2O 
90:49 v/v). Column material was removed by NP column chromatography (Merck-
silica gel 60/40-63 µm, 2.0 × 3.5 cm, step gradient, application: CHCl3/MeOH/2.5 M 
NH3 60:35:5 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v). After 
lyophilization, d18:1/18:0-GD1a·2NH3 was obtained as a colorless powder (89.5 mg).   
 
 
Analytics: 
 
Molecular Formula:    C84H154N6O39 
Molecular Weight:      1872.16 g/mol 
Rf = 0.18 (CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v) 
 
1H-NMR (400 MHz, DMSO-d6, RT): δ [ppm] = 8.13 (bs, 1H, GalNAc, NH), 7.50 (d, 
1H, 3JNH-H5 = 8.9 Hz, NeuAc, NH), 7.20 (bs, 1H, NeuAc , NH), 7.07 (d, 1H, 3JNH-H2 = 
7.1 Hz, Cer, NH), 5.89 (bs, OH), 5.61 – 5.45 (m, 1H, Cer, H-5), 5.34 (dd, 1H, 3JH4-H5, 
trans = 15.2 Hz, 3JH4-H3 = 7.1 Hz, Cer, H-4), 5.21 – 4.36 (m, 16H, OH), 4,24 (m, 2H, Gal 
(ll) H-1, Gal (lV) H-1), 4,14 (d, 1H, 3JH1-H2 = 7,6 Hz, Glc, H-1), 4.05 – 2.96 (m, 42H), 
2.55 (m, 2H, NeuAc A and B, H-3e), 2.02 (t, 2H, 3JH2'-H3' = 7.3 Hz, Cer, H-2'), 1.92 (m, 
2H, Cer, H-6), 1.88 (s, 3H, NeuAc, CH3CO2R), 1.88 (s, 3H, NeuAc, CH3CO2R), 1.74 
(s, 3H, GalNAc, CH3CO2R), 1.60 (m, 2H, NeuAc A and B, H-3a), 1.41 (m, 2H, Cer, H-
3'), 1.23 (m, 50H), 0.85 (t, 6H, 3JH18'-H17' = 6.8 Hz, 3JH18-H17 = 6,8 Hz, Cer, H18, H-18'). 
 
1H NMR (400 MHz, DMSO-d6, RT) (exchangeable Protons were exchanged by 
deuterium prior to measurement): δ [ppm] = 5.58 – 5.48 (m, 1H, Cer, H-5), 5.34 (dd, 
1H, 3JH4-H5, trans = 15.3 Hz, 3JH4-H3 = 7.2 Hz, Cer, H-4), 4.76 (d, 1H, 3JH1-H2 = 8.0 Hz, 
GalNAc, H-1), 4.27 (d, 3JH1-H2 = 7.9 Hz, Gal, H-1), 4.23 (d, 1H, 3JH1-H2 = 7.6 Hz, Gal, 
H-1), 4.15 (d, 1H, 3JH1-H2 = 7.7 Hz, Glc, H-1), 4.04 – 2.97 (m, 42H), 2.54 (m, 2H, 
NeuAc A and B, H-3e), 2.02 (t, 3JH2'-H3' = 7.3 Hz, Cer, H-2'), 1.92 (m, 2H, Cer, H-6), 
1.87 (s, 3H, NeuAc, CH3CO2R), 1.85 (s, 3H, NeuAc, CH3CO2R), 1.77 (s, 3H, GalNAc, 
CH3CO2R), 1.65 (m, 2H, NeuAc A and B, H-3a), 1.50 – 1.37 (m, 2H, Cer, H-3'), 1.23 
(m, 50H), 0.85 (t, 3JH18'-H17' = 6.8 Hz, 3JH18-H17 = 6.8 Hz, H-18, H-18'). 
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MS (ESI, pos. Mode, MeOH): m/z (%) = 1859.92 (2.0) [M + Na]+, 1854.98 (1.5) [M + 
NH4]+, 1837.98 (0.43) [M + H]+, 1181.71 (20) [Y2α + 2H]+, 957.41 (7.3) [M + 2K]2+, 
949.43 (37) [M + K + Na]2+, 946.95 (12) [M + K + NH4]2+, 938.44 (32) [M + K + H]2+, 
941.44 (45) [M + 2Na]2+, 938.95 (72) [M + Na + NH4]2+, 930.45 (32) [M + Na + H]2+, 
936.48 (56) [M + 2NH4]2+, 927.97 (34) [M + NH4 + H]2+, 919.46 (100) [M + 2H]2+.     
 
MS/MS (m/z = 919.46): m/z (%) = 1366.77 (5.6) [Z3α]+, 1181.71 (13) [Y2α + 2H]+, 
1163.70 (15) [Z2α]+, 1075.69 (3.0) [Z3α/B1β + H]+, 919.46 (10) [M + 2H]2+, 890.62 (4.3) 
[Y2α/B1β + 3H]+, 872.62 (8.8) [Z2α/B1β + H]+, 819.26 (3.5) [B4/B1β + H]+, 728.59 (15) [Y1 
+ 2H]+, 710.58 (18) [Z1]+, 657.22 (99) [B3α]+, 566.54 (10) [Y0 + 2H]+, 548.53 (43) [Z0]+, 
454.15 (22) [B2α]+, 366.14 (24) [B3α/B1α + H]+, 292.10 (100) [B1α o. B1β]+, 274.10 (87) 
[B1α – H2O o. B1β – H2O]+, 204.10 (45) [B3α/B2α + H]+, 186.10 (8.0) [B3α/B2α + H – 
H2O]+. 
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 53.89   H: 8.29   N: 4.49 
Measured (wt %): C: 48.71   H: 8.43   N: 4.45 
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5.2.9 Separation of d20:1/18:0-GD1b·2NH3 and d18:1/18:0-
GD1b·2NH3 to obtain d20:1/18:0-GD1b·2NH3 (4) 
 
 
Experimental procedure: 
GD1b (76 mg) was separated into its lipoforms by RP column chromatography 
(Merck-LiChroprep RP-18/40-63 µm, 2.0 × 4.0 cm, isocratic, eluent: MeOH/H2O 
90:40 v/v). Column material was removed by NP column chromatography on silica 
gel (Merck-silica gel 60/40-63 µm, 2.0 × 3.5 cm, step gradient, application: 
CHCl3/MeOH/2.5 M NH3 60:35:6 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 60:44:12 
v/v/v) again. After lyophilization, d20:1/18:0-GD1b·2NH3 was obtained as a colorless 
powder (19.1 mg).   
 
 
Analytics: 
 
Molecular Formula:    C86H158N6O39 
Molecular Weight:      1900.21 g/mol 
Rf = 0.19 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
 
1H-NMR (400 MHz, DMSO-d6, RT): δ [ppm] = 7.99 (m, 2H, NH), 7.50 (d, 1H, 3JNH-H5 = 
9.0 Hz, NeuAc, NH), 5.51 (dt, 1H, 3JH5-H4, trans = 15.4 Hz, 3JH5-H6 = 6.6 Hz, Cer, H-5), 
5.33 (dd, 1H, 3JH4-H5, trans = 15.3 Hz, 3JH4-H3 = 7.1 Hz, Cer, H-4), 4.87 (d, 1H, 3JH1-H2 = 
8.6 Hz, GalNAc, H-1), 4.29 (d, 2H, 3JH1-H2 = 8.0 Hz, Gal, H-1), 4.13 (d, 1H, 3JH1-H2 = 
7.6 Hz, Glc, H-1), 4.00 – 2.90 (m, 42H), 2.84 (m, 1H, NeuAc, H-3e), 2.07 (s, 1H, OH), 
2.00 (t, 2H, 3JH2'-H3' = 7.3 Hz, Cer, H-2'), 1.92 (m, 2H, Cer, H-6), 1.86 (s, 6H, NeuAc, 
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CH3CO2R), 1.74 (s, 3H, GalNAc, CH3CO2R), 1.42 (m, 2H, Cer, H-3'), 1.22 (m, 54H), 
0.88 – 0.79 (t, 6H, 3JH18'-H17' = 6,8 Hz, 3JH20-H19 = 6.8 Hz, H-18', H-20). 
 
1H NMR (400 MHz, DMSO-d6, RT) (exchangeable Protons were exchanged by 
deuterium prior to measurement): δ [ppm] = 5.51 (dt, 1H, 3JH5-H4, trans = 15.2 Hz, 3JH5-
H6 = 6.8 Hz, Cer, H-5), 5.33 (dd, 1H, 3JH4-H5, trans = 15.2 Hz, 3JH4-H3 = 7.1 Hz, Cer, H-4), 
4.31 (d, 1H, 3JH1-H2 = 7.6 Hz, Gal, H-1), 4.27 (d, 3JH1-H2 = 6.8 Hz, Gal, H-1), 4.13 (d, 
1H, 3JH1-H2 = 7.8 Hz, Glc, H-1), 4.04 – 2.98 (m, 42H), 2.77 (m, 1H, NeuAc, H-3e), 
2.59 (m, 1H, NeuAc, H-3e), 2.00 (t, 2H, 3JH2'-H3' = 7.3 Hz, Cer, H-2'), 1,91 (m, 2H, Cer, 
H-6), 1,86 (s, 6H, NeuAc, CH3CO2R), 1.76 (s, 3H, GalNAc, CH3CO2R), 1.42 (m, 2H, 
Cer, H-3'), 1.22 (m, 54H), 0.91 – 0.76 (t, 6H, 3JH18'-H17' = 6.8 Hz, 3JH20-H19 = 6.8 Hz, H-
18', H-20). 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1888.11 (1.0) [M + Na]+, 1883.11 (0.7) [M + 
NH4]+, 1866.15 (0.9) [M + H]+, 1250.35 (2.4) [2M + NH4 + 2H]2+, 963.48 (11) [M + K + 
Na]2+, 952.49 (18) [M + K + H]2+, 955.50 (21) [M + 2Na]2+, 952.99 (21) [M + Na + 
NH4]2+, 944.50 (58) [M + Na + H]2+, 942.02 (20) [M + NH4 + H]2+, 933.51 (98) [M + 
2H]2+. 
 
MS/MS (m/z = 933.51): m/z (%) = 1265.82 (3.5) [Z2α]+, 1191.79 (5.8) [Y2β/C1α + H]+, 
1103.77 (5.6) [Z3β/B2α + H]+, 900.69 (14) [Z2β/B2α + H]+, 738.64 (15) [Z1]+, 576.58 (43) 
[Z0]+, 558.57 (7.6) [Z0 – H2O]+, 454.17 (3.6) [Y2β/B1α/B3 + 2H], 366.15 (99) [B2β]+, 
292.10 (58) [B1α]+, 274.10 (100) [B1α – H2O]+, 204.09 (61) [B2β/B1β + H]+, 186.08 (20) 
[B2β/B1β + H – H2O]+. 
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 54.36   H: 8.38   N: 4.42 
Measured (wt %): C: 49.00   H: 8.06   N: 4.36 
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5.2.10 Separation of d20:1/18:0-GT1b·3NH3 and d18:1/18:0-
GT1b·3NH3 to obtain d20:1/18:0-GT1b·3NH3 (5) 
 
 
Experimental procedure: 
GT1b (382 mg) was separated into its lipoforms by RP column chromatography 
(Merck-LiChroprep RP-18/40-63 µm, 2.7 × 4.0 cm, isocratic, eluent: MeOH/H2O 
90:40 v/v). By this, 69.6 mg of crude d18:1/18:0-GT1b and 109 mg of crude 
d20:1/18:0-GT1b were obtained. In order to remove column material, 45 mg of the 
crude d20:1/18:0-GT1b were purified by NP column chromatography on silica gel 
(Merck-silica gel 60/40-63 µm, 1.5 × 2.8 cm, step gradient, application: 
CHCl3/MeOH/2.5 M NH3 60:35:7 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 60:50:15 
v/v/v). After lyophilization, d20:1/18:0-GT1b·3NH3 (5) was obtained as a colorless 
powder (40.4 mg).   
 
 
Analytics: 
 
Molecular formula:    C97H178N8O47 
Molecular weight:      2208.50 g/mol 
Rf = 0.24 (CHCl3/MeOH/2.5 M NH3 60:50:15 v/v/v) 
 
1H-NMR (400 MHz, DMSO-d6, RT): δ [ppm] = 7.97 (m, 3H, NH), 7.53 – 7.42 (d, 1H, 
3JNH-H5 = 8.8 Hz, NeuAc, NH), 5.52 (dt, 1H, 3JH5-H4, trans = 15.6 Hz, 3JH5-H6 = 6.7 Hz, 
Cer, H-5), 5.33 (dd, 1H, 3JH4-H5, trans = 15.2 Hz, 3JH4-H3 = 7.0 Hz, Cer, H-4), 4.91 (m, 
GalNAc, H-1), 4.29 (d, 1H, 3JH1-H2 = 7.9 Hz, Gal, H-1), 4.13 (d, 3JH1-H2 = 7.6 Hz, Glc, 
H-1), 4.02 – 2.89 (m, 49H), 2.08 (s, OH), 2.01 (t, 2H, 3JH2'-H3' = 7.3 Hz, Cer, H-2'), 
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1.95 – 1.88 (m, 2H, Cer, H-6), 1.86 (s, 3H, NeuAc, CH3CO2R), 1.85 (s, 3H, NeuAc, 
CH3CO2R), 1.81 (s, 3H, NeuAc, CH3CO2R), 1.77 (s, 3H, GalNAc, CH3CO2R), 1.41 
(m, 2H, Cer, H-3'), 1.22 (m, 54H), 0.88 – 0.80 (t, 6H, 3JH18'-H17' = 6.8 Hz, 3JH20-H19 = 
6.8 Hz, H18', H-20). 
 
MS (ESI, pos. Mode, MeOH, M3 = 2185.13): m/z (%) = 1109.54 (8.0) [M + K + Na]2+, 
1107.07 (3.4) [M + K + NH4]2+, 1101.55 (16) [M + 2 Na]2+, 1098.55 (14) [M + K + H]2+, 
1090.55 (24) [M + Na + H]2+, 1088.07 (12) [M + NH4 + H]2+, 1079.56 (100) [M + 2H]2+, 
1131,51 (4,0) [M3 + 2K]2+, 1123,53 (4,4) [M3 + K + Na]2+, 1112,54 (8,6) [M3 + K + 
H]2+, 1109,54 (8,0) [M3 + 2NH4]2+, 1093,58 (6,4) [M3 + 2H]2+. 
 
MS/MS (m/z = 1242.16): m/z (%) = 1191.78 (3.8) [Y3β/C3α + H]+, 1079.56 (14) [M + 
2H]2+, 900.69 (7.1) [Y2α/C2β + H]+, 738.64 (7.9) [Z1]+, 657.25 (53) [B3α]+, 576.58 (29) 
[Z0]+, 558.57 (4.6) [Z0 – H2O]+, 454.16 (16) [B2α]+, 366.15 (19) [B3α/B1α + H]+, 292.11 
(100) [B1α o. B1β]+, 274.11 (95) [B1α – H2O]+, 204.11 (32) [B3α/B2α + H]+, 186.11 (6.4) 
[B3α/B2α + H – H2O]+. 
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 52.75   H: 8.12   N: 5.07 
Measured (wt %): C: 45.85   H: 8.09   N: 5.44 
 
 
5.2.11 Separation of d20:1/18:0-GQ1b·4NH3 and d18:1/18:0-
GQ1b·4NH3 to obtain d20:1/18:0-GQ1b·4NH3 (6) 
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Experimental procedure: 
GQ1b (130 mg) was separated into its lipoforms by RP chromatography (Merck-
LiChroprep RP-18/40-63 µm, 2.0 × 3.7 cm, isocratic, eluent: MeOH/H2O 90:50 v/v). 
By this, 37.9 mg of crude d18:1/18:0-GQ1b and 89.2 mg of crude d20:1/18:0-GQ1b 
were obtained. In order to remove column material, 59.2 mg of crude d20:1/18:0-
GQ1b were purified by NP column chromatography on silica gel (Merck-silica gel 
60/40-63 µm, 1.5 × 2.8 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 
60:35:8 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v). After lyophilization, 
d20:1/18:0-GQ1b·4NH3 (6) was obtained as a colorless powder (55.3 mg).   
 
 
Analytics: 
 
Molecular formula:    C108H198N10O55 
Molecular weight:      2516.79 g/mol 
Rf = 0.25 (CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v) 
 
1H-NMR (400 MHz, DMSO-d6, RT): δ [ppm] = 8.06 (d, 4H, 3JNH-H5 = 7.2 Hz, NH), 7.50 
(d, 1H, 3JNH-H5 = 9.0 Hz, NeuAc, NH), 5.52 (dt, 1H, 3JH5-H4,
 trans = 15.5 Hz, 3JH5-H6 = 6.7 
Hz, Cer, H-5), 5.33 (dd, 1H, 3JH4-H5, trans = 15.3 Hz, 3JH4-H3 = 7.0 Hz, Cer, H-4), 4.64 
(bs, OH), 4.26 (d, 2H, 3JH1-H2 = 7.8 Hz, Gal, H-1), 4.14 (d, 1H, 3JH1-H2 = 7.6 Hz, Glc, 
H-1), 4.03 – 2.96 (m, 56H), 2.85 (m, 2H, NeuAc, H-3e), 2.75 (m, 2H, NeuAc, H-3e), 
2.08 (s, OH), 2.01 (t, 2H, 3JH2'-H3' = 7.3 Hz, Cer, H-2'), 1.92 (m, 2H, Cer, H-6), 1.88 – 
1.85 (2s, 12H, NeuAc, CH3CO2R), 1.73 (s, 3H, GalNAc, CH3CO2R), 1.41 (m, 2H, 
Cer, H-3'), 1.22 (m, 54H), 0.90 – 0.77 (t, 6H, 3JH18'-H17' = 7.0 Hz, 3JH20-H19 = 7.0 Hz, H-
18', H-20). 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1263.10 (48) [M + 2K]2+, 1255.10 (60) [M + K 
+ Na]2+, 1252.62 (82) [M + K + NH4]2+, 1244.13 (88) [M + K + H]2+, 1244.63 (83) [M + 
Na + NH4]2+, 1242.16 (100) [M + 2NH4]2+, 1233.65 (93) [M + NH4 + H]2+, 1225.14 (64) 
[M + 2H]2+, 842.72 (21) [M + 2K + H]3+, 829.74 (33) [M + K + 2H]3+. 
 
MS/MS (m/z = 1242.16): m/z (%) = 1500.86 (6.9) [Y2α + 2H]+, 1482.85 (6.5) [Z2α]+, 
1225.13 (40) [M + 2H]2+, 1191.81 (5.4) [Y3β/C4α + H]+, 1079.58 (8.5) [Y5α + 3H]2+, 
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948.36 (55) [B4α]+, 918.71 (8.2) [Y2β/B4α + 3H]+, 900.70 (5.6) [Y2β/B4α + 3H – H2O]+, 
756.66 (8.8) [Y1 + 2H]+, 745.28 (14) [B3α]+, 738.65 (6.7) [Z1]+, 657.26 (21) [B4α/B1α 
+H]+, 594.61 (13) [Y0 + 2H]+, 583.23 (31) [B2α o. B2β]+, 576.60 (25) [Z0]+, 454.18 (31) 
[B3α/B1α + H]+, 366.16 (11) [B4α/B2α + H]+, 292.11 (100) [B1α o. B1β]+, 274.09 (33) [B1β 
– H2O]+, 204.07 (6.1) [B4α/B3α + H]+. 
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 51.54   H: 7.93   N: 5.57 
Measured (wt %): C: 44.16   H: 7.77   N: 5.67 
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5.2.12 Photometric sialic acid determination of d18:1/18:0-
GM1·NH3 and d18:1/18:0-GD1a·2NH3 
 
1. N-Acetylneuraminic acid as reference for calibration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ganglioside M (g/mol) c (µg/mL) calc. cNANA (µg/mL) 
d18:1/18:0-GM1·NH3 (1) 1563.85 25.0 4.94 
d18:1/18:0-GD1a·2NH3 (3) 1872.14 25.0 8.26 
 
Abs. 1 Abs. 2 Mean measured CNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.052 0.049 0.0505 3.65 -1.29 -26.1 
0.102 0.084 0.0930 6.72 -1.54 -18.6 
 
 
 
 
 
 
Fig. 5.2.2: Sialic acid determination of d18:1/18:0-GM1·NH3 (1) and 
d18:1/18:0-GD1a·2NH3 (3) by using pure sialic acid as external standard. 
The calculated cNANA was determined by weighing.  
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2. α1-Acid glycoprotein as reference for calibration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ganglioside M (g/mol) c (µg/mL) calc. cNANA (µg/mL) 
d18:1/C18:0-GM1·NH3 1563.85 25.0 4.94 
d18:1/C18:0-GD1a·2NH3 1872.14 25.0 8.26 
 
Abs. 1 Abs. 2 Mean measured CNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.052 0.049 0.0505 4.93 -0.01 -0.3 
0.102 0.084 0.0930 9.08 0.82 10.0 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2.3: Sialic acid determination of d18:1/18:0-
GM1·NH3 (1) and d18:1/18:0-GD1a·2NH3 (3) by using 
α1-acid glycoprotein as external standard. 
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5.3 Preparation of lysogangliosides 
 
5.3.1 Chemical preparation of d18:1-lyso-GM1·NH3 (7) 
 
 
Experimental procedure: 
All steps were performed under an argon atmosphere. Anhydrous 1-propanol was 
degassed by adding a stream of argon for 1 h. Then, 20.0 mg (12.8 µmol) of 
d18:1/18:0-GM1·NH3 (1) were dissolved in 9.2 mL of this solvent. 2.3 mL of a 1 M 
KOH solution in 1-propanol were added and the reaction mixture was heated to 
90 °C for 20 h. After cooling to RT, the reaction mixture was brought to pH 9 by 
adding an aq. ammonium chloride buffer. The solvent was removed in a stream of 
nitrogen, the crude product was dried in vacuum and subsequently purified by RP 
column chromatography (Merck LiChroprep RP-18/40-63 µm, 1.5 × 3.6 cm, isocratic, 
eluent: MeOH/H2O 90:40 v/v). A second purification step was performed by NP 
column chromatography (Merck-silica gel 60/25-40 µm, 2.0 × 21.5 cm, isocratic, 
eluent:CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v). In order to remove column material, 
the product was purified by NP column chromatography on silica gel (Merck-silica 
gel/40-63 µm, 0.9 × 2.5 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 
60:35:6 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) again. After 
lyophilization, d18:1-lyso-GM1·NH3 was obtained as a colorless powder (8.69 mg, 
52 %).  
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Analytics: 
 
Molecular formula:    C55H100N4O30 
Molecular weight:      1297.40 g/mol 
Rf = 0.12 (CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1292.12 (3.1) [3M + 2NH4 + H]3+, 1280.62 
(100) [M + H]+, 989.53 (29) [Y2β + 2H]+, 981.35 (22) [B4]+, 915.49 (78) [Y2α + 2H]+, 
659.79 (5.3) [M + K + H]2+, 651.80 (26) [M + Na + H]2+, 649.33 (6.3) [M + NH4 + H]2+, 
640.81 (64) [M + 2H]2+. 
 
MS/MS (m/z = 1280.62): m/z (%) = 1280.63 (17) [M + H]+, 989.54 (50) [Y2β + 2H]+, 
971.53 (5.3) [Z2β]+, 915.50 (8.0) [Y2α + 2H]+, 624.41 (17) [Y2α/B1β + 3H]+, 606.40 (7.1) 
[Y2α/C1β + H]+, 462.35 (9.7) [Y1 + 2H]+, 444.34 (8.8) [Z1]+, 366.15 (100) [B2α]+, 300.30 
(6.9) [Y0 + 2H]+, 292.11 (7.3) [B1β]+, 282.29 (20) [Z0]+, 264.28 (85) [Z0 – H2O]+, 204.09 
(64) [B2α/B1α + H]+, 186.08 (15) [B2α/B1α + H – H2O]+. 
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Photometric sialic acid determination: 
 
 
Ganglioside M (g/mol) c (µg/mL) calc. cNANA (µg/mL) 
d18:1-lyso-GM1·NH3 (7) 1297.40 124 29.6 
d18:1/14:0-GM2·NH3 (21) 1345.62 85.9 19.7 
 
Abs. 1 Abs. 2 Mean measured CNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.369 0.406 0.3875 28.9 -0.73 -2.5 
0.255 0.259 0.2570 19.2 -0.59 -3.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.1: Sialic acid determination of d18:1-lyso-GM1·NH3 
(7) and d18:1/14:0-GM2·NH3 (21) by using d18:1/18:0-
GM1·NH3 (1) as reference standard  
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5.3.2 Chemical preparation of d18:1-lyso-GD1a·2NH3 (8)  
 
Experimental procedure: 
All steps were performed under an argon atmosphere. Dry MeOH was degassed by 
adding a stream of argon gas for 1 h. 30.0 mg (16.0 µmol) of d18:1/18:0-GD1a·2NH3 
(3) were dissolved in 11.7 mL of this solvent. Afterwards, 2.9 mL of a 1 M KOH 
solution in MeOH were added and the reaction mixture was heated to 90 °C for 23 h. 
After cooling to RT, the reaction mixture was brought to pH 9 by adding an aq. 
ammonium chloride buffer. The solvent was removed in a stream of nitrogen, the 
crude product was dried in vacuum and subsequently purified by RP column 
chromatography (Merck LiChroprep RP-18/40-63 µm, 1.5 × 3.5 cm, isocratic, eluent: 
MeOH/H2O 90:60 v/v). A second purification step was performed by NP column 
chromatography (Merck-silica gel 60/25-40 µm, 2.2 × 25.5 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). Product containing fractions that were not 
pure enough were purified by preparative HPTLC (developing solvent: 
CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v). All product containing fractions were 
pooled, the solvent was removed under reduced pressure and the product was dried 
in vacuum. In order to remove column material the product was purified by NP 
column chromatography on silica gel (Merck-silica gel 60/40-63 µm, 0.9 × 2.5 cm, 
step gradient, application: CHCl3/MeOH/2.5 M NH3 60:35:6 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 60:50:15 v/v/v) again. After lyophilization, d18:1-lyso-
GD1a·2NH3 was obtained as a colorless powder (1.23 mg, 4.8 %).   
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Analytics: 
 
Molecular Formula:    C66H120N6O38 
Molecular Weight:      1605.69 g/mol 
Rf = 0.24 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1571.75 (3.3) [M + H]+, 1272.45 (11) [B5]+, 
1048.14 (5.2) [2M + 3H]3+, 915.50 (100) [Y2α + 2H]+, 808.35 (5.9) [M + 2Na]2+, 805.35 
(3.0) [M + K + H]2+, 808.35 (5.9) [M + 2Na]2+, 797.36 (38) [M + Na + H]2+, 794.88 (14) 
[M + NH4 + H]2+, 786.37 (13) [M + 2H]2+. 
 
MS/MS (m/z = 786.37): m/z (%) = 1280.63 (6.0) [Y4α + 2H]+, 1272.46 (4.9) [B5]+, 
1118.59 (3.9) [Y3α + 2H]+, 915.50 (89) [Y2α + 2H]+, 786.36 (8.5) [M + 2H]2+, 657.24 
(100) [B3α]+, 624.40 (15) [Y2α/B1β + 3H]+, 606.39 (4.5) [Y2α/C1β + H]+, 462.35 (8.3) [Y1 
+ 2H]+, 454.16 (14) [B2α]+, 444.34 (3.1) [Z1]+, 366.15 (14) [B3α/B1α + H]+, 300.30 (36) 
[Y0 + 2H]+, 292.11 (80) [B1α o. B1β]+, 282.29 (34) [Z0]+, 274.10 (68) [B1α – H2O o. B1β – 
H2O]+, 204.09 (35) [B3α/B2α + H]+, 186.08 (5.6) [B3α/B2α – H2O]+. 
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Photometric sialic acid determination: 
 
 
Ganglioside M (g/mol) c (µg/mL) calc. cNANA (µg/mL) 
d18:1-lyso-GD1a·2NH3 1605.68 76.2 29.4 
d18:1/17:0-GD1a·2NH3      1858.11 73.7 24.5 
 
Abs. 1 Abs. 2 Mean measured cNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.291 0.294 0.2925 23.6 -5.80 -19.8 
0.299 0.278 0.2885 23.2 -1.31 -5.35 
 
 
 
 
 
 
5.3.3 Control experiment for the chemical deacylation of d18:1/18:0-
GD1a·2NH3  
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 15.0 mg (8.01 µmol) of 
d18:1/18:0-GD1a·2NH3 were dissolved in 5.8 mL of dry degassed 1-propanol. 
Fig. 5.3.2: Sialic acid determination of d18:1-lyso-GD1a·2NH3 (8) and 
d18:1/17:0-GD1a·2NH3 (16) by using d18:1/18:0-GD1a·2NH3 (3) as 
reference standard  
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Afterwards, 1.5 mL of a 1 M potassium tert-butoxide solution in the same solvent 
were added and the reaction mixture was heated to 90 °C for 12 h. 
A second experiment was performed under the same reaction conditions except that 
the reaction temperature was changed to 80 °C. The formed d18:1-lyso-GD1a was 
quantified at different reaction times. 4 µL of the reaction mixture were taken each 
time and quantified by HPTLC followed by densitometry.  
 
 
5.3.4 Enzymatic preparation of d18:1-lyso-GD1a·2NH3 (8)  
 
Experimental procedure: 
0.919 mg (491 nmol) of d18:1/18:0-GD1a·2NH3 (3) were dissolved in 500 µL of 
50 mM sodium acetate buffer (pH 6.0), which contained 0.8 % of Triton™ X-100. The 
mixture was exposed to an ultrasonic bath for 15 s. Then, 3.6 µL (18 mU) of a 
SCDase solution (in 50 mM sodium acetate buffer, pH 6.0) were added, the aqueous 
phase was covered with 5 mL of n-decane to remove the fatty acid from the 
equilibrium, and the mixture was incubated at 37 °C. Every 2 h the n-decane phase 
was replaced. To obtain a complete conversion of the educt further 36 mU of enzyme 
were added over a period of 2 d. The reaction was stopped by the addition of a few 
drops of 2.5 M ammonia. The solvent was removed in a stream of nitrogen, the crude 
product was dried in vacuum and subsequently purified by NP column 
chromatography (2.0 × 23 cm, CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). In order to 
remove column material, the crude product was purified by NP column 
chromatography again (Merck-silica gel 60/40-63 µm, 0.6 × 2.0 cm, step gradient, 
application: CHCl3/MeOH/2.5 M NH3 60:35:7 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 
60:44:12 v/v/v). After lyophilization, d18:1-lyso-GD1a·2NH3 (8), was obtained as a 
colorless powder (0.74 mg, 47 % from two preparations), 
 
Analytics: 
 
Molecular Formula:    C66H120N6O38 
Molecular Weight:      1605.69 g/mol 
Rf = 0.25 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
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MS (ESI, pos. Mode, MeOH): m/z (%) = 1571.67 (5.2) [M + H]+, 1272.39 (14) [B5]+, 
915.46 (100) [Y2α + 2H]+, 816.30 (1.6) [M + K + Na]2+, 808.31 (4.4) [M + 2Na]2+, 
805.30 (5.2) [M + K + H]2+, 797.32 (31) [M + Na + H]2+, 794.84 (15) [M + NH4 + H]2+, 
786.33 (15) [M + 2H]2+. 
 
MS/MS (m/z = 786.33): m/z (%) = 1280.55 (4.2) [Y4α + 2H]+, 1272.35 (5.9) [B5]+, 
915.44 (76) [Y2α + 2H]+, 786.32 (4.0) [M + 2H]2+, 657.20 (100) [B3α]+, 624.37 (8.3) 
[Y2α/B1β + 3H]+, 606.36 (3.6) [Y2α/C1β + H]+, 462.32 (7.2) [Y1 + 2H]+, 454.13 (8.5) 
[B2α]+, 444.32 (4,2) [Z1]+, 366.12 (11) [B3α/B1α + H]+, 300.28 (25) [Y0 + 2H]+, 292.09 
(46) [B1α o. B1β]+, 282.26 (37) [Z0]+, 274.08 (59) [B1α o. B1β – H2O]+, 204.07 (29) 
[B3α/B2α + H]+, 186.08 (7.1) [B3α/B2α + H – H2O]+. 
 
Fluorimetric sialic acid determination:  
 
 
 
 
 
Ganglioside M (g/mol) c (mM) calc. cNANA (mM) 
d18:1-lyso-GD1a·2NH3 1605.69 0.152 0.0507 
measured ∆F measured cNANA (mM) Dev. (mM) Dev. (%) 
237.85 0.0334 -0.0172 -34.0 
Fig. 5.3.3: Sialic acid determination of d18:1-lyso-
GD1a·2NH3 (8) by using d18:1/18:0-GD1a·2NH3 (3) 
as reference standard  
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5.3.5 Enzymatic preparation of d20:1-lyso-GD1b·2NH3 (9)  
 
 
Experimental procedure: 
d20:1-Lyso-GD1b·2NH3 was prepared by the method described in section 5.3.4. 
3.74 mg (1.97 mmol) of d20:1/18:0-GD1b·2NH3 (4) and 216 mU of SCDase were 
applied over a period of 3 d. The crude product was purified by NP column 
chromatography on silica gel (Merck-silica gel 60/25-40 µm, column: Ø = 2.5 × 
19.9 cm, isocratic, eluent: CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v). In order to 
remove column material, it was purified by NP column chromatography (Merck-silica 
gel 60/40-63 µm, 0.6 × 2.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 
60:35:7 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) again. After 
lyophilization, d20:1-lyso-GD1b·2NH3 was obtained as a colorless powder (1.72 mg, 
53 %).   
 
 
Analytics: 
 
Molecular Formula:    C68H124N6O38 
Molecular Weight:  1633.74 g/mol 
Rf = 0.18 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1621.64 (0.41) [M + Na]+, 1599.67 (8.8) [M + 
H]+, 1571.66 (0.28) [M – 2CH2 + H]+, 1308.59 (6.8) [Y3α + 2H]+, 819.32 (5,4) [M + K + 
H]2+, 822.32 (5.3) [M + 2Na]2+, 811.32 (29) [M + Na + H]2+, 808.85 (16) [M + NH4 + 
H]2+, 800.33 (100) [M + 2H]2+, 786.32 (3.2) [M – 2CH2 + 2H]2+. 
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MS/MS (m/z = 800.28): m/z (%) = 1308.58 (37) [Y3α + 2H]+, 1234.55 (9.7) [Y2β + 2H]+, 
1146.54 (5.7) [Y3β/B1α + 3H]+, 1017.51 (21) [Y2α + 2H]+, 943.48 (6.0) [Y2β/B1α + 3H]+, 
855.47 (4.4) [Y3α/B2α + 3H]+, 800.33 (7.3) [M + 2H]2+, 652.40 (5.4) [Y2β/B2α + 3H]+, 
490.36 (4.2) [Y1 + 2H]+, 366.13 (45) [B2β]+, 328.31 (7.6) [Y1 + 2H]+, 310.30 (7.6) [Z1]+, 
292.09 (78) [B1α]+, 274.08 (100) [B1α - H2O]+, 204.07 (20) [B2β/B1β + H]+.      
 
Fluorimetric sialic acid determination: 
 
Ganglioside M (g/mol) c (mM) calc. cNANA (mM) 
d20:1-lyso-GD1b·2NH3 1633.74 0.152 0.0506 
 
measured ∆F measured cNANA (mM) Dev. (mM) Dev. (%) 
307.15 0.0499 -0.0007 -1.38 
 
 
 
 
 
 
 
 
 
Fig. 5.3.4: Sialic acid determination of d20:1-lyso-
GD1b·2NH3 (9) by using d20:1/18:0-GD1b·2NH3 (4) 
as reference standard  
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5.3.6 Enzymatic preparation of d20:1-lyso-GT1b·3NH3 (10)  
 
 
Experimental procedure: 
d20:1-Lyso-GT1b·3NH3 was prepared by the method described in section 5.3.4. 
2.16 mg (978 nmol) of d20:1/18:0-GT1b·3NH3 (5) and 72 mU of SCDase were 
applied over a period of 2 d. The crude product was purified by NP column 
chromatography on silica gel (Merck-silica gel 60/25-40 µm, 2.0 × 19.5 cm, isocratic, 
eluent: CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v). In order to remove column material, 
it was purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 0.6 × 
2.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 60:40:8 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v) again. After lyophilization, d20:1-lyso-
GT1b·3NH3 was obtained as a colorless powder (1.16 mg, 61 %).   
 
 
Analytics: 
 
Molecular Formula:    C79H144N8O46 
Molecular Weight:      1942.03 g/mol 
Rf = 0.26 (CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1890.74 (0.53) [M + H]+, 1260.87 (0.89) [2M 
+ 3H]3+, 1234.59 (3.1) [Y2α + 2H]+, 964.87 (4.5) [M + K + H]2+, 967.89 (3.7) [M + 
2Na]2+, 956.89 (17) [M + Na + H]2+, 954.40 (8.3) [M + NH4 + H]2+, 945.90 (100) [M + 
2H]2+, 931.88 (4.9) [M – 2CH2 + 2H]2+. 
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MS/MS (m/z = 945.90): m/z (%) = 1599.64 (14) [Y4α + 2H]+, 1563.42 (4.0) [B5]+, 
1437.59 (4.1) [Y3α + 2H]+, 1308.56 (11) [Y2β + 2H]+, 1234.54 (25) [Y2α + 2H]+, 1017.50 
(4.0) [Y4α/B2β + 3H]+, 943.47 (20) [Y2α/B1β + 3H]+, 855.46 (4.5) [Y3α/B2β + 3H]+, 657.20 
(88) [B3α]+, 652.39 (6.7) [Y2α/B2β + 3H]+, 583.17 (6.9) [B2β]+, 490.35 (6.6) [Y1 + 2H]+, 
454.13 (15) [B2α]+, 366.12 (9.4) [B3α/B1α + H]+, 328.30 (37) [Y0 + 2H]+, 310.30 (15) 
[Z0]+, 292.09 (100) [B1α o. B1β]+, 274.08 (85) [B1α o. B1β – H2O]+, 204.07 (14) [B3α/B2α 
+ H]+. 
 
Fluorimetric sialic acid determination: 
 
Ganglioside M (g/mol) c (mM) calc. cNANA (mM) 
d20:1-lyso-GT1b·3NH3 1942.01 0.170 0.0848 
 
measured ∆F measured cNANA (mM) Dev. (mM) Dev. (%) 
706.20 0.0838 -0.001 -1.18 
 
 
 
 
 
 
 
Fig. 5.3.5: Sialic acid determination of d20:1-lyso-
GT1b·3NH3 (10) by using d20:1/18:0-GT1b·3NH3 (5) 
as reference standard  
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5.3.7 Enzymatic preparation of d20:1-lyso-GQ1b·4NH3 (11)  
 
 
Experimental procedure: 
d20:1-Lyso-GQ1b·4NH3 was prepared by the method described in section 5.3.4. 
2.44 mg (969 nmol) of d20:1/18:0-GQ1b·4NH3 (6) and 72 mU of SCDase were 
applied over a period of 2 d. The crude product was purified by NP column 
chromatography on silica gel (Merck-silica gel 60/25-40 µm, 2.0 × 21.1 cm, isocratic, 
eluent: CHCl3/MeOH/2.5 M NH3 60:50:13 v/v/v). In order to remove column material, 
it was purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 0.6 × 
2.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v) again. After lyophilization, d20:1-lyso-
GQ1b·4NH3 was obtained as a colorless powder (0.97 mg, 44 %).   
 
 
Analytics: 
 
Molecular Formula:    C90H164N10O54 
Molecular Weight:      2250.32 g/mol 
Rf = 0.26 (CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1462.91 (5.0) [2M + Na + 2H]3+, 1455.59 
(2.8) [2M + 3H]3+, 1121.90 (7.2) [M + K + Na]2+, 1110.92 (10) [M + K + H]2+, 1113.92 
(15) [M + 2Na]2+, 1102.93 (71) [M + Na + H]2+, 1099.95 (18) [M + NH4 + H]2+, 1091.93 
(100) [M + 2H]2+.  
 
MS/MS (m/z = 1091.46): m/z (%) = 1890.78 (3.3) [Y5α + 2H]+, 1599.70 (10) [Y4α + 
2H]+, 1437.65 (3.2) [Y3α + 2H]+, 1308.62 (4.4) [Y2β/B1α + 2H]+, 1234.58 (27) [Y2α + 
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2H]+, 1091.94 (18) [M + 2H]2+, 948.31 (36) [B4α]+, 943.50 (24) [Y2α/B1β + 3H]+, 745.24 
(7.3) [Y2α/Y1 + H]+, 657.22 (14) [B4α/B1α + H]+, 583.19 (21) [B2α o. B2β]+, 490.37 (5.1) 
[Y1 + 2H]+, 454.15 (22) [B3α/B1α + H]+, 366.13 (6.5) [B4α/B2α + H]+, 328.32 (34) [Y0 + 
2H]+, 310.30 (9.6) [Z0]+, 292.09 (100) [B1α o. B1β]+, 274.08 (53) [B1α o. B1β – H2O]+, 
204.07 (4.6) [B4α/B3α + H]+. 
 
Fluorimetricsialic acid determination: 
 
Ganglioside M (g/mol) c (mM) calc. cNANA (mM) 
d20:1-lyso-GQ1b·4NH3 2250.30 0.110 0.0734 
 
measured ∆F measured cNANA (mM) Dev. (mM) Dev. (%) 
229.7 0.0473 -0.0261 -35.5 
 
 
 
 
 
 
 
 
 
Fig. 5.3.6: Sialic acid determination of d20:1-lyso-
GQ1b·4NH3 (11) by using d20:1/18:0-GQ1b·4NH3 
(6) as reference standard  
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5.4 Reacylation of lysogangliosides 
 
5.4.1 Synthesis of 2,5-dioxopyrrolidin-1-yl tetradecanoate (12) 
 
 
 
 
 
 
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 3.00 g (13.1 mmol) of 
tetradecanoic acid and 3.24 g (15.7 mmol) of DCC were dissolved in 26.2 mL of dry 
THF and stirred at RT for 10 min. Then, 1.81 g (15.7 mmol) of N-hydroxysuccinimide 
in 14.1 mL of dry THF were added and the reaction mixture was stirred at RT for 
22.5 h. TLC-analysis (CHCl3/MeOH 50:1 v/v) revealed a complete conversion of the 
educt. After this, the reaction mixture was filtrated by suction. The solvent was 
removed under reduced pressure and the residue was recrystallized from EtOH 
containing a trace of water. The product was obtained as a colorless solid (3.08 g, 
72 %). 
 
 
Analytics: 
 
Molecular Formula:    C18H31NO4 
Molecular Weight:      325.45 g/mol 
Rf = 0.09 (CHCl3) 
 
1H-NMR (300 MHz, CDCl3, RT): δ [ppm] = 2.83 (s, 4H, H-3, 4), 2.60 (t, 2H, 3JH2'-H3' = 
7.5 Hz, H-2'), 1.74 (tt, 2H, 3JH3'-H4' = 7.5 Hz, 3JH3'-H2' = 7.5 Hz, H-3'), 1.46 – 1.18 (m, 
20H), 0.88 (t, 3H, 3JH14'-H13' = 6.7 Hz, H-14'). 
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13C-NMR (75 MHz, CDCl3, RT): δ [ppm] = 169.15 (RCON, C-2, 5), 168.68 (RCO2R', 
C-1'), 31.90 (CH2, C-2'), 30.93 (CH2, C-12'), 29.63-28.77 (8 CH2), 25.57 (CH2, C-3, 
4), 24.56 (CH2, C-3'), 22.67 (CH2, C-13'), 14.09 (CH3, C-14'). 
 
DEPT 135 (75 MHz, CDCl3, RT): δ [ppm] = 31.90 (CH2, C-2'), 30.93 (CH2, C-12'), 
29.63-28.77 (8 CH2), 25.57 (CH2, C-3, 4), 24.56 (CH2, C-3'), 22.67 (CH2, C-13'), 
14.09 (CH3, C-14'). 
 
MS: (EI, 70eV, 100 °C) m/z (%) = 211.3 (100) [M+· - C4H4NO3·], 129.1 (15) [C8H17O+], 
112.2 (17) [C8H16+], 98.2 (42) [C7H14+·], 84.1 (18) [C6H12+·], 71.2 (16) [C5H11+], 57.2 
(25) [C4H9+].                                                                                                                                           
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 66.43   H: 9.60   N: 4.30 
Measured (wt %): C: 66.03   H: 9.63   N: 4.29 
 
 
5.4.2 Synthesis of 2,5-dioxopyrrolidin-1-yl heptadecanoate (13) 
 
 
 
 
 
 
 
 
Experimental procedure: 
2,5-Dioxopyrrolidin-1-yl heptadecanoate was synthesized by the method described in 
section 5.4.1. 1.00 g (3.70 mmol) of heptadecanoic acid were applied. The product 
was obtained as a colorless solid (0.897 g, 66 %). 
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Analytics: 
 
Molecular Formula:    C21H37NO4 
Molecular Weight:      367.53 g/mol 
Rf = 0.09 (CHCl3) 
 
1H NMR (400 MHz, CDCl3, RT): δ [ppm] = 2.83 (s, 4H, H-3, 4), 2.59 (t, 1H, 3JH2'-H3' = 
7.5 Hz, H-2'), 1.74 (tt, 2H, 3JH3'-H4' = 7.5 Hz, 3JH3'-H2' = 7,5 Hz, H-3'), 1.45 – 1.19 (m, 
26H), 0.88 (t, 3H, 3JH17'-H16' = 6.9 Hz, H-17'). 
 
13C-NMR (75 MHz, CDCl3, RT): δ [ppm] = 169.15 (RCON, C-2, 5), 168.68 (RCO2R', 
C-1'), 31.90 (CH2, C-2'), 30.93 (CH2, C-15'), 29.66-28.78 (11 CH2), 25.57 (CH2, C-
3,4), 24.56 (C-3'), 22.67 (CH2, C-16'), 14.10 (CH3, C-17'). 
 
DEPT 135 (75 MHz, CDCl3, RT): δ [ppm] = 31.90 (CH2, C-2'), 30.93 (CH2, C-15'), 
29.66-28.78 (11 CH2), 25.57 (CH2, C-3,4), 24.56 (C-3'), 22.67 (CH2, C-16'), 14.10 
(CH3, C-17'). 
 
MS (EI, 70 eV): m/z (%) = 367.3 (16) [M+·], 349.3 (16) [M+·– H2O], 335.3 (11) [M+·– 
O2], 253.3 (100) [M+·– C4H4NO3·], 154.2 (4,9) [C11H22+·], 112.2 (17) [C8H16+·], 98.1 
(47) [C7H14+·], 84.1 (16) [C6H12+·], 71.2 (18) [C5H11+], 57.1 (22) [C4H9+]. 
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 68.63   H: 10.15   N: 3.81 
Measured (wt %): C: 68.63   H: 10.14   N: 3.75 
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5.4.3 Synthesis of d18:1/14:0-GM1·NH3 (14)  
 
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 19.4 mg (15.0 µmol) of d18:1-
lyso-GM1·NH3 were mixed with 75 µL (0.44 mmol) of Hünig’s base and dissolved in 
1.5 mL abs. DMF. Then, 12.0 mg (36.9 µmol) of 2,5-dioxopyrrolidin-1-yl 
tetradecanoate in 0.38 mL of abs. DMF were added and the reaction mixture was 
stirred at 30 °C for 3 d and 18 h. The reaction was stopped by the addition of a few 
drops of 2.5 M ammonia. The solvent was removed in a nitrogen stream, the crude 
product was dried in vacuum and subsequently purified by NP column 
chromatography (Merck-silica gel 60/40-63 µm, 2.5 × 20.0 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M aq. NH3 60:40:9 v/v/v). After lyophilization, d18:1/14:0-GM1·NH3 
was obtained as a colorless powder (6.32 mg, 28 %).   
 
 
Analytics: 
 
Molecular Formula:    C69H126N4O31 
Molecular Weight:      1507.76 g/mol 
Rf = 0.20 (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1528.66 (0.5) [M + K]+, 1512.71 (0.32) [M + 
Na]+, 1507.73 (2.5) [M + NH4]+, 1499.23 (0.30) [2M + NH4 + H]2+, 1490.72 (0.71) [M + 
H]+, 783.81 (3.8) [M + 2K]2+, 775.83 (2.8) [M + K + Na]2+, 773.35 (3.1) [M + K + 
NH4]2+, 764.83 (17) [M + K + H]2+, 756.85 (6.5) [M + Na + H]2+, 762.88 (5.3) [M + 
2NH4]2+, 754.37 (39) [M + NH4 + H]2+, 745.86 (100) [M + 2H]2+. 
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MS/MS (m/z = 745.86): m/z (%) = 1181.63 (3.1) [Z2β]+, 1107.60 (15) [Z2α]+, 1019.59 
(9.7) [Y3α/C1β + H]+, 816.52 (25) [Y2α/C1β + H]+, 672.50 (4.3) [Y1 + 2H]+, 654.49 (28) 
[Z1]+, 510.45 (6.9) [Y0 + 2H]+, 492.45 (55) [Z0]+, 474.44 (11) [Z0 – H2O]+, 366.12 (100) 
[B2α]+, 292.09 (27) [B1β]+, 274.09 (53) [B1β – H2O]+, 264.27 (18) [Z0 – myristic acid]+,  
204.11 (90) [B2α/B1α+ H]+, 186.12 (28) [B2α/B1α + H – H2O]+. 
 
 
Densitometry: 
 
 
Ganglioside  M (g/mol) calc. n (nmol) measured Abs 
d18:1/14:0-GM1·NH3 1507,76 3,32 8150,8 
measured n (nmol) Dev. (nmol) Dev. (%) 
2,67 -0,650 -19,6 
 
 
 
 
 
 
 
 
Fig. 5.4.1: Densitometric analysis of d18:1/14:0-
GM1·NH3 (14) by using d18:1/18:0-GM1·NH3 (1) as 
reference standard  
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Photometric sialic acid determination: 
 
Ganglioside  M (g/mol) c (mg/mL) calc. cNANA (µg/mL) 
d18:1/14:0-GM1·NH3 1507.76 1.00 10.0 
d18:1/18:0-GM2·NH3 1401.73 0.200 10.0 
Abs. 1 Abs. 2 Mean Meancorr. meas. cNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.893 0.883 0.888 0.230 8.92 -1.08 -10.8 
0.732 0.734 0.733 0.0745 2.89 -7,11 -71.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4.2: Sialic acid determination of d18:1/14:0-
GM1·NH3 (14) and d18:1/18:0-GM2·NH3 (20) by 
using d18:1-lyso-GM1·NH3 (7) as reference standard  
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5.4.4 Synthesis of d18:1/14:0-GD1a·2NH3 (15)  
 
 
Experimental procedure: 
d18:1/14:0-GD1a·2NH3 was synthesized by the method described in section 5.4.3. 
1.87 mg (1.16 µmol) of d18:1-lyso-GD1a·2NH3 were applied. 11.0 mg (33.8 µmol) of 
2,5-dioxopyrrolidin-1-yl tetradecanoate and 67.8 µL (0.399 µmol) of Hünig’s base 
were added over a period of 4.5 d. The crude product was purified by RP column 
chromatography (Merck LiChroprep RP-18/40-63 µm, 2.7 × 3.9 cm, eluent: 
MeOH/H2O 90:50 v/v). After lyophilization, d18:1/C14:0-GD1a·2NH3 was obtained as 
a colorless powder (0.88 mg, 42 %).   
 
  
Analytics: 
 
Molecular Formula:    C80H146N6O39 
Molecular Weight:      1816.05 g/mol 
Rf = 0.25 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 929.32 (20) [M + 2K]2+, 921.34 (27) [M + K + 
Na]2+, 918.86 (35) [M + K + NH4]2+, 913.35 (9.8) [M + 2Na]2+, 910.86 (38) [M + Na + 
NH4]2+, 902.36 (13) [M + Na + H]2+, 908.39 (100) [M + 2NH4]2+, 899.88 (59) [M + NH4 
+ H]2+, 891.37 (77) [M + 2H]2+.  
 
MS/MS (m/z = 891.37): m/z (%) = 1310.62 (5.8) [Z3α]+, 1107.56 (10) [Z2α]+, 1019.55 
(5.5) [Z3α/B1β + H]+, 816.50 (14) [Z2α/B1β + H]+, 672.47 (5.6) [Y1 + 2H]+, 657.17 (33) 
[B3α]+, 654.47 (22) [Z1]+, 510.44 (5.9) [Y0 + 2H]+, 492.43 (49) [Z0]+, 454.11 (12) [B2α]+, 
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366.11 (26) [B3α/B1α+ H]+, 292.08 (88) [B1α]+, 274.08 (100) [B1α – H2O]+, 204.11 (51) 
[B3α/B2α+ H]+, 186.11 (7,9) [B3α/B2α+ H – H2O]+. 
 
Photometric sialic acid determination: 
 
 
Ganglioside  M (g/mol) c (mg/mL) calc. cNANA (µg/mL) 
d18:1-lyso-GD1a·NH3 1605.69 0.200 10.0 
d18:1/14:0-GD1a·2NH3 1816.05 0.200 10.0 
Abs. 1 Abs. 2 Mean Meancorr. meas. cNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.821 0.822 0.822 0.190 6.57 -3.43 -34,3 
0.722 0.722 0.722 0.0905 3.13 -6.87 -68,7 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4.3: Sialic acid determination of d18:1/14:0-GD1a·2NH3 (15) and d18:1-
lyso-GD1a·2NH3 (8) by using d18:1/18:0-GD1a·2NH3 (3) as reference standard. 
8 was already quantified by fluorimetric sialic acid determination (section 5.3.4). 
The deviance between both methods was 0.87 %.   
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5.4.5 Synthesis of d18:1/17:0-GD1a·2NH3 (16)  
 
 
Experimental procedure: 
d18:1/17:0-GD1a·2NH3 was synthesized by the method described in section 5.4.3. 
0.98 mg (0,610 µmol) of d18:1-lyso-GD1a·2NH3 were applied. 1.43 mg (3.89 µmol) of 
2,5-dioxopyrrolidin-1-yl heptadecanoate and 7.75 µL (45.6 µmol) of Hünig’s base 
were added over a period of 30 h. The crude product was purified by NP column 
chromatography (Merck-silica gel 60/15-40 µm, 2.0 × 20.0 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). In order to remove column material it was 
purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 0.6 × 1.0 cm, 
step gradient, application: CHCl3/MeOH/2.5 M NH3 60:35:5 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) again. After lyophilization, d18:1/17:0-
GD1a·2NH3 was obtained as a colorless powder (0.98 mg, 86 %).   
 
Analytics: 
 
Molecular Formula:    C83H152N6O39 
Molecular Weight:      1858.13 g/mol 
Rf = 0.18 (CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1216.97 (3.2) [2M + 3H]3+, 1167.74 (24) [Y2α 
+ 2H]+, 931.98 (3.7) [M + Na + NH4]2+, 929.51 (16) [M + 2NH4]2+, 923.48 (6.1) [M + 
Na + H]2+,  921.00 (22) [M + NH4 + H]2+, 912.48 (100) [M + 2H]2+.  
 
MS/MS (m/z = 912.48): m/z (%) = 1352.80 (6.4) [Z3α]+, 1167.74 (13) [Y2α + 2H]+, 
1149.73 (15) [Z2α]+, 1061.71 (4.8) [Z3α/B1β + H]+, 912.48 (13) [M + 2H]2+, 858.64 (11) 
[Z2α/B1β + H]+, 819.30 (3.6) [B4/B1β + H]+, 714.59 (15) [Y1 + 2H]+, 696.58 (21) [Z1]+, 
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657.24 (94) [B3α]+, 552.54 (10) [Y0 + 2H]+, 534.53 (44) [Z0]+, 516.52 (6.8) [Z0 – H2O]+, 
454.16 (22) [B2α]+, 366.15 (26) [B3α/B1α + H]+, 292.11 (100) [B1α o. B1β]+, 274.10 (93) 
[B1α – H2O o. B1β – H2O]+, 204.09 (49) [B3α/B2α + H]+, 186,08 (7.5) [B3α/B2α + H – 
H2O]+. 
 
Photometric sialic acid determination:  
 
The results of the photometric sialic acid determination are given in Fig. 5.3.2. The 
content of d18:1/17:0-GD1a·2NH3 (16) was 94.7 % compared to d18:1/18:0-
GD1a·2NH3 (3) as reference standard. 
 
 
5.4.6 Synthesis of d20:1/14:0-GD1b·2NH3 (17)  
 
 
Experimental procedure: 
d20:1/14:0-GD1b·2NH3 was synthesized by the method described in section 5.4.3. 
1.63 mg (0,998 µmol) of d20:1-lyso-GD1b·2NH3 were applied. 1.34 mg (4.12 µmol) of 
2,5-dioxopyrrolidin-1-yl tetradecanoate and 8.2 µL (48.2 µmol) of Hünig’s base were 
added over a period of 23 h. The crude product was purified by NP column 
chromatography (Merck-silica gel 60/15-40 µm, 2.0 × 22.0 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). In order to remove column material, it was 
purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 0.6 × 2.0 cm, 
step gradient, application: CHCl3/MeOH/2.5 M NH3 60:35:6 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) again. After lyophilization, d20:1/14:0-
GD1b·2NH3 was obtained as a colorless powder (1.28 mg, 70 %). 
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The experiment was repeated one time. 0.97 mg (0.594 µmol) of d20:1-lyso-
GD1b·2NH3 were applied. The crude product was purified by RP column 
chromatography (Merck LiChroprep RP-18/40-63 µm, 1.5 cm × 3.2 cm, eluent: 
MeOH/H2O 90:40 v/v). Then, it was purified by preparative HPTLC (Merck TLC silica 
gel 60, 20 x 20 cm glass plate, eluent: CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v). In 
order to remove TLC material it was purified by NP column chromatography (Merck-
silica gel/40-63 µm, column: Ø = 0.6 × 2.0 cm, step gradient, application: 
CHCl3/MeOH/2.5 M NH3 60:35:6 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 60:44:12 
v/v/v) again. After lyophilization, d20:1/14:0-GD1b·2NH3 was obtained as a colorless 
powder (0.62 mg, 57 %). 
 
 
Analytics (experiment 1): 
 
Molecular Formula:    C82H150N6O39 
Molecular Weight:      1844.10 g/mol 
Rf = 0.21 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1831.89 (0.29) [M + Na]+, 1826.92 (0.68) [M 
+ NH4]+, 1818.44 (0.13) [2M + NH4 + H]2+, 1809.92 (1.3) [M + H]+, 927.44 (6.4) [M + 
2Na]2+, 924.94 (3.9) [M + Na + NH4]2+, 916.44 (22) [M + Na + H]2+, 913.96 (8.6) [M + 
NH4 + H]2+, 905.45 (100) [M + 2H]2+, 891.44 (3.5) [M + 2H – 2CH2]2+. 
 
MS/MS (m/z = 905.45): m/z (%) = 1518.73 (2.5) [Y3α + 2H]2+, 1500.75 (2.0) [Z3α]+, 
1426.70 (3.1) [Z2β]+, 1209.66 (3.5) [Z2α]+, 1135.64 (4.7) [Y2β/C1α + H]+, 1047.62 (4.9) 
[Y3β/C2α + H]+, 905.41 (22) [M + 2H]2+, 844.56 (11) [Y2β/C2α + H]+, 700.53 (3.3) [Y1 + 
2H]2+, 682.52 (13) [Z1]+, 583.17 (5.8) [B2α]+, 538.49 (5.2) [Y0 + 2H]2+,  520.48 (39) 
[Z0]+, 502.47 (9.3) [Z0 – H2O]+, 454.13 (3.3) [Y2β/B1α/Y1 + 2H]+, 366.12 (99) [B2β]+, 
292.09 (69) [B1α]+, 274.08 (100) [B1α – H2O]+, 204.08 (68) [B2β/B1β + H]+, 186.08 (28) 
[B2β/B1β + H – H2O]+. 
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Photometric sialic acid determination: 
 
 
Ganglioside  M (g/mol) c (mg/mL) calc. cNANA (µg/mL) 
d20:1/14:0-GD1b·2NH3 1844.10 0.200 10.0 
d18:1/18:0-GD2·2NH3 1738.07 0.200 10.0 
d18:1/14:0-GD2·2NH3 1681.96 0.200 10.0 
Abs. 1 Abs. 2 Mean Meancorr. meas. cNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.844 0.847 0.846 0.211 7.53 -2.47 -24.7 
0.711 0.711 0.711 0.0765 2.73 -7.27 -72.7 
0.838 0.835 0.837 0.202 7.21 -2.79 -27.9 
 
 
 
 
 
Analytics (experiment 2): 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1826.86 (0.68) [M + NH4]+, 1809.87 (0.34) 
[M + H]+, 935.45 (2.7) [M + K + Na]2+, 927.45 (11) [M + 2Na]2+, 924.97 (16) [M + Na + 
NH4]2+, 916.47 (21) [M + Na + H]2+, 922,49 (13) [M + 2NH4]2+, 913.99 (33) [M + NH4 + 
H]2+, 905.48 (100) [M + 2H]2+. 
 
Fig. 5.4.4: Sialic acid determination of d20:1/14:0-GD1b·2NH3 
(17), d20:1/18:0-GD2·2NH3 (22), and d20:1/14:0-GD2·2NH3 (23) 
by using d20:1/18:0-GD1b·2NH3 (4) as reference standard  
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MS/MS (m/z = 905.48): m/z (%) = 1518.84 (4.5) [Y3α + 2H]2+, 1426.80 (5.4) [Z2β]+, 
1209.75 (4.7) [Z2α]+, 1135.71 (4.5) [Y2β/C1α + H]+, 1047.69 (3.9) [Y3β/C2α + H]+, 905.47 
(80) [M + 2H]2+, 896.46 (14) [Y2β/B2α + 2NH4 + H]+, 862.63 (7.1) [Y2β/B2α + 3H]+, 
844.62 (5.1) [Y2β/C2α + H]+, 700.58 (5.8) [Y1 + 2H]2+, 682.56 (6.1) [Z1]+, 583.20 (9.7) 
[B2α]+, 538.53 (7.0) [Y0 + 2H]2+, 520.51 (14) [Z0]+, 454.16 (4.5) [Y2β/B1α/Y1 + 2 H]+, 
366.14 (100) [B2β]+, 292.10 (76) [B1α]+, 274.09 (43) [B1α – H2O]+, 204.09 (20) [B2β/B1β 
+ H]+, 186.08 (2.4) [B2β/B1β + H – H2O]+. 
 
 
5.4.7 Synthesis of d20:1/14:0-GT1b·3NH3 (18)  
 
 
Experimental procedure: 
d20:1/14:0-GT1b·3NH3 was synthesized by the method described in section 5.4.3. 
1.06 mg (0.546 µmol) of d20:1-lyso-GT1b·3NH3 were applied. 2.21 mg (6.79 µmol) of 
2,5-dioxopyrrolidin-1-yl tetradecanoate and 13.6 µL (80.0 µmol) of Hünig’s base were 
added over a period of 6 d. The crude product was purified by NP column 
chromatography on silica gel (Merck-silica gel 60/15-40 µm, 2.0 × 25.0 cm, isocratic, 
eluent: CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v). In order to remove column material, 
it was purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 0.6 × 
2.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 60:40:8 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 60:50:15 v/v/v) again. After lyophilization, d20:1/14:0-
GT1b·3NH3 was obtained as a colorless powder (0.40 mg, 34 %).   
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Analytics: 
 
Molecular Formula:    C93H170N8O47 
Molecular Weight:      2152.39 g/mol 
Rf = 0.24 (CHCl3/MeOH/2.5 M NH3 60:50:15 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1081.47 (6.6) [M + K + Na]2+, 1070.48 (13) 
[M + K + H]2+, 1073.48 (8.1) [M + 2Na]2+, 1070.99 (11) [M + Na + NH4]2+, 1062.49 
(20) [M + Na + H]2+, 1060.02 (7.2) [M + NH4 + H]2+, 1051.50 (100) [M + 2H]2+, 
1037.49 (5.0) [M + 2H – 2CH2]2+.  
 
MS/MS (m/z = 1051.50): m/z (%) = 1135.69 (3.3) [Y3β/C3α + H]+, 1051.50 (17) [M + 
2H]2+, 844.60 (4.8) [Y2β/C3α + H]+, 682.55 (7.1) [Z1]+, 657.23 (38) [B3α]+, 583.19 (4.9) 
[B2β]+, 538.51 (2.7) [Y0 + 2H]+, 520.50 (26) [Z0]+, 502.48 (4.8) [Z0 – H2O]+, 454.15 (11) 
[Y2α/B1β/Y1 + 2H]+, 366.14 (14) [B3α/B1α + H]+, 292.10 (81) [B1α o. B1β]+, 274.09 (100) 
[B1α o. B1β – H2O]+, 204.09 (33) [B3α/B2α + H]+, 186.08 (9.9) [B3α/B2α + H – H2O]+. 
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Photometric sialic acid determination: 
 
 
Ganglioside  M (g/mol) c (mg/mL) calc. cNANA (µg/mL) 
d20:1/14:0-GT1b·3NH3 2152.39 0.200 10.0 
Abs. 1 Abs. 2 Mean Meancorr. meas. cNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.783 0.784 0.784 0.125 4,86 -5,14 -51,4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4.5: Sialic acid determination of d20:1/14:0-GT1b·3NH3 (18), 
by using d20:1/18:0-GT1b·3NH3 (5) as reference standard  
126 
 
5.4.8 Synthesis of d20:1/14:0-GQ1b·4NH3 (19)  
 
 
Experimental procedure: 
d20:1/14:0-GQ1b·4NH3 was synthesized by the method described in section 5.4.3. 
0.92 mg (0,409 µmol) of d20:1-lyso-GQ1b·4NH3 were applied. 2.54 mg (7.80 µmol) 
of 2,5-dioxopyrrolidin-1-yl tetradecanoate and 15.6 µL (91.7 µmol) of Hünig’s base 
were added over a period of 6 d. The crude product was purified by NP column 
chromatography (Merck-silica gel 60/15-40 µm, 2.0 × 25.4 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M NH3 60:50:13 v/v/v). In order to remove column material, it was 
purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 0.6 × 2.0 cm, 
step gradient, application: CHCl3/MeOH/2.5 M NH3 60:40:8 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v) again. After lyophilization, d20:1/14:0-
GQ1b·4NH3 was obtained as a colorless powder (0.19 mg, 19 %).  
 
 
Analytics: 
 
Molecular Formula:    C104H190N10O55 
Molecular Weight:      2460.68 g/mol 
Rf = 0.27 (CHCl3/MeOH/2.5 M NH3 50:50:16 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1235.01 (3.9) [M + 2K]2+, 1227.01 (17) [M + 
K + Na]2+, 1224.55 (9.1) [M + K + NH4]2+, 1216.02 (100) [M + K + H]2+, 1208.03 (22) 
[M + Na + H]2+, 1205.55 (12) [M + NH4 + H]2+, 1197.04 (95) [M + 2H]2+.   
 
MS/MS (m/z = 1196.54): m/z (%) = 1197.05 (8.0) [M + 2H]2+, 1135.67 (3.3) [Y3β/C4α + 
H]+, 948.31 (16) [B4α]+, 844.61 (7.4) [Y2β/C4α + H]+, 745.24 (4.5) [B3α]+, 682.55 (8.7) 
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[Z1]+, 657.23 (13) [B4α/B1α + H]+, 583.19 (9.7) [B2α o. B2β]+, 520.51 (29) [Z0]+, 454.15 
(18) [Y2α/B1β/Y1 + 2H]+, 366.14 (17) [B4α/B2α + H]+, 292.10 (100) [B1α o. B1β]+, 274.09 
(67) [B1α o. B1β – H2O]+, 204.09 (15) [B4α/B3α + H]+. 
 
Photometric sialic acid determination: 
 
 
Ganglioside  M (g/mol) c (mg/mL) calc. cNANA (µg/mL) 
d20:1/14:0-GQ1b·4NH3 2460.68 0.200 10.0 
Abs. 1 Abs. 2 Mean Meancorr. meas. cNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.704 0.708 0.706 0.0470 1.94 -8.06 -80.6 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4.6: Sialic acid determination of d20:1/14:0-GQ1b·4NH3 
(19), by using d20:1/18:0-GQ1b·4NH3 (6) as reference standard  
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5.5 Preparation of ganglioside standards by enzymatic 
degalactosylation  
 
5.5.1 Preparation of d18:1/18:0-GM2·NH3 (20)  
 
Experimental procedure: 
1.00 mg (0.639 µmol) of d18:1/18:0-GM1·NH3 (1) were dissolved in 87.8 µL of 
100 mM McIlvaine buffer (citric acid/disodium hydrogen phosphate, pH 4.3), which 
contained 3.9 mM sodium taurodeoxycholate. The mixture was exposed to an 
ultrasonic bath for 15 s. Then, 83.2 µL (85.7 mU) of a beta-galactosidase solution (in 
aq. 3.2 M (NH4)2SO4) were added and the mixture was incubated at 37 °C. After 4 d, 
TLC-analysis (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) revealed only a slight 
conversion of the educt. The reaction volume was duplicated to reduce micelle 
formation of the gangliosides. After a further day no increase of the conversion was 
observed. Next, 171 µL of a 2.4 mM Triton X-100 solution that contained 2 mM 
sodium taurodeoxycholate were added. After two further days a slightly better 
conversion was observed. Then, 83.2 µL (85.7 mU) of beta-galactosidase solution 
were added. After 3 further days almost 90 % of the educt was converted. Hence, 
23.6 µL (24.3 mU) of beta-galactosidase solution were added. After at all 12 d the 
reaction was stopped by the addition of a few drops 2.5 M aq. NH3. The solvent was 
removed in a nitrogen stream and the residue was redissolved in 0.5 mL of methanol. 
The enzyme was separated by centrifugation (12100 × g), which was repeated five 
times. The supernatant was separated and the solvent was evaporated in a nitrogen 
stream. The crude product was purified by preparative HPTLC (Merck TLC silica gel 
60, 20 x 20 cm glass plate, eluent: CHCl3/MeOH/2.5 M aq. NH3 60:40:9 v/v/v). In 
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order to remove TLC material, it was purified by NP column chromatography (Merck-
silica gel 60/40-63 µm, 0.5 × 3.0 cm, step gradient, application: CHCl3/MeOH 2:1 v/v, 
elution: CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) again. After lyophilization, d18:1/18:0-
GM2·NH3 was obtained as a colorless powder (0.32 mg, 36 %). 
  
 
Analytics: 
 
Molecular Formula:    C67H124N4O26 
Molecular Weight:      1401.73 g/mol 
Rf = 0.25 (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1422.78 (4.0) [M + K]+, 1406.80 (6.5) [M + 
Na]+, 1401.85 (12) [M + NH4]+, 1384.83 (2.0) [M + H]+, 730.87 (4.4) [M + 2K]2+, 
722.88 (8.2) [M + K + Na]2+, 711.89 (19) [M + K + H]2+, 712.40 (16) [M + Na + NH4]2+, 
703.90 (16) [M + Na + H]2+, 701.42 (15) [M + NH4 + H]2+, 692.91 (100) [M + 2H]2+. 
 
MS/MS (m/z = 692.91): m/z (%) = 1163.66 (7.3) [Z2β]+, 1075.65 (12) [Z2α]+, 872.59 
(26) [Y2β/C1α + H]+, 710.55 (27) [Z1]+, 548.51 (59) [Z0]+, 530.50 (27) [Z0 – H2O]+, 
366.12 (9.4) [B2/B1α + H]+, 292.09 (21) [B1α]+, 274.09 (61) [B1α – H2O]+, 264.27 (28) 
[Z0 – stearic acid]+, 204.09 (100) [B1β]+, 186.09 (35) [B1β – H2O]+, 126.09 (11) [B1β – 
H2O – 2CO]+. 
 
Photometric sialic acid determination:  
 
The results of the photometric sialic acid determination are given in Fig. 5.4.2. The 
content of d18:1/C18:0-GM2·NH3 (20) was 28.9 % compared to d18:1-lyso-GM1·NH3 
(7) as reference standard. 
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5.5.2 Preparation of d18:1/14:0-GM2·NH3 (21)  
 
 
Experimental procedure: 
1.34 mg (0.889 µmol) of d18:1/C14:0-GM1·NH3 (14) were dissolved in 410 µL of 
100 mM McIlvaine buffer (pH = 4.3), which contained 3.9 mM sodium 
taurodeoxycholate. Then, 200 µL of buffer containing 3.2 mM Triton X-100 and 
40.5 µL of pure buffer were added. The mixture was exposed to an ultrasonic bath for 
15 s. Then, 149.5 µL (133.5 mU) of a beta-galactosidase solution were added and 
the mixture was incubated at 37 °C. After 1 d, TLC-analysis (CHCl3/MeOH/2.5 M aq. 
NH3 60:40:9 v/v/v) revealed a conversion of approx. 50 %. Hence, 149.5 µL of the 
enzyme solution were added. After at all 2 d the conversion was complete and the 
reaction was stopped by addition of a few drops 2.5 M aq. NH3. The solvent was 
removed in a nitrogen stream and the residue was redissolved in 1 mL of MeOH. The 
enzyme was separated by centrifugation (12100 × g), which was repeated 5 times. 
The supernatant was separated and evaporated in a nitrogen stream. The crude 
product was purified by preparative HPTLC (Merck TLC silica gel 60, 20 x 20 cm 
glass plate, eluent: CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v). In order to remove TLC 
material, it was purified by NP column chromatography (Merck-silica gel 60/40-63 
µm, 0.6 × 2.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 60:35:2 v/v/v, 
elution: CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) again. After lyophilization, 
d18:1/C14:0-GM2·NH3 was obtained as a colorless powder (1.84 mg, 77 % from two 
preparations). 
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Analytics: 
 
Molecular Formula:    C63H116N4O26 
Molecular Weight:      1345.62 g/mol 
Rf = 0.27 (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1350.76 (2.2) [M + Na]+, 1345.81 (22) [M + 
NH4]+, 1337.79 (1.1) [2M + NH4 + H]2+, 1328.78 (5.0) [M + H]+, 675.88 (10) [M + Na + 
H]2+, 681.49 (16) [M + 2NH4]2+, 673.41 (9.3) [M + NH4 + H]2+, 664.89 (100) [M + 
2H]2+.   
 
MS/MS (m/z = 664.89): m/z (%) = 1107.67 (13) [Z2β]+, 1019.66 (17) [Z2α]+, 834.60 
(6.0) [Y2β/B1α + 3H]+, 816.59 (21) [Y2β/C1α + H]+, 672.55 (7.0) [Y1 + 2H]+, 664.47 (9.3) 
[M + H]2+, 654.53 (22) [Z1]+, 552.34 (3.5) [2,6X1 + H]+, 510.49 (5.3) [Y0 + 2H]+, 492.48 
(42) [Z0]+, 474.47 (12) [Z0 – H2O]+, 366.14 (11) [B2/B1α + H]+, 292.10 (35) [B1α]+, 
274.09 (56) [B1α – H2O]+, 264.27 (36) [Z0 – myristic acid]+, 204.09 (100) [B1β]+, 186.09 
(28) [B1β – H2O]+, 126.10 (9.5) [B1β– H2O – 2CO]+. 
 
Photometric sialic acid determination:  
 
The results of the photometric sialic acid determination are given in Fig. 5.3.1. The 
content of d18:1/14:0-GM2·NH3 (21) was 97.0 % compared to d18:1/18:0-GM1·NH3 
(1) as reference standard. 
 
 
 
 
 
 
 
 
 
 
 
132 
 
5.5.3 Preparation of d20:1/18:0-GD2·2NH3 (22) 
 
 
Experimental procedure: 
d20:1/18:0-GD2·2NH3 was prepared by the method described in section 5.5.2. The 
concentrations of enzyme and detergents were doubled. 0.500 mg (0.263 µmol) of 
d20:1/18:0-GD1b·2NH3 and 160 µL (142 mU) of beta-galactosidase solution were 
applied. The crude product was purified by NP-chromatography (Merck-silica gel 
60/40-63 µm, 0.6 × 2.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 
60:35:4 v/v/v, elution 1: CHCl3/MeOH/2.5 M NH3 60:35:6 v/v/v, elution 2: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). This purification step was repeated one 
time. After lyophilization, d20:1/18:0-GD2·2NH3 was obtained as a colorless powder 
(0.28 mg, 61 %).   
 
 
Analytics: 
 
Molecular Formula:    C80H148N6O34 
Molecular Weight:      1738.07 g/mol 
Rf = 0.30 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1725.90 (0.95) [M + Na]+, 1720.93 (1.6) [M + 
NH4]+, 1712.38 (0.43) [2M + NH4 + H]2+, 1703.91 (2.9) [M + H]+, 1412.82 (3.2) [Y3α + 
2H]+, 874.43 (8.2) [M + 2Na]2+, 871.93 (3.8) [M + Na + NH4]2+, 863.44 (23) [M + Na + 
H]2+, 860.96 (6.4) [M + NH4 + H]2+, 852.45 (100) [M + 2H]2+. 
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MS/MS (m/z = 852.48): m/z (%) = 1394.81 (6.8) [C1α]+, 1191.74 (4.8) [C1α/B1β + H]+, 
1103.73 (16) [C2α]+, 918.66 (3.9) [Y2α/B1β + 3H]+, 900.66 (11) [C2α/B1β + H]+, 738.61 
(12) [Z1]+, 583.19 (6.6) [B1α]+, 576.56 (36) [Z0]+, 558.55 (7.6) [Z0 – H2O]+, 454.15 (3.6) 
[C3/C1β/B1α+ 2H]+, 366.13 (11) [C3/C2α + H]+, 292.10 (76) [B1α]+, 274.09 (100) [B1α – 
H2O]+, 204.09 (72) [B1β]+, 186.08 (17) [B1β – H2O]+. 
 
Photometric sialic acid determination:  
 
The results of the photometric sialic acid determination are given in Fig. 5.4.4. The 
content of d20:1/18:0-GD2·2NH3 (22) was 27.3 % compared to d20:1/18:0-
GD1b·2NH3 (4) as reference standard. 
 
 
5.5.4 Preparation of d20:1/14:0-GD2·2NH3 (23)  
 
Experimental procedure: 
d20:1/14:0-GD2·2NH3 was synthesized by the method described in section 5.5.3. 
0.452 mg (0.245 µmol) of d20:1/14:0-GD1b·2NH3 and 98.4 µL (87.9 mU) of beta-
galactosidase solution were applied. The crude product was purified by NP column 
chromatography (Merck-silica gel 60/15-40 µm, 1.1 × 23.1 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). In order to remove column material, it was 
purified by NP column chromatography again (Merck-silica gel 60/40-63 µm, 0.6 × 
1.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 60:35:4 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v). After lyophilization, d20:1/14:0-GD2·2NH3 
was obtained as a colorless powder (0.25 mg, 61 %). 
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Analytics: 
 
Molecular Formula:    C76H140N6O34 
Molecular Weight:      1681.96 g/mol 
Rf = 0.30 (CHCl3/MeOH/2.5 M NH3 60:44:12 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1669.89 (1.0) [M + Na]+, 1664.93 (1.7) [M + 
NH4]+, 1647.92 (0.6) [M + H]+, 854.42 (3.4) [M + K + Na]2+, 846.43 (18) [M + 2Na]2+, 
843.94 (8.4) [M + Na + NH4]2+, 835.44 (36) [M + Na + H]2+, 841.47 (28) [M + 2NH4]2+, 
832.96 (53) [M + NH4 + H]2+, 824.45 (100) [M + 2H]2+, 810.44 (3.3) [M + 2H – 
2CH2]2+.   
 
MS/MS (m/z = 824.45): m/z (%) = 1338.73 (2.7) [C1α]+, 1135.66 (2.5) [C1α/B1β + H]+, 
1047.65 (8.5) [C2α]+, 844.58 (7.9) [C2α/B1β + H]+, 682.54 (9.4) [Z1]+, 520.50 (33) [Z0]+, 
502.49 (8.4) [Z0 – H2O]+, 366.13 (7.3) [C3/C2α + H]+, 310.30 (8.7) [Y0 + 2H – myristic 
acid]+, 292.29 (78) [B1α]+, 274.08 (100) [B1α – H2O]+, 204.08 (65) [B1β]+, 186.06 (29) 
[B1β – H2O]+. 
 
Photometric sialic acid determination:  
 
The results of the photometric sialic acid determination are given in Fig. 5.4.4. The 
content of d20:1/14:0-GD2·2NH3 (23) was 72.1 % compared to d20:1/18:0-
GD1b·2NH3 (4) as reference standard. 
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5.5.5 Preparation of d18:1-lyso-GM2·NH3 (24) 
 
 
Experimental procedure: 
d18:1-lyso-GM2·NH3 was prepared by the method described in section 5.5.2. 
0.585 mg (0.451 µmol) of d18:1-lyso-GM1·NH3 (7) and 140 µL (125 mU) of beta-
galactosidase solution were applied. The crude product was purified by NP column 
chromatography (Merck-silica gel 60/15-40 µm, 1.1 × 20.2 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). In order to remove column material, it was 
purified by NP column chromatography again (Merck-silica gel 60/40-63 µm, 0.6 × 
1.0 cm, step gradient, application: CHCl3/MeOH/2.5 M NH3 60:35:2 v/v/v, elution: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). After lyophilization, d18:1-lyso-GM2·NH3 
was obtained as a colorless powder (0.40 mg, 78 %).   
 
 
Analytics: 
 
Molecular Formula:    C49H90N4O25 
Molecular Weight:      1135.26 g/mol 
Rf = 0.16 (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1140.57 (3.7) [M + Na]+, 1129,57 (1.6) [2M + 
Na + H]2+, 1118.57 (100) [M + H]+, 827.49 (3.7) [Y2α + 2H]+, 581.77 (2.5) [M + 2Na]2+, 
578.77 (0.74) [M + K + H]2+, 570.78 (7.5)  [M + Na + H]2+, 568.31 (3.5) [M + NH4 + 
H]2+, 559.79 (13) [M + 2H]2+. 
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MS/MS (m/z = 1118.57): m/z (%) = 1118.58 (28) [M + H]+, 1100.56 (2.5) [M + H – 
H2O]+, 827.49 (51) [Y2α + 2H]+, 809.48 (8.9) [Z2α]+, 624.41 (5.1) [Y2β/B1α + 3H]+, 
606.40 (3.8) [Y2α/C1β + H]+, 462.35 (8.2) [Y1 + 2H]+, 444.34 (9.6) [Z1]+, 426.33 (3.9) 
[Z1 – H2O]+, 366.15 (20) [B2/B1α + H]+, 300.30 (6.7) [Y0 + 2H]+, 292.12 (10) [B1α]+, 
282.30 (24) [Z0]+, 274.11 (10) [B1α – H2O]+, 264.29 (7.1) [Z0 – H2O]+, 222.12 (4.7) [C1β 
+ 2H]+, 204.11 (100) [B1β]+, 186.11 (16) [B1β – H2O]+. 
 
Photometric sialic acid determination: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ganglioside  M (g/mol) c (mg/mL) calc. cNANA (µg/mL) 
d17:1-lyso-GM1·NH3 1283.38 0.200 10.0 
d18:1-lyso-GM2·NH3 1135.36 0.200 10.0 
d17:1-lyso-GM2·NH3 1121.24 0.200 10.0 
Abs. 1 Abs. 2 Mean Meancorr. meas. cNANA (µg/mL) Dev. (µg/mL) Dev. (%) 
0.860 0.860 0.860 0.205 7.53 -2.47 -24,8 
0.849 0.850 0.850 0.194 7.13 -2.87 -28,7 
0.900 0.902 0.901 0.246 9.04 -0.960 -9,60 
 
 
 
Fig. 5.5.1: Sialic acid determination of d17:1-lyso-GM1·NH3 
(31), d18:1-lyso-GM2 (24), and d17:1-lyso-GM2·NH3 (32) by 
using d18:1-lyso-GM1·NH3 (7) as reference standard  
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5.6 Development of a new synthetic method to modify the 
sphingosine chain of gangliosides 
 
5.6.1 Synthesis of methyl (E)-10-phenyldec-9-enoate (25)  
 
 
 
 
 
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 25.0 mg (84.3 µmol) of methyl 
oleate and 152 mg (843 µmol) of (E)-stilbene were dissolved in 2.5 mL of dry CH2Cl2. 
Then, 2.64 mg (4.22 µmol, 0.46 mol%) of Hoveyda-Grubbs catalyst 2nd gen (Fig. 
2.3.1). were added and the reaction mixture was stirred at RT for 2 h. TLC monitoring 
(hexane/EtOAc 40:1 v/v) revealed a conversion of approx. 80 %. The solvent was 
removed in a nitrogen stream, the crude product was dried in vacuum and 
subsequently purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 
1.5 × 3.0 cm, step gradient, application: Hexane/EtOAc 80:1 v/v, elution: 
Hexane//EtOAc 40:1 v/v). This purification step was repeated one time in order to 
remove residuals of (E)-stilbene. After drying in vacuum, the product was obtained as 
colorless oil (18.5 mg, 84 %).  
 
 
Analytics: 
 
Molecular Formula:    C17H24O2 
Molecular Weight:      260.38 g/mol 
Rf = 0.18 (Hexane/EtOAc 40:1 v/v) 
 
1H NMR (300 MHz, CDCl3, RT): δ [ppm] = 7.34 (dd, 2H, 3JH2'-H3' = 8.4 Hz, 4JH2'-H4' = 
1.5 Hz, H-2', 6'), 7.28 (m, 2H, H-3', 5'), 7.22 – 7.15 (m, 1H, H-4'), 6.37 (d, 1H, 3JH10-H9, 
trans = 15.8 Hz, H-10), 6.21 (dt, 1H, 3JH9-H10, trans = 15.8 Hz, 3JH9-H8 = 6.7 Hz, H-9), 3.67 
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(s, 3H, H-1''), 2.31 (t, 2H, 3JH2-H3 = 7.5 Hz, H-2), 2.25 – 2.15 (m, 2H, H-8), 1.72 – 1.57 
(m, 2H, H-3), 1.52 – 1.25 (m, 8H). 
 
13C NMR (75 MHz, CDCl3, RT): δ [ppm] = 174.28 (RCO2R', C-1), 137.89 (sp2-C, C-
1'), 131.07 (sp2-CH, C-10), 129.75 (sp2-CH, C-4'), 128.44 (sp2-CH, C-3', 5'), 126.73 
(sp2-CH, C-9), 125.88 (sp2-CH, C-2', 6'), 51.42 (CH3, C-1''), 34.08 (CH2, C-2), 32.97 
(CH2, C-8), 29.26-28.98 (4 CH2), 24.92 (CH2, C-3). 
 
DEPT 135 (75 MHz, CDCl3, RT): δ [ppm] = 131.07 (sp2-CH, C-10), 129.75 (sp2-CH, 
C-4'), 128.44 (sp2-CH, C-3', 5'), 126.73 (sp2-CH, C-9), 125.88 (sp2-CH, C-2', 6'), 
51.42 (CH3, C-1''), 34.08 (CH2, C-2), 32.97 (CH2, C-8), 29.26-28.98 (4 CH2), 24.92 
(CH2, C-3). 
 
MS (EI, 70 eV): m/z (%) = 260.20 (18) [M+·], 228.15 (7.4) [M+·– MeOH], 137.1 (11) 
[M+·– MeOH – Toluene·], 131.10 (17) [Butenylbenzene+], 117.10 (83) [Propenylben-
zene+], 104.10 (100) [Ethylbenzene+·], 91.10 (26) [Toluene+]. 
 
GC-MS:  
Peak tR (min) Peak area (%) Compound 
1 11.463 0.75 Methyl (Z)-10-phenyldec-9-enoate 
2 11.848 99.25 Methyl (E)-10-phenyldec-9-enoate 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 5.6.1: GC-MS analysis of the synthesized 
methyl (E)-10-phenyldec-9-enoate (25).  
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5.6.2 Synthesis of methyl (E)-tetradec-9-enoate (26)  
 
 
 
 
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 16.4 mg (63.0 µmol) of methyl 
(E)-10-phenyldec-9-enoate (25) and 88.4 mg (630 µmol) of (E)-dec-5-ene were 
dissolved in 1.70 mL of dry CH2Cl2. Then, 1.97 mg (3.14 µmol, 0.45 mol%) of 
Hoveyda-Grubbs catalyst 2nd gen. were added and the reaction mixture was stirred 
at RT for 2 h. TLC monitoring (hexane/EtOAc 40:1 v/v) revealed a conversion of 
approx. 70 %. The solvent was removed in a nitrogen stream and the crude product 
was purified by NP column chromatography (Merck-silica gel 60/40-63 µm, 1.5 × 
3.0 cm, step gradient, application: hexane/EtOAc 80:1 v/v, elution: hexane/EtOAc 
40:1 v/v). After drying in vacuum (50 mbar), the product was obtained as colorless oil 
(9.72 mg, 64 %).  
 
 
Analytics: 
 
Molecular Formula:    C15H28O2 
Molecular Weight:      240.39 g/mol 
Rf = 0.26 (Hexane/EtOAc 40:1 v/v) 
 
 
1H NMR (400 MHz, CDCl3, RT) δ [ppm] = 5.38 (pt, 2H, 3JH9-H8 = 3.68 Hz, H-9, 10), 
5.36 – 5.32 (t, 2H, 3JH9-H8 = 3.30 Hz, H-9isomer, 10isomer), 3.66 (s, 3H, H-1'), 2.30 (t, 2H, 
3JH2-H3 = 7.6 Hz, H-2), 2.17 (s, EtOAc), 2.04 – 1.91 (m, 4H, H-8, 11), 1.61 (tt, 2H, 3JH3-
H2 = 7.4 Hz, 3JH3-H4 = 7.4 Hz, H-3), 1.38 – 1.21 (m, 12H), 0.88 (t, 2H, 3JH14-H13 = 7.1 
Hz, H-14). 
 
13C NMR (75 MHz, CDCl3, RT): δ [ppm] = 174.32 (RCO2R', C-1), 130.40 (CH, C-9), 
130.22 (CH, C-10), 129.93 (CH, C-9isomer), 129.75 (CH, C-10isomer), 51.41 (CH3, C-1'), 
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34.10 (CH2, C-2), 32.53-26.90 (7 CH2), 24.93 (CH2, C-3), 22.33 (CH2, C-13isomer), 
22.17 (CH2, C-13), 13.94 (CH3, C-14). 
 
DEPT 135 (75 MHz, CDCl3, RT): δ [ppm] = 130.40 (CH, C-9), 130.22 (CH, C-10), 
129.93 (CH, C-9isomer), 129.75 (CH, C-10isomer), 51.41 (CH3, C-1'), 34.10 (CH2, C-2), 
32.53-26.90 (7 CH2), 24.93 (CH2, C-3), 22.33 (CH2, C-13isomer), 22.17 (CH2, C-13), 
13.94 (CH3, C-14). 
 
MS (EI, 70 eV): m/z (%) = 240.20 (5,9) [M+·], 208.20 (20) [M+·– MeOH], 166.20 (27) 
[Dodecene+·], 137.15 (15) [M+· – MeOH – Pentane·], 124.15 (31) [Nonene+·], 110.11 
(31) [Octene+·], 98.10 (44) [C6H10O+·], 96.10 (50) [Heptene+·], 86.10 (48) [Methyl 
propanoate+·] 84.10 (46) [C5H8O+·], 74.10 (63) [Methyl acetate+·], 69.10 (59) [C5H9+], 
55.05 (100) [C4H7+]. 
 
GC-MS: 
Peak tR (min) Peak area (%) Compound 
1 9.270 2.91  Methyl (E)-tridec-8-enoate 
2 9.839 91.54  Methyl (E)-tetradec-9-enoate 
3 10.378 5.55  Methyl (E)-pentadec-10-enoate 
 
 
 
 
5.6.3 Synthesis of (E)-hexacos-13-ene (27)   
 
 
 
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 380 mg (1.94 mmol) of 1-
tetradecene and 44.1 mg (0.408 mmol, 21 mol%) p-benzoquinone were dissolved in 
5.50 mL of dry CH2Cl2. Then, 12.0 mg (19.2 µmol, 0.99 mol%) of Hoveyda-Grubbs 
catalyst 2nd gen. were added and the reaction mixture was stirred at RT for 3 h. RP-
TLC monitoring (CHCl3/MeOH 2:5 v/v) revealed a conversion of approx. 60 %. The 
solvent was removed in a nitrogen stream and the catalyst was removed by NP 
Tab. 5.6.2: GC-MS analysis of the synthesized 
methyl (E)-tetradec-9-enoate (26) 
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column chromatography (Merck-silica gel 60/40-63 µm, 1.5 × 3.0 cm, step gradient). 
The crude product was applied to the column in hexane/EtOAc 80:1 v/v. The column 
was washed by four column volumes of the same solvent. Fractions containing the 
product were pooled, the solvent was removed in a nitrogen stream and 
subsequently dried in vacuum. Then, it was recrystallized from 4 °C cold ethanol. The 
product was obtained as a colorless solid (0.106 g, 30 %). 
The experiment was repeated one time using dry toluene instead of dry CH2Cl2 and 
tetrafluoro-1,4-benzoquinone instead of p-benzoquinone. Ethylene was removed 
during the reaction by an argon stream which was introduced via two needles 
through the vial septum. The yield was 32 %.      
 
Analytics (Experiment 1): 
 
Molecular Formula:    C26H52 
Molecular Weight:      364.70 g/mol 
Rf = 0.18 (RP TLC, CHCl3/MeOH 2:5 v/v) 
 
1H NMR (400 MHz, CDCl3, RT): δ [ppm] = 5.38 (tt, 2H, 3JH13-H12 = 3.6 Hz, 4JH13-H11 = 
1.4 Hz, H-13, 14), 1.97 (m, 4H, H12, 15), 1.26 (m, 40H), 0.88 (t, 6H, 3JH1-H2 = 6.8 Hz, 
H-1, 26). 
 
13C NMR (100 MHz, CDCl3, RT): δ [ppm] = 130.36 (sp2-CH, C-13, 14), 32.62 (CH2, 
C-3, 24), 31.94 (CH2, C-12, 15), 29.71-29.18 (16 CH2), 22.70 (CH2, C-2, 25), 14.12 
(CH3, C-1, 26). 
 
DEPT 135 (100 MHz, CDCl3, RT): δ [ppm] = 130.36 (sp2-CH, C-13, 14), 32.62 (CH2, 
C-3, 24), 31.94 (CH2, C-12, 15), 29.71-29.18 (16 CH2), 22.70 (CH2, C-2, 25), 14.12 
(CH3, C-1, 26). 
 
MS (EI, 70 eV): m/z (%) = 364.45 (13) [M+·], 153.20 (11) [C11H21+], 139.20 (22) 
[C10H19+], 125.20 (39) [C9H17+], 111.20 (65) [C8H15+], 97.15 (100) [C7H13+], 83.10 (79) 
[C6H11+], 69.07 (56) [C5H9+], 57.10 (65) [C4H9+], 55.05 (47) [C4H7+]. 
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GC-MS: 
Peak tR (min) Peak area (%) Compound 
1 13.030 0.45 (E)-Tetracos-13-ene 
2 13.538 0.49 (E)-Pentacos-13-ene 
3 14.126 98.21 (E)-Hexacos-13-ene 
4 15.609 0.84 (E)-Octacos-13-ene 
 
 
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 85.63   H: 14.37    
Measured (wt %): C: 85.44   H: 14.19 
 
 
Analytics (Experiment 2): 
 
MS (EI, 70 eV): m/z (%) = 364.45 (13) [M+·], 153.20 (11) [C11H21+], 139.20 (20) 
[C10H19+], 125.20 (39) [C9H17+], 111.15 (63) [C8H15+], 97.10 (100) [C7H13+], 83.10 (80) 
[C6H11+], 69.00 (55) [C5H9+], 57.10 (74) [C4H9+], 55.05 (52) [C4H7+]. 
 
GC-MS: 
Peak tR (min) Peak area (%) Compound 
1 14.143 100 (E)-Hexacos-13-ene 
 
 
 
 
CHN-Analysis: 
 
Theoretical (wt %):      C: 85.63   H: 14.37    
Measured (wt %): C: 85.21   H: 14.11 
 
 
Tab. 5.6.3: GC-MS analysis of the synthesized (E)-
hexacos-13-ene (27) 
Tab. 5.6.4: GC-MS analysis of the synthesized (E)-
hexacos-13-ene (27)  
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5.6.4 Synthesis of pentadeca-O-acetyl-GM1 (d20:1/18:0) sialoyl-II2-
lactone (28)  
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 30.9 mg (19.4 µmol) of 
d20:1/18:0-GM1·NH3 (2) and 0.5 mg (4.09 µmol) of DMAP were suspended in 
832 µL of anhydrous pyridine and 413 µL of Ac2O. The reaction mixture was stirred 
at RT for 15 h (after a few hours the reactants dissolved completely). The solvent 
was removed in a nitrogen stream and the crude product was purified by NP column 
chromatography (Merck-silica gel 60/15-40 µm, 2.0 × 21 cm, isocratic, eluent: 
toluene/acetone 5:4 v/v). After drying in vacuum, the product was obtained as 
colorless solid (26.3 mg, 62 %).  
 
 
Analytics: 
 
Molecular Formula:    C105H163N3O45 
Molecular Weight:      2187.43 g/mol 
Rf = 0.23 (toluene/acetone 5:4 v/v) 
 
1H NMR (400 MHz, CDCl3, RT): δ [ppm] = 6.44 (d, 3H, 3JNH-H2 = 7.9 Hz, NH), 5.76 
(dt, 1H, 3JH5-H4, trans = 15.1 Hz, 3JH5-H6 = 6.8 Hz, Cer, H-5), 5.63 (d, 1H, 3JH1-H3 = 9.1 
Hz, GalNAc, H-1), 5.49 (dt, 1H, 3JH4-H5 = 10.8 Hz, 3JH4-H3 = 5.5 Hz, NeuAc, H-4), 5.44 
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– 5.20 (m, 8H), 5.08 – 5.05 (m, 1H, NeuAc, H-9a), 5.04 (d, 1H, 3JH1-H2 = 7.7 Hz, Gal, 
H-1), 4.94 (dd, 1H, 3JH5-H4 = 10.5 Hz, 4JH5-H6 = 3.4 Hz, NeuAc, H-5), 4.88 (dd, 1H, 
3JH3-H2 = 9.6 Hz, 3JH3-H4 = 7.8 Hz, GalNAc, H-3), 4.76 (d, 1H, 3JH1-H2 = 7.8 Hz, Glc, H-
1), 4.62 – 3.50 (m, 28H), 2.48 (dd, 2JH3e-H3a = 13.5 Hz, 3JH3e-H4 = 5.5 Hz, NeuAc, H-
3e), 2.26 – 1.77 (13s, 51 H, CH3CO2R), 2.26-1.77 (m, 2H, Cer, H-2'), 1.57 (m, 2H, 
Cer, H-3'), 1.24 (m, 54H), 0.90 – 0.84 (t, 6H, 3JH18'-H17' = 6.9 Hz, 3JH20-H19 = 6.9 Hz, 
Cer, H-18, 18'). 
 
MS (ESI, pos. Mode, MeOH, M = 2187.06): m/z (%) = 2237.11 (3.4) [M
 
+ MeOH + 
NH4]+, 2220.10 (0.26) [M + MeOH + H]+, 2205.09 (1.7) [M + NH4]+, 2188.07 (0.11) [M 
+ H]+, 1127.56 (100) [M
 
+ MeOH + 2NH4]2+, 1119.05 (62) [M + MeOH + NH4 + H]2+, 
1110.54 (10) [M
 
+ MeOH + 2H]2+, 1111.55 (85) [M + 2NH4]2+, 1103.04 (61) [M + NH4 
+ H]2+, 1094.53 (4.7) [M + 2H]2+. 
 
MS/MS (m/z = 1102.54): m/z (%) = 1797.95 (22) [Y3α + 2H – H3CCO2H]+, 1509.85 
(3.5) [Y2α + 2H – H3CCO2H]+, 1064.52 (15) [M + 2H – H3CCO2H]2+, 772.24 (5.5) 
[Y2α/Z0 + 3H – 3H3CCO2H]+, 618.21 (12) [B2α]+, 586.18 (6.9) [Y2α/Y1 + H – 
H3CCO2H]+, 558.57 (3.7) [Z0 – H3CCO2H]+, 331.11 (100) [B1α]+, 292.30 (16) [Y0 + 2H 
– stearic acid – H3CCO2H]+, 288.11 (16) [B2α/B1α + H]+, 211.06 (14) [B1α – 
2H3CCO2H]+, 169.04 (85) [C1α + 2H – 3H3CCO2H]+, 150.05 (11) [B2α/B1α + H – 
2H3CCO2H – H2O]+, 127.03 (11) [C1α + 2H + H2O – 4 H3CCO2H]+, 109.02 (19) [C1α + 
2H – 4H3CCO2H]+. 
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5.6.5 Synthesis of O-(tetradeca-O-acetylmonosialogangliotetraosyl)-
(11)-(2R,3S,4E)-3-O-acetyl-2-octadecanoylamino-5-phenyl-
pent-4-ene-1-ol sialoyl-II2-lactone (29)  
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 39.7 mg (18.3 µmol) of a 1:1 
mixture of pentadeca-O-acetyl-GM1 (d20:1/18:0) sialoyl-ll2-lactone (28) and 
pentadeca-O-acetyl-GM1 (d20:1/18:0) sialoyl-ll2-lactone (M = 2173.41 gmol-1) were 
dissolved in 477 µL of dry CH2Cl2 in a 1 mL glass vial. 33.0 mg (183 µmol) of (E)-
stilbene and 23.9 mg (28.2 µmol, 14 mol%) of Grubbs catalyst 2nd gen. were added 
and the reaction mixture was stirred at 43 °C for 46 h. TLC monitoring 
(toluene/acetone 1:1 v/v) revealed a conversion larger than 90 %. The solvent was 
removed in a nitrogen stream, the crude product was dried in vacuum and 
subsequently purified by NP column chromatography (Merck-silica gel 60/15-40 µm, 
2.0 × 22.2 cm, isocratic, toluene/acetone 10:9 v/v). To remove traces of catalyst it 
was purified by NP column chromatography again (Merck-silica gel 60/40-63 µm, 1.5 
× 2.5 cm, step gradient, application: toluene/acetone 2:1 v/v, elution: toluene/acetone 
4:5 v/v). After drying in vacuum, the product was obtained as colorless solid 
(25.7 mg, 68 %). 
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Analytics: 
 
Molecular Formula:    C96H137N3O45 
Molecular Weight:      2053.13 g/mol 
Rf = 0.15 (Toluene/Acetone 5:4 v/v) 
 
1H NMR (400 MHz, CDCl3, RT): δ [ppm] = 7.36 (dd, 2H, 3JH2’'-H3’' = 7.1 Hz, 4JH2'’-H3’' = 
1.6 Hz, H-2’', 6’'), 7.30 (pt, 2H, 3JH3’'-H2'’' = 7.3 Hz, H-3'’, 5’'), 7.21 – 7.12 (m, 1H, H-4’'), 
6.65 (d, 1H, 3JH5-H4, trans = 15.9 Hz, Cer, H-5), 6.52 (s, 3H, NH), 6.09 (dd, 1H, 3JH4'-H5', 
trans = 15.9 Hz, 3JH4-H3 = 7.7 Hz, Cer, H-4), 5.74 (d, 1H, 3JH1-H2 = 9.2 Hz, GalNAc, H-1), 
5.35 (m, 8H), 5.07 (dd, 3JH9a-H8 = 8.0 Hz, 4JH9a-H7 = 4.3 Hz, NeuAc, H-9a), 5.04 (d, 1H, 
3JH1-H2 = 7.7 Hz, Gal, H-1), 4.94 (dd, 1H, 3JH5-H4 = 10.5 Hz, 3JH5-H6 = 3.3 Hz, NeuAc, 
H-5), 4.90 (dd, 1H, 3JH3-H2 = 9.59 Hz, 3JH3-H4 = 7.95 Hz, GalNAc, H-3), 4.76 (d, 1H, 
3JH1-H2 = 7.8 Hz, Glc, H-1), 4.63 – 3.45 (m, 28H), 2.49 (dd, 2JH3e-H3a = 13.5 Hz, 3JH3e-H4 
= 5.4 Hz, NeuAc, H-3e), 2.25 – 1.76 (13s, 51H, CH3CO2R), 1.50 (m, 2H, Cer, H-3'), 
1.31 – 1.03 (m, 28H), 0.86 (t, 3H, 3JH18'-H17' = 6.9 Hz, Cer, H-18'). 
 
MS (ESI, pos. Mode, MeOH, M = 2052,86): m/z (%) = 2107.93 (0.58) [M
 
+ MeOH + 
Na]+, 2102.94 (15) [M
 
+ MeOH + NH4]+, 2086.94 (2.3) [2M + MeOH + 2NH4]+, 
2085.94 (1.2) [M
 
+ MeOH + H]+, 2070.92 (8.3) [M + NH4]+, 2053.90 (0.92) [M + H]+, 
1065.46 (3.9) [M
 
+ MeOH + 2Na]2+, 1062.46 (6.9) [M
 
+ MeOH + K + H]2+, 1060.46 
(100) [M
 
+ MeOH + 2NH4]2+, 1051.95 (99) [M + MeOH + NH4 + H]2+, 1043.44 (20) [M 
+ MeOH + 2H]2+, 1044.45 (93) [M + 2NH4]2+, 1035.94 (56) [M + NH4 + H]2+, 1027.43 
(5.0) [M + 2H]2+, 1021.94 (19) [M
 
+ MeOH + NH4 + H – H3CCO2H]2+, 1013.43 (14) [M 
+ MeOH + 2H – H3CCO2H]2+, 1005.93 (34) [M + NH4 + H – H3CCO2H]2+, 997.42 (4.0) 
[M + 2H – H3CCO2H]2+. 
 
MS/MS (m/z = 1035.44): m/z (%) = 1662.69 (20) [Y3α + 2H – H3CCO2H]+, 1101.31 
(3.3) [B4/B1α + H – 2H3CCO2H]+, 997.38 (17) [M + 2H – H3CCO2H]2+, 772.21 (5.6) 
[Y2α/Z0 + 3H – 3H3CCO2H]+, 618.19 (9.5) [B2α]+, 586.17 (6.8) [Y2α/Y1 + H – 
H3CCO2H]+, 424.35 (5.5) [Z0 – H3CCO2H]+, 331,10 (100) [B1α]+, 288.1 (20) [B2α/B1α + 
H]+, 211.06 (14) [B1α – 2H3CCO2H]+, 169.04 (89) [C1α + 2H – 3H3CCO2H]+, 150.06 
(13) [B2α/B1α + H – 2H3CCO2H – H2O]+, 127.05 (11) [C1α + 2H + H2O – 4H3CCO2H]+, 
109.04 (21) [C1α + 2H – 4H3CCO2H]+. 
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5.6.6 Synthesis of pentadeca-O-acetyl-GM1 (d17:1/18:0) sialoyl-II2-
lactone (30) 
 
Experimental procedure: 
All steps were performed under an argon atmosphere. 15.5 mg (7.55 µmol) of 29, 
55.0 mg (151 µmol) of (E)-hexacos-13-ene (27), and 3.43 mg (31.7 µmol, 20 mol%) 
of p-benzoquinone were dissolved in 271 µL of dry CH2Cl2 in a 1 mL glass vial. Then, 
19.8 mg (31.6 µmol, 20 mol%) of Hoveyda-Grubbs catalyst 2nd gen. were added and 
the reaction mixture was stirred at 40 °C. After 1d TLC monitoring (toluene/acetone 
1:1 v/v) revealed a conversion of approximately 70 %. Further 19.8 mg of catalyst 
and 3.43 mg of p-benzoquinone were added and the reaction was stirred at 40 °C for 
another day. After a total of 41 h, the solvent was removed in a nitrogen stream, the 
crude product was dried in vacuum and subsequently purified by NP column 
chromatography (Merck-silica gel 60/15-40 µm, 2.0 × 23.0 cm, isocratic, eluent: 
toluene/acetone 10:9 v/v). In order to remove column material it was purified by NP 
column chromatography again (Merck-silica gel 60/40-63 µm, 0.9 × 2.5 cm, step 
gradient, application: toluene/acetone 3:1 v/v, elution: toluene/acetone 1:1 v/v). After 
drying in vacuum, the product was obtained as colorless solid (9.91 mg, 61 %). 
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Analytics: 
 
Molecular Formula:    C102H157N3O45 
Molecular Weight:      2145.35 g/mol 
Rf = 0.20 (Toluene/Acetone 5:4 v/v) 
 
1H NMR (400 MHz, CDCl3, RT): δ [ppm] = 6.47 (s, 3H, NH), 5.83 – 5.71 (dt, 1H, 3JH5-
H4, trans = 15.2 Hz, 3JH5-H6 = 6.7 Hz, Cer, H-5), 5.64 (d, 1H, 3JH1-H2 = 9.2 Hz, GalNAc, 
H-1), 5.49 (dt, 1H, 3JH4-H5 = 10.8 Hz, 3JH4-H3 = 5.5 Hz, NeuAc, H-4), 5.44 – 5.17 (m, 
8H), 5.07 (dd, 3JH9a-H8 = 8.0 Hz, 4JH9a-H7 = 1.9 Hz, NeuAc, H-9a), 5.04 (d, 1H, 3JH1-H2 = 
7.7 Hz, Gal, H-1), 4.94 (dd, 1H, 3JH5-H4 = 10.4 Hz, 4JH5-H6 = 3.5 Hz, NeuAc, H-5), 4.89 
(dd, 1H, 3JH3-H2 = 9.6 Hz, 3JH3-H4 = 7.8 Hz, GalNAc, H-3), 4.76 (d, 1H, 3JH1-H2 = 7.8 Hz, 
Glc, H-1), 4.64 – 3.49 (m, 28H), 2.48 (dd, 2JH3e-H3a = 13.5 Hz, 3JH3e-H4 = 5.5 Hz, 
NeuAc, H3e), 2.21 – 1.85 (13s, 51H, CH3CO2R), 1.58 (m 2H, Cer, H-3'), 1.25 (m, 
48H), 0.92 – 0.83 (t, 6H, 3JH17-H16 = 6.9 Hz, 3JH18'-H17' = 6.9 Hz, Cer, H-17', 18). 
 
MS (ESI, pos. Mode, MeOH, M = 2145.01): m/z (%) = 2200.07 (0.20) [M
 
+ MeOH + 
Na]+, 2195.10 (1.6) [M
 
+ MeOH + NH4]+, 2179.07 (0.38) [2M + MeOH + 2NH4]+, 
2178.10 (0.24) [M
 
+ MeOH + H]+, 2163.07 (3.1) [M + NH4]+, 2146.05 (0.40) [M + H]+, 
1106.56 (35) [M
 
+ MeOH + 2NH4]2+, 1098.04 (41) [M + MeOH + NH4 + H]2+, 1092.53 
(7.0) [M + K + H]2+, 1089.53 (12) [M
 
+ MeOH + 2H]2+, 1090.54 (76) [M + 2NH4]2+, 
1082.02 (100) [M + NH4 + H]2+, 1073.52 (14) [M + 2H]2+, 1052.02 (7.4) [M + NH4 + H 
– H3CCO2H]2+. 
 
MS/MS (m/z = 1081.52): m/z (%) = 1754.90 (18) [Y3α + 2H – H3CCO2H]+, 1467.83 
(3.2) [Y2α + 2H – H3CCO2H]+, 1082.02 (66) [M + NH4 + H]2+, 1073.52 (11) [M + 2H]2+, 
1043.51 (15) [M + 2H – H3CCO2H]2+, 618.22 (10) [B2α]+, 331.11 (100) [B1α]+, 288.11 
(6) [B2α/B1α + H]+, 211.06 (11) [B1α – 2H3CCO2H]+, 169.04 (48) [C1α + 2H – 
3H3CCO2H]+, 109.00 (6.9) [C1α + 2H – 4H3CCO2H]+. 
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5.6.7 Preparation of d17:1-lyso-GM1·NH3 (31)  
 
Experimental procedure: 
Pentadeca-O-acetyl-GM1 (d17:1/18:0) sialoyl-II2-lactone (30) was deacetylated and 
deacylated by the method described in section 5.3.1. 9.40 mg (4.38 µmol) of 30 were 
applied. The reaction time was 19 h. The crude product was purified by RP column 
chromatography (Merck LiChroprep RP-18/40-63 µm, 0.9 × 2.8 cm, eluent: 
MeOH/H2O 90:40 v/v). A second purification step was done by NP column 
chromatography (Merck-silica gel 60/25-40 µm, 2.0 × 19.0 cm, isocratic, eluent: 
CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). MS analysis revealed that the product 
contained 4.8 % of the d16:1-lyso-GM1 isomer, so the product was purified by 
isocratic RP column chromatography again (Merck LiChroprep RP-18/40-63 µm, 1.0 
× 22.5 cm, eluent: MeOH/H2O 90:31 v/v). Then, column material was removed by NP 
column chromatography (Merck-silica gel 60/40-63 µm, 0.9 × 2.0 cm, step gradient, 
application: CHCl3/MeOH/2.5 M NH3 60:35:6 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 
60:44:12 v/v/v) again. After lyophilization, d17:1-lyso-GM1·NH3 was obtained as a 
colorless powder (1.93 mg, 34 %).   
 
 
Analytics: 
 
Molecular Formula:    C54H98N4O30 
Molecular Weight:      1283.38 g/mol 
Rf = 0.12 (CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v) 
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MS (ESI, pos. Mode, MeOH): m/z (%) = 1288.60 (1.3) [M + Na]+, 1266.62 (43) [M + 
H]+, 1252.61 (1.8) [M + H – CH2]+, 981.35 (14) [B4]+, 975.52 (13) [Y2β + 2H]+, 901.48 
(33) [Y2α + 2H]+, 663.78 (1.2) [M + K + Na]2+, 655.79 (4.6) [M + 2Na]2+, 652.78 (5.0) 
[M + K + H]2+, 644.80 (23) [M + Na + H]2+, 642.32 (24) [M + NH4 + H]2+, 633.81 (100) 
[M + 2H]2+, 626.80 (5.0) [M + 2H – CH2]2+.  
 
MS/MS (m/z = 1266.62): m/z (%) = 1266.61 (26) [M + H]+, 975.52 (56) [Y2β + 2H]+, 
957.51 (5.8) [Z2β]+, 901.48 (8.7) [Y2α + 2H]+, 610.39 (18) [Y2α/B1β + 3H]+, 592.38 (8.2) 
[Y2α/C1β + H]+, 448.34 (11) [Y1 + 2H]+, 430.33 (9.8) [Z1]+, 366.15 (100) [B2α]+, 292.11 
(7.2) [B1β]+, 286.28 (7.0) [Y0 + 2H]+, 274.11 (6.8) [B1β – H2O]+, 268.28 (22) [Z0]+, 
250.27 (8.2) [Z0 – H2O]+, 204.11 (69) [B2α/B1α + H]+, 186.10 (17) [B2α/B1α + H – H2O]+. 
 
After RP-chromatography: 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1304.58 (3.0) [M + K]+, 1288.59 (11) [M + 
Na]+, 1283.6 (7.1) [M + NH4]+, 1266.60 (100) [M + H]+, 1104.55 (37) [Y3α + 2H]+, 
981.34 (11) [B4]+, 975.51 (23) [Y2ß + 2H]+, 901.47 (92) [Y2α + 2H]+, 813,46 (25) 
[Y3α/B1β + 3H]+, 671.77 (4.4) [M + 2K]2+, 663.77 (13) [M + K + Na]2+, 661,28 (7.3) [M + 
K + NH4]2+, 655.78 (22) [M + 2Na]2+, 652.78 (38) [M + K + H]2+, 644.79 (91) [M + Na 
+ H]2+, 642.31 (41) [M + NH4 + H]2+, 633.88 (84) [M + 2H]2+. 
 
Photometric sialic acid determination:  
 
The results of the photometric sialic acid determination are given in Fig. 5.5.1. The 
content of d17:1-lyso-GM1·NH3 (31) was 74.2 % compared to d18:1-lyso-GM1·NH3 
(7) as reference standard. 
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5.6.8 Preparation of d17:1-lyso-GM2·NH3 (32)  
 
Experimental procedure: 
d17:1-Lyso-GM2·NH3 was prepared by the method described in section 5.5.2. 
1.09 mg (0.849 µmol) of d17:1-lyso-GM1·NH3 and 352 µL (314 mU) of beta-
galactosidase solution were applied. The reaction time was 15.5 h. The crude 
product was purified by NP column chromatography (Merck-silica gel 60/15-40 µm, 
2.0 × 19.2 cm, isocratic, eluent: CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). In order to 
remove column material, it was purified by NP column chromatography again (Merck-
silica gel 60/40-63 µm, 0.6 × 2.0 cm, step gradient, application: CHCl3/MeOH/2.5 M 
NH3 60:35:2 v/v/v, elution: CHCl3/MeOH/2.5 M NH3 60:40:10 v/v/v). After 
lyophilization, d17:1-lyso-GM2·NH3 was obtained as a colorless powder (0.66 mg, 
69 %).   
 
 
Analytics: 
 
Molecular Formula:    C48H88N4O25 
Molecular Weight:      1121.24 g/mol 
Rf = 0.14 (CHCl3/MeOH/2.5 M NH3 60:40:9 v/v/v) 
 
MS (ESI, pos. Mode, MeOH): m/z (%) = 1126.53 (18) [M + Na]+, 1124,03 (4.7) [2M + 
Na + NH4]2+, 1115,54 (14) [2M + Na + H]2+, 1104.54 (100) [M + H]+, 901.47 (4.1) [Y2β 
+ 2H]+, 813.46 (12) [Y2α + 2H]+, 582.74 (7.9) [M + K + Na]2+, 574.76 (17) [M + 2Na]2+, 
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571.75 (15) [M + K + H]2+, 563.76 (50) [M + Na + H]2+, 561.28 (42) [M + NH4 + H]2+, 
552.77 (59) [M + 2H]2+. 
 
MS/MS (m/z = 1104.54): m/z (%) = 1104.55 (11) [M + H]+, 901.48 (1.9) [Y2β + 2H]+, 
813.46 (38)  [Y2α + 2H]+, 795.45 (7.7) [Z2α]+, 610.38 (5.2) [Y2β/B1α + 3H]+, 592.37 (4.0) 
[Y2α/C1β + H]+, 448.33 (8.5) [Y1 + 2H]+, 430.32 (10) [Z1]+, 412.31 (3.9) [Z1 – H2O]+, 
366.14 (19) [B2/B1α + H]+, 292.11 (11) [B1α]+, 286.26 (7.6) [Y0 + 2H]+, 274.09 (11) [B1α 
– H2O]+, 268.27 (25) [Z0]+, 250.25 (7.4) [Z0 – H2O]+, 222.09 (5.3) [C1β + 2H]+, 204.08 
(100) [B1β]+, 186.07 (16) [B1β – H2O]+. 
 
Photometric sialic acid determination:  
 
The results of the photometric sialic acid determination are given in Fig. 5.5.1. The 
content of d17:1-lyso-GM2·NH3 (32) was 90.2 % compared to d18:1-lyso-GM1·NH3 
(7) as reference standard. 
 
 
5.6.9 Validation of 31 and 32 as calibrators 
Six different concentrations of d18:1-lyso-GM1·NH3 and of d18:1-lyso-GM2·NH3 
(0 µM, 5 µM, 10 µM, 15 µM, 20 µM, 25 µM, and 35 µM) in methanol were prepared. 
The d18:1-lyso-GM1·NH3 solutions were spiked each by d17:1-lyso-GM1·NH3 (31) to 
a final concentration of 13.4 µM of the internal standard, and the d18:1-lyso-
GM2·NH3 solutions were spiked by d17:1-lyso-GM2·NH3 (32) to a final concentration 
of 14.0 µM of the internal standard. The solutions were measured in the full scan 
mode and the ratio of the peak height of the most intensive peak ([M + K + H]2+) was 
plotted against the concentration of the analyte (Fig. 3.5.5). All measurement were 
performed in duplicate. 
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